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CV 
I graduated from the University of Aalborg in 2013 with a master’s degree in 
Medicine with Industrial Specialization which combines medicine, pharmacology, 
and research. During the last year of my master education, I did a research project 
about the age dependence of risk factors for stroke and death in young patients with 
atrial fibrillation in collaboration with the Aalborg Thrombosis Research Unit, 
Department of Clinical Medicine, Faculty of Health, Aalborg University. Here I 
gathered a strong interest in risk stratification and cardiovascular diseases which 
lead to my PhD project. I started as a PhD student at the Aalborg Thrombosis 
Research Unit in August 2013.  
During my time as a PhD student, I have participated in several international 
conferences where I have presented my research work, e.g., at the ESC Congress in 
London in 2015 where I was selected as the winner of the Young Investigator 
Award Session within thrombosis. Additionally, I spent one month at the Centre for 
Cardiovascular Sciences, University of Birmingham, City Hospital, Birmingham, 
United Kingdom, where I collaborated with international experts within the field 
and was involved in the research environment. My dissertation is based on four 
papers.
III 
ENGLISH SUMMARY 
Heart failure represents a major and growing public health problem due to its high 
prevalence and mortality. With the aging of the general population, the public 
health impact of heart failure is expected to increase substantially in the coming 
years. The heart failure population carries a very high mortality risk, but heart 
failure also ranks second as a cause of cardiogenic stroke. Epidemiological and 
pathophysiological data link heart failure to an increased risk of blood clot 
formation, leading to ischemic stroke and thromboembolism. Patients with heart 
failure do not only have an increased risk of stroke but also of stroke-related 
mortality and morbidity, as well as impaired quality of life. Risk stratification using 
readily available clinical variables may help identify patients at low and high risk of 
ischemic stroke and thromboembolism. Simple clinical risk scores have been useful 
in other settings to identify subgroups with a high risk of thromboembolic events. 
However, the potential of stroke risk stratification has not been studied in the heart 
failure population, neither has high-risk subgroups within this population been 
identified in detail. 
 
The CHA2DS2-VASc score is a widely used risk score for clinical stroke risk 
stratification in atrial fibrillation. The score gives points according to the presence 
of different clinical risk factors, including congestive heart failure, hypertension, 
diabetes mellitus, previous stroke/transient ischemic attack/systemic embolism, 
vascular disease, age 65-74 years, age ≥75 years, and female sex. Recent research 
has indicated that the CHA2DS2-VASc score may be useful for predicting ischemic 
stroke in populations other than atrial fibrillation, including patients with acute 
coronary syndrome or sinus node dysfunction. However, its potential in predicting 
ischemic stroke risk among heart failure patients has not yet been explored in spite 
of opportunities to optimize prevention of such events in this population if managed 
correctly. 
 
To better characterize patients with a diagnosis of heart failure who are at increased 
risk of stroke and thromboembolism and to assess the usefulness of the CHA2DS2-
VASc score in these patients, we have linked data from Danish national registries. 
As the CHA2DS2-VASc score was originally developed for use in populations with 
atrial fibrillation, the extent to which the specific risk components of the score 
relate to the risk of stroke and thromboembolism in a heart failure population is 
unexplored. Three of these individual components have been selected for in-depth 
investigations of their usefulness for stroke risk stratification purposes. These 
include female sex, diabetes mellitus, and vascular disease (peripheral artery 
disease or prior myocardial infarction). 
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In a Danish heart failure population without atrial fibrillation, we found an 
association between the CHA2DS2-VASc score and an increased risk of ischemic 
stroke. When examining the discriminatory properties of the CHA2DS2-VASc 
score, the predictive accuracy of the score was modest in the heart failure 
population without atrial fibrillation. When investigating some of the individual 
components of the score, we found an association between a diagnosis of peripheral 
artery disease and diabetes mellitus and higher risk of ischemic stroke when 
compared with patients without these comorbidities, whereas we did not find an 
association between prior myocardial infarction and increased risk. Contrary to 
observations from populations with atrial fibrillation, we found an inverse 
association between female sex and ischemic stroke which attenuated with 
increasing age. 
 
The research contained in this PhD project has contributed to identifying the 
individual and collective importance of a number of risk factors for ischemic stroke 
and thromboembolism, as defined by the CHA2DS2-VASc score, in patients with 
heart failure and without atrial fibrillation. The identification of high-risk subgroups 
is an important first step towards providing a basis for evidence-based clinical risk 
stratification for preventing stroke and thromboembolism among heart failure 
patients without atrial fibrillation.  
  
V 
DANSK RESUME 
Hjertesvigt er et betydende og voksende sundhedsproblem med høj prævalens og 
mortalitet. I takt med at den generelle befolkning bliver ældre, forventes 
betydningen af hjertesvigt i befolkningen at blive væsentlig større i fremtiden. 
Hjertesvigt er associeret med en høj mortalitet, men rangerer også som nummer to 
på listen over årsager til kardioembolisk apopleksi. Resultater fra epidemiologiske 
og patofysiologiske studier forbinder hjertesvigt med en øget risiko for 
trombedannelse og dermed iskæmisk apopleksi og tromboemboli. Patienter med 
hjertesvigt har således en øget risiko for apopleksi og for apopleksi-relateret 
mortalitet og morbiditet samt nedsat livskvalitet. Risikostratificering ved 
anvendelse af tilgængelige kliniske faktorer kan muligvis identificere patienter med 
lav og høj risiko for iskæmisk apopleksi og tromboemboli. I andre sygdoms-
sammenhænge har simple kliniske risikoscoresystemer vist sig brugbare til at 
identificere patientgrupper med en høj risiko for tromboemboli. Potentialet for 
risikostratificering for apopleksi i hjertesvigtspopulationen er dog ikke blevet 
undersøgt, ligesom høj-risiko patientgrupper ikke er identificeret. 
 
For klinisk at risikostratificere patienter med forkammerflimmer i forhold til 
apopleksi bruges i dag CHA2DS2-VASc-scoresystemet. Dette scoresystem giver 
point ud fra tilstedeværelsen af forskellige kliniske risikofaktorer såsom hjertesvigt, 
hypertension, diabetes mellitus, tidligere apopleksi/forbigående iskæmisk 
anfald/tromboemboli, vaskulær sygdom, alder 65-74 år, alder ≥75 år og kvindekøn. 
I de seneste år er anvendelse af CHA2DS2-VASc-scoresystemet til at risiko-
stratificere og prædiktere iskæmisk apopleksi blevet udvidet til andre 
sygdomsgrupper end den oprindelige patientgruppe med forkammerflimmer, men 
scoresystemets anvendelighed i en hjertesvigtspopulation er uafklaret. Dette på 
trods af en potentiel mulighed for at forhindre hændelser i denne population ved 
bedre identifikation af høj-risiko individer. 
 
For bedre at kunne identificere patienter med en hjertesvigtsdiagnose, som har en 
øget risiko for apopleksi og tromboemboli, samt for at vurdere anvendeligheden af 
CHA2DS2-VASc-scoresystemet på denne patientgruppe har vi koblet informationer 
fra de danske nationale registre. Da CHA2DS2-VASc-scoresystemet oprindeligt er 
udviklet til patienter med forkammerflimmer, er det ikke undersøgt, hvorvidt de 
specifikke komponenter i scoresystemet relaterer til risikoen for apopleksi og 
tromboemboli hos hjertesvigtspatienter. Tre af disse komponenter er derfor blevet 
udvalgt til dybdegående undersøgelse af deres anvendelighed ved risiko-
stratificering for apopleksi i hjertesvigtspopulationen. Disse komponenter 
inkluderer kvindekøn, diabetes mellitus og vaskulær sygdom (perifer arteriesygdom 
eller tidligere myokardieinfarkt). 
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I hjertesvigtspopulationen uden forkammerflimmer fandt vi en sammenhæng 
mellem CHA2DS2-VASc-scoresystemet og risiko for iskæmisk apopleksi. Da vi 
undersøgte de diskriminerende egenskaber af CHA2DS2-VASc-scoresystemet, fandt 
vi en moderat prædiktiv præcision ved scoresystemet i hjertesvigtspopulation uden 
forkammerflimmer. Ved undersøgelse af de individuelle komponenter af CHA2DS2-
VASc-scoresystemet fandt vi en sammenhæng mellem en diagnose for perifer 
arteriesygdom samt diabetes mellitus og en højere risiko for iskæmisk apopleksi, 
hvorimod vi ikke fandt denne sammenhæng mellem tidligere myokardieinfarkt og 
iskæmisk apopleksi. Modsat observationer fra populationer med forkammerflimmer 
fandt vi en invers sammenhæng mellem kvindekøn og iskæmisk apopleksi hos 
hjertesvigtspopulationen uden forkammerflimmer, som dog svækkedes ved højere 
alder.  
 
Den opnåede viden fra dette ph.d.-projekt har bidraget til anerkendelse af den 
individuelle og kollektive betydning af en række risikofaktorer for iskæmisk 
apopleksi og tromboemboli, defineret ud fra CHA2DS2-VASc-scoresystemet, hos 
hjertesvigtspatienter uden forkammerflimmer. Identificeringen af høj-risiko 
patientgrupper er et vigtigt skridt i forhold til at standardisere klinisk risiko-
stratificering af hjertesvigtspatienter uden forkammerflimmer som et led i 
forebyggelsen af iskæmisk apopleksi og tromboemboli.  
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ACRONYMS AND ABBREVIATIONS 
 
AF: atrial fibrillation 
CHA2DS2-VASc: congestive heart failure, hypertension, age ≥75 (double), diabetes 
mellitus, previous stroke/transient ischemic attack/systemic embolism (double), 
vascular disease, age 65-74, sex category (female) 
COPD: chronic obstructive pulmonary disease 
ESC: European Society of Cardiology 
HF: heart failure 
HFpEF: heart failure with preserved ejection fraction 
HFrEF: heart failure with reduced ejection fraction 
HR: hazard rate ratio 
MI: myocardial infarction 
NOAC: non-vitamin K antagonist oral anticoagulant 
NYHA: New York Heart Association 
PAD: peripheral artery disease 
RR: relative risk 
TE: thromboembolic event 
TIA: transient ischemic attack 
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CHAPTER 1. INTRODUCTION 
1.1. THE HEART FAILURE EPIDEMIC 
The European Society of Cardiology (ESC) defines heart failure (HF) as an 
abnormality of cardiac structure or function leading to failure of the heart to deliver 
sufficient oxygen to the metabolizing tissues[1]. In some situations, the heart 
delivers the necessary amount of oxygen but only at the expense of increased left 
ventricular filling pressure[1]. HF can be described as a clinical syndrome rather 
than a disease in which patients have typical symptoms (e.g., dyspnea, abnormal 
fluid accumulation, and fatigue) and signs (e.g., elevated jugular vein pressure, 
pulmonary crackles, and displaced apex beat) of HF resulting from an abnormality 
of cardiac structure or function[2,3]. The diagnosis of HF requires a clinical 
evaluation incorporating both elements of the clinical history and signs plus 
physical examination and testing[3]. Since many of the symptoms of HF are 
unspecific, the diagnosis of HF can be troublesome. Therefore, determining a 
plausible underlying cause of the failure of the heart is an important step when 
diagnosing HF[2,4]. 
HF is an important healthcare issue, and with the aging of the population, the 
impact of HF is expected to increase substantially[5]. HF has a major impact on 
mortality and health economics[6]. Although survival has improved during the last 
twenty years due to improved treatment options, the prognosis still remains poor 
with a 5-year case fatality proportion of approximately 50% and a very high 
hospital readmission rate[7,8]. Age is a very important risk factor for HF, and the 
prevalence and incidence of HF increase progressively with age, with the 
prevalence exceeding ≥10% among persons 70 years or older[9]. In Denmark, 
approximately 1.5-2% of the population has shown signs of chronic HF, with half 
of these persons definitely having HF[10]. The incidence rate of chronic HF is 1-1.5 
per 1000 Danish subjects per year, and the mean age at onset is 75 years, where the 
incidence rate is 12-30 per 1000 subjects[10].  
The cardiac cause of HF is often myocardial disease (e.g., coronary artery disease) 
leading to permanent injury and systolic ventricular dysfunction[11]. Other 
common causes of HF are atrial fibrillation (AF), hypertension, or abnormalities of 
the ventricular diastolic function, valves, pericardium, or endocardium[2,12]. In 
most patients with HF, abnormalities of systolic and diastolic dysfunction coexist, 
irrespective of ejection fraction[12]. The pathophysiological damages in patients 
with left ventricular systolic dysfunction lead to remodeling of the ventricle with 
dilatation, increased mass, and impaired contractility[4]. Once ventricular 
dysfunction occurs, a sequence of compensatory systemic mechanisms is triggered 
which leads to structural and neurohormonal adaptations, including activation of the 
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renin-angiotensin-aldosterone system and the sympathetic nervous system[11]. 
These systems have a detrimental effect on several body components and induce a 
pathophysiological “vicious cycle”, which accounts for many of the clinical 
symptoms and signs of HF[11]. The treatment of HF aims at interrupting these 
processes[2,4]. The etiology of chronic HF in Denmark is mainly due to ischemic 
heart disease (50-60%), with unknown/idiopathic (20-15%), hypertension (10-
15%), valvular disease (5-10%), AF (3-4%), and other causes (4-10%) accounting 
for the remaining cases[10].  
In 2010, the mortality risk of hospitalized Danish patients with HF was reported to 
be 26% within the first six months after diagnosis[13]. Among patients with chronic 
HF, the 2-year mortality risk was 41%, and the 5-year mortality risk has been 
estimated to be between 50 and 75%[13]. The high mortality risk in Denmark is 
similar to that found in other HF cohorts in developed countries[7,14]. The 
mortality risk in patients with HF is not homogeneous, and several risk factors have 
been identified to help stratify HF patients into low and high risk[15]. However, 
both sudden death and death due to progressive HF may be caused by unrecognized 
atheroembolic events[16]. Besides death, the most feared major adverse outcome in 
patients with HF is stroke[17]; nonetheless, until now only minor attempts have 
been made to identify HF patients with a high risk of stroke. 
 
1.2. STROKE AND THROMBOEMBOLISM IN HEART FAILURE 
HF ranks second as a cause of cardiogenic stroke after AF[18]. HF does not only 
increase the risk of stroke, but also stroke-related mortality and morbidity, as well 
as impaired quality of life[19].  
Despite the large number of patients with HF and the importance of stroke, little is 
known about the prevalence and incidence of this outcome in patients with HF who 
do not have AF, as most studies of patients with HF did not exclude patients with 
concomitant AF. For many years, AF has been subject to extensive research and is a 
known risk factor for stroke[20], but the focus on stroke in patients with HF and 
without AF is emerging.  
Several studies have found an increased risk of stroke and thromboembolic events 
(TE) in patients with HF (summarized by Haeusler et al. in 2011)[17]. However, 
the long-term risk of stroke and its relationship to comorbidity in patients with HF 
and without AF is not well described[21]. In one study, the stroke risk in patients 
with HF was demonstrated to be higher especially within the first six months after a 
new HF diagnosis compared with persons without HF[22]. Compared with the 
general population, another study found a 17.4-fold increased risk of ischemic 
stroke during the first month after HF diagnosis and a persistently elevated risk 
3 
during the 5-year follow-up period[23]. However, none of these studies excluded 
patients with AF. The prevalence of “silent strokes” (ischemic brain lesions with no 
symptomatic presentation) is higher in patients with HF compared with subjects 
without HF (27-39% vs. 3.6%)[24]. This indicates that the prevalence of 
cerebrovascular disease may be higher in patients with HF than expected. 
Moreover, the risk of recurrent stroke is doubled in patients with HF and a prior 
stroke compared with patients without HF and a prior stroke[23]. A previous 
clinical diagnosis of HF has been demonstrated to be associated with a markedly 
higher mortality rate in patients with acute stroke compared with patients without 
HF[25,26], implying a poor prognosis of patients with HF who experience a stroke. 
Again, these studies did not exclude patients with AF. 
 
Figure 1. Pathophysiology of thrombosis in heart failure (recreated from Eur J Heart Fail 2012;14: 
681–695 with permission from Oxford University Press). 
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Several mechanisms have been associated with an increased risk of stroke and TE 
in patients with HF[27]. When AF is present, thrombus formation is frequently due 
to stasis in the left atrial appendages[19]. But patients with HF and without AF also 
have an increased risk of stroke events[28]. In general, three key characteristics 
have been associated with the formation of thrombi and contribute to a 
prothrombotic or hypercoagulable state; (1) blood flow abnormalities, (2) vessel 
wall abnormalities, and (3) abnormal blood constituents[29]. The pathophysiology 
of thrombogenesis in patients with HF may be explained through these 
multifactorial mechanisms[29], as illustrated in Figure 1. The etiology of HF may 
also impact on the mechanisms causing a stroke and on the clinical pattern of a 
stroke[30]. A study by Vemmos et al. showed that strokes in patients with HF are 
primarily of cardioembolic origin, especially if AF is present or in patients with HF 
with dilated cardiomyopathy or valvular diseases[31]. However, in patients with 
coronary artery disease or hypertension, strokes were predominantly atherosclerotic 
and lacunar, respectively. Especially, underlying atherosclerosis may play a 
dominant role in stroke occurrence, as many patients with HF have concomitant 
ischemic comorbidity. This diversity of stroke etiologies observed in the HF 
population reflects the fact that many predisposing factors for HF are also well-
known causes of stroke even in the absence of HF. 
 
1.3. STROKE RISK STRATIFICATION 
Prediction models are increasingly used to complement clinical reasoning and 
decision making in modern medicine, in particular in the cardiovascular field[32–
34]. Risk prediction models use predictors to estimate the absolute probability that a 
certain outcome will occur within a specific time period in an individual with a 
particular predictor profile (prognostic prediction model)[32]. Predictors may range 
from subject characteristics (e.g., age and sex), disease history, and physical 
examination results, to imaging, blood, urine, or genetic markers[32]. Prognostic 
prediction models are developed to guide healthcare professionals in their decision-
making regarding further management such as initiating or withholding treatment 
and to inform individuals about their risk of developing a particular disease[34,35]. 
They are not meant to replace qualitative reasoning, but rather to supplement 
clinical decision-making by providing more objectively estimated proba-
bilities[33,35].  
Many cardiovascular disease risk scores have been developed using individuals 
from the general population or from more specific population subgroups, such as 
the AF population. In the latter population, simple clinical risk scores using readily 
available clinical variables have aided in the identification of patients at low and 
high risk of ischemic stroke and TE[36]. For example, the CHA2DS2-VASc score 
has been developed for stroke risk stratification in the AF population and is 
5 
recommended in current guidelines[37,38]. Based on the CHA2DS2-VASc score, 
patients are given 1 point for congestive HF, hypertension, age 65 to 74 years, 
diabetes mellitus, vascular disease, and female sex and 2 points for age ≥75 years 
and previous stroke/transient ischemic attack (TIA)/systemic embolism; thus, 9 
possible points (as age gives either 1 or 2 points), with higher scores indicating 
higher risk[20]. The score performs particularly well in identifying the patients with 
AF who are truly at low risk of TE[39,40]. 
In recent years, the use of the CHA2DS2-VASc score in predicting ischemic stroke 
and TE has extended beyond the original disease state for which it was 
proposed[41,42]. The CHA2DS2-VASc score has been applied to cohorts of patients 
without AF and has been reported to have modest predictive value for predicting 
ischemic stroke and TE in these cohorts[41,43–45]. For example, the CHA2DS2-
VASc score can predict long-term outcomes in patients with acute ischemic stroke 
but without AF[43]. Indeed, in this study, patients with pre-stroke CHA2DS2-VASc 
scores of 0 had lower rates of mortality, stroke recurrence, and cardiovascular 
events compared with patients in the high-risk subgroups. Additionally, among 
patients with sinus node dysfunction and permanent pacemakers, the CHA2DS2-
VASc score predicted a combined end point of stroke or death independent of a 
previous history of AF[44]. In patients with acute coronary syndrome but no AF, 
the CHA2DS2-VASc score predicted ischemic stroke/TIA events with an accuracy 
similar to that observed in historical populations with AF[42]. Furthermore, in a 
community study from Taiwan, the performance of the CHA2DS2-VASc score in 
predicting stroke was broadly similar in patients without and with AF[41]. 
The existing literature suggests that this simple clinical risk score, the CHA2DS2-
VASc score, may provide a tool for easy clinical prognostic stroke risk stratification 
even among patients without AF[42–44]. To date, the use of stroke risk 
stratification in patients with HF has not been comprehensively studied. The 
prognostic weight of the individual risk factors of the CHA2DS2-VASc score may 
be different in patients with HF than that observed among patients with AF. Thus, 
besides assessing the performance of the CHA2DS2-VASc score in the HF 
population the next natural step is to examine each individual component of the 
score in the HF setting.  
Stroke risk stratification has been useful in the AF population where the CHA2DS2-
VASc score aids the decision whether or not to initiate anticoagulant therapy. The 
potential benefit of thromboprophylaxis in patients with HF and without AF is 
currently discussed in the literature[46–49]. However, it has been hypothesized that 
there is a rationale for using antithrombotic therapy as thromboprophylaxis in 
subgroups of patients with chronic HF and without AF[50]. Yet, information is 
lacking on the extent to which risk factors influence the prognosis among patients 
with HF and without AF. While studies of stroke risk stratification do not directly 
address the issue as to whether antithrombotic therapy is beneficial for HF patients, 
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they can nonetheless aid the clinician in assessing which patients could eventually 
be considered for thromboprophylactic management.  
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CHAPTER 2. AIMS AND HYPOTHESES 
The aim of this PhD project was to contribute to the identification of risk factors for 
ischemic stroke and TE in patients with incident HF and without AF, thereby 
providing further knowledge of the disease burden associated with incident HF in 
combination with different comorbidities in order to potentially reduce the stroke 
burden in this population. The findings of this thesis may provide an important first 
step towards developing risk stratification methods for routine clinical use in HF 
patients, and thus, form the basis of evidence-based clinical risk stratification for 
preventing ischemic stroke and TE among HF patients without AF. 
This thesis is based on four substudies. The first substudy assessed the properties of 
the CHA2DS2-VASc score for predicting ischemic stroke and TE risk in a 
population of patients with incident HF, with and without AF. The remaining three 
substudies evaluated selected components of the CHA2DS2-VASc score by 
examining the associations between sex, vascular disease, and diabetes and the risk 
of ischemic stroke and TE, respectively, in the context of the CHA2DS2-VASc 
score. The following list describes the specific aims and hypotheses of each 
substudy. 
 
Substudy 1:  
Aim: To assess the predictive properties of the CHA2DS2-VASc score in predicting 
ischemic stroke, TE, and all-cause death in a population with incident HF with and 
without diagnosed AF.  
Hypothesis: The CHA2DS2-VASc score predicts ischemic stroke, TE, and all-cause 
death in incident HF patients without diagnosed AF similar to the performance 
observed among patients diagnosed with AF. 
 
Substudy 2:  
Aim: To examine the association between sex, and the interaction between age and 
sex, and the risk of ischemic stroke, TE, and all-cause mortality in patients with 
incident HF without diagnosed AF. 
Hypothesis: Female sex is associated with an increased risk of ischemic stroke, TE, 
and all-cause mortality in patients with incident HF without diagnosed AF, but age 
may affect this association.  
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Substudy 3:  
Aim: To examine the risk of ischemic stroke and all-cause mortality in patients 
with incident HF without diagnosed AF and with a previous diagnosis of vascular 
disease (peripheral artery disease (PAD) or prior myocardial infarction (MI)). 
Hypothesis: A previous diagnosis of vascular disease is associated with an 
increased risk of ischemic stroke and all-cause mortality in patients with incident 
HF without diagnosed AF. However, PAD and prior MI may not confer the same 
risk. 
 
Substudy 4:  
Aim: To examine the association between diabetes mellitus and the risk of ischemic 
stroke, TE, and all-cause mortality in patients with incident HF without diagnosed 
AF, and additionally, to explore the role of duration of diagnosed diabetes and risk 
of outcomes.  
Hypothesis: A diagnosis of diabetes mellitus is associated with an increased risk of 
ischemic stroke, TE, and all-cause mortality in patients with incident HF without 
diagnosed AF, and longer duration is associated with a higher risk of each end 
point. 
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CHAPTER 3. REGISTER DATA 
SOURCES 
In our four substudies, data from three Danish nationwide registries were linked 
using a unique person identification number (CPR number) which is used 
throughout all Danish national registries. The CPR is an abbreviation of “Central 
Person Register”, which is the Danish name for the National Civil Registration 
System (described below)[51]. Once a person has been given a CPR number, this 
will follow the person forever[52]. Information from the Danish registries has been 
an important tool in health research and has resulted in numerous publications 
within different research fields[53]. The strengths of register-based research are the 
reduced time and cost that data collection would otherwise require, the large sample 
size, the representativeness, and the reduced risk of some common sources of bias 
(e.g., recall bias, non-response bias, or selection bias due to loss to follow-up)[54]. 
In the four substudies, all three registries were updated to December 31, 2013. A 
brief description of the three Danish national registries used in the four substudies is 
given below. 
 
The National Civil Registration System  
In Denmark, national registration of residents was done manually from 1924, but in 
1968 the registration was recorded electronically in the National Civil Registration 
System[51]. This registry holds information on date of birth, vital status, date of 
death, and sex of all residents in Denmark[51,55]. Additionally, information about 
place of residence, citizenship, immigration/emigration, parents, and siblings, 
among other variables, is stored in the registry[52].  
 
The Danish National Patient Registry 
Risk factors and comorbidities within the study population were partly identified 
using the Danish National Patient Registry, which holds information on all hospital 
admissions along with diagnoses since 1977. Until 1994, all diagnoses were coded 
according to the 8
th
 revision of the International Classification of Diseases (ICD-8). 
Subsequently, all diagnoses are coded according to the 10
th
 revision of the 
International Classification of Diseases (ICD-10)[56–58]. In 1995, the Danish 
National Patient Registry extended to also include contacts to emergency rooms, 
specialist outpatient clinics, and psychiatric wards[58]. In 2003, all contacts to 
private hospitals were included; however, contacts to private hospitals account for 
only a very small proportion of all hospital contacts in the Danish health care 
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system[58]. The physician discharging the patient is responsible for determining the 
diagnostic codes related to the hospital stay. This registry was also used to identify 
the events of interest in our four substudies (death excluded which is registered in 
the National Civil Registration System). 
 
The Danish National Prescription Registry 
The Danish Registry of Medicinal Product Statistics collects individual-level data 
on all prescriptions dispensed from Danish pharmacies since 1994, coded according 
to the Anatomical Therapeutic Chemical (ATC) Classification System[57,59]. 
Individual-level over-the-counter medications are not included in this registry, but 
aggregated data on sales of over-the-counter drugs are included. For research 
purposes, an encrypted copy of this registry called the Danish National Prescription 
Registry became available in 2003, enabling linkage to an individual’s prescription 
history using the CPR number[59]. This latter registry contains data from 1995 
through present. Co-medication within the study population was identified using the 
Danish National Prescription Registry. Furthermore, this registry was used to 
ascertain the antithrombotic treatment status of each patient and, in some cases, 
used in combination with the Danish National Patient Registry to define comorbid 
conditions.  
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CHAPTER 4. STROKE RISK FACTORS 
IN HEART FAILURE 
In the following sections, each substudy of the PhD thesis will be discussed. Due to 
the limited space in scientific papers, the following sections will provide additional 
information about each risk factor and critical deliberation of the results of each 
paper in a more general perspective. Furthermore, other putative stroke risk factors 
in the HF population will be evaluated together with the potential of stroke risk 
stratification in patients with HF. First of all, however, some methodological 
concerns, which are unavoidable when assessing stroke risk in a high-mortality 
population, will be outlined and discussed. 
 
4.1. STROKE RISK ASSESSMENT IN A HIGH-MORTALITY 
POPULATION 
Many cardiovascular studies use the time to a disease event as the primary outcome 
and thus, statistical methods developed for survival data are usually applied such as 
the Cox regression model[60,61]. When using the Cox regression model, hazard 
rates are compared. A hazard rate is a measure of the average frequency or “speed” 
with which an event occurs in a defined population in a defined time and answers 
the question: “if 100 persons were alive at some unspecified time point during 
follow-up, how many would we expect to experience the outcome during the next 
year”[60,62]. However, for risk stratification and prediction of an event for the 
individual patient, risks are more relevant from a clinical perspective[35]. A risk is 
the probability that an event will occur, e.g., that an individual will become ill or 
die within a stated period of time, and answers the question: “out of 100 persons at 
baseline, how many would we expect to experience the outcome during a specified 
follow-up period”[60,62]. In other words, rates are relative to a dynamic population 
(the at-risk population), whereas risks are relative to the baseline population.  
In most cases, variables which are risk factors on the rate scale will also be risk 
factors on a risk scale[62]. In these cases, it is reasonable to use the (rate-based) 
Cox regression model to identify risk factors, which can be used in risk prediction 
and stratification. However, in some situations, the time to a specific event is of 
primary interest, but competing events may preclude its occurrence or greatly alter 
the chances to observe it[60,62]. In a population with a high mortality rate, such as 
the HF population, this is often the case. A patient who dies from any cause during 
follow-up is no longer at risk for any other event, such as ischemic stroke or 
TE[60,61]. In this situation, the one-to-one correspondence between risk factors on 
the rate scale and risk factors on the risk scale fails[62]. For example, a baseline 
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characteristic associated with a substantially higher stroke rate (i.e., the number of 
new strokes in the at-risk population) may have little influence on the absolute 
stroke risk if the characteristic is even more strongly associated with mortality; 
simply because patients die before developing a stroke. Risks and rates are two 
complementary ways of describing time-to-event data; and only when there are no 
competing risks and the outcome of interest is relatively rare can they be expected 
to be similar[62]. Competing risk from death may lead to bias by underestimating 
the association between exposure and outcome. When competing risk from death is 
present in a study, it is convenient to handle the issue of competing risks simply by 
studying a composite end point of mortality and a disease outcome[60]. On the 
other hand, this is a much less specific approach and cannot stand alone when risk 
prediction is used to support interventions which specifically target disease 
outcomes or if the frequency of each end point differs greatly[63]. Therefore, a 
better approach is to analyze the event of interest and take into account the 
competing risk[60]. 
In summary, these considerations underline two essential aspects: when the target is 
risk stratification, the experimenter should make statements about the behavior of 
risks, not rates; second, while statements about event rates can sometimes be 
directly translated to statements about absolute risk, this is not the case in a high-
mortality population, such as the HF population. Both aspects can be readily dealt 
with by simply staying on an absolute risk scale from the offset[60]. 
 
Survival data and absolute risks: the pseudo-observations method 
The primary reason why rate calculations and Cox regression models are most often 
used is that they are readily available in most statistical software. Oppositely, 
methods for risk calculation are less widely available. If we had complete follow-
up, risk calculations would be easy because all observations would be categorized 
as either 0 or 1[61]. In that case, regression methods for binary data can be readily 
applied. For example, using a generalized linear model with a log link function 
would provide risk ratios. However, with survival data, observations are typically 
censored – so there is a subset of observations for which the status at the end of 
follow-up is unknown[60]. Simply discarding these observations disregards the 
information they contribute during the follow-up (i.e., the knowledge that the 
patients were event-free until censoring). A computationally convenient way to 
utilize this information is the pseudo-observations method[64]. Informally, the 
pseudo-observations method replaces unobserved survival status by an inputted 
pseudo-value. It can be shown that when the pseudo-values are inputted in a 
generalized linear model for binary data, associations on absolute risk scale are 
estimated correctly[65–67]. An advantage of the pseudo-value approach to assess 
associations on a risk scale is that it is easy to take competing risks into account 
[64]. In the substudies of this thesis, we used the pseudo-observations method to 
estimate the risk of the outcomes. 
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4.2. PAPER 1: PERFORMANCE OF THE CHA2DS2-VASC SCORE 
IN HEART FAILURE 
As previously described, the use of the CHA2DS2-VASc score in predicting 
ischemic stroke and TE has extended beyond the original disease state for which it 
was proposed[41,42]. In patients with HF and without AF, it is unknown to date 
whether the risk of ischemic stroke increases with increasing CHA2DS2-VASc 
score in a similar fashion to that reported in patients with AF and, thus, whether the 
CHA2DS2-VASc score is a useful tool for stroke risk stratification in patients with 
HF. 
In substudy 1[68], the risk of ischemic stroke, TE, and death was increasing with 
increasing CHA2DS2-VASc scores in patients without AF. At high CHA2DS2-
VASc scores (≥4), the 1-year absolute risk of TE was relatively high, also in 
patients without AF (9.7%, 11.9%, and 18.0% for scores 4, 5, and 6, respectively). 
For the discriminatory properties of the CHA2DS2-VASc score, the score performed 
modestly in the HF population without AF (C-statistics: 0.63-0.69), but the 
performance depended on the choice of end point and the duration of follow-up. 
Our findings are consistent with another study, performed simultaneously with our 
study, where TE risk in patients with HF and without AF also increased with an 
increasing CHA2DS2-VASc score[69]. However, this concurrent study did not 
compare the properties of the CHA2DS2-VASc score and the event risk in HF 
patients with and without AF, which is an important comparison as HF patients 
with high scores may have an increased risk regardless of whether AF is present. 
 
A good prediction model 
Prognostic models are developed to provide objective estimates of outcome 
probabilities to complement clinical intuition and guidelines[35]. The underlying 
assumption is that accurately estimated probabilities improve clinicians’ decision 
making and, consequently, improves patient outcome[70]. A good risk prediction 
model should exhibit good discrimination (the ability of the model to separate 
individuals who develop events from those who do not)[71]. Discrimination is most 
often reported using a C-statistic, as we did in our study. In the case of binary data, 
the C-statistic is the probability that a randomly selected case has a higher value of 
a risk score than a randomly selected non-case[71]. The C-statistic is calculated as 
the area under the receiver-operating curve which plots the sensitivity (the 
proportion of future cases scoring above a given threshold in a prediction model) 
against 1 minus specificity (the proportion of future non-cases scoring below a 
given threshold in a prediction model) for consecutive cut-offs for the predicted 
risk[71,72]. In survival analysis without censoring, sensitivity and specificity can be 
estimated by empirical true positive and true negative fractions, as all subjects can 
be classified as cases or controls[67,73]. However, with incomplete follow-up 
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(censoring), the interpretation of the C-statistic is less obvious, because the status of 
subjects lost to follow-up before a specified time is unknown[67]. Furthermore, in 
the setting of competing risks, two definitions of the specificity can be considered 
depending on the way to deal with subjects who undergo the competing 
event[66,67]. If the competing risk is death of any cause (as in our study), controls 
can be defined as either ‘alive and event free’ or ‘alive and event free or dead’, 
leading to two different interpretations. The C-statistic ranges from 0 to 1; a value 
below 0.5 indicates negative discriminative ability, a value of 0.5 indicates no 
discriminative ability (random concordance), and values above 0.5 indicate positive 
discriminative ability, with a value of 1 reflecting perfect discrimination[74]. It is 
undecided what constitutes an “acceptable” C-statistic, but clinically implemented 
risk scores typically have a C-statistic around 0.65-0.75[36,41,75]. In our study, we 
examined the discriminatory ability of the CHA2DS2-VASc score using C-statistics 
and defined controls as patients who were alive and event free at the specified time 
points. According to previous assessments of a good C-statistic, we interpreted the 
obtained C-statistics in our study as modest. 
A good risk prediction model should also exhibit good calibration (whether 
predicted risks agree with observed risks across the whole range of a risk score). In 
the context of stroke risk stratification, there has been limited emphasis on the 
calibration properties of risk scores[41]. This is justly so because of the way that 
stroke risk scores are used in, for example, AF: their purpose is to identify low risk 
patients, not to accurately predict risk across the full patient population. Calibration 
(in addition to discrimination) of prediction rules is often worthwhile to assess, 
particularly when one is interested in the performance of a risk score across the full 
range of the score. However, in our study predicted risks equal observed risks by 
definition, as there is no source population providing predicted risk estimates since 
our study was the first to address this particular setting. Additionally, calibration is 
essential for the aspect of external validation which is not relevant in our study[76]. 
The CHA2DS2-VASc score has been demonstrated to be a useful tool for 
identifying “low-risk” patients in various studies examining risks in AF 
patients[39,40]. Identification of truly low-risk patients requires a high negative 
predictive value (NPV) of a risk score[74], i.e., the ratio of event-free patients and 
the number of patients classified as low-risk. In our study, we found moderately 
high 1-year NPVs (approximately 90%) for identifying patients at low risk of 
events as defined by a score of 1, confirming that the CHA2DS2-VASc score is a 
useful tool for identifying low-risk patients in the HF population without AF.   
 
Study-specific limitations 
As our definition of comorbidity relied on information from the Danish National 
Patient Registry, we cannot eliminate that the true score is actually higher than what 
we assessed, since some patients may have unregistered comorbidity. This would 
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underestimate the risk score level and potentially overestimate the event risk 
associated with a specific risk score level. Additionally, changes in clinical practice 
over time can influence the application of prognostic models, and improvements in 
diagnostic tests, biomarker measurement, or treatments may change the prognosis 
of patients over time[35]. As the inclusion and follow-up period extended over 12 
years in our study, temporal changes with improvements in treatment for HF/AF 
might be an issue. This may limit the generalizability of these historical data to 
align with risks observed under contemporary treatment standards. Therefore, it was 
important to do a split sample analysis according to early and late study period. In 
this analysis, we found similar absolute risks as in the main analysis indicating a 
robustness of our findings to changes in standard HF diagnostic and treatment 
modality during 2000-2012. Thus, the performance of the CHA2DS2-VASc score 
was not influenced by changes in clinical practice during the study period.   
 
Clinical considerations  
In the HF population, it is unknown whether each component of the CHA2DS2-
VASc score contributes equally to an increased stroke risk. The CHA2DS2-VASc 
score was not originally developed for patients with HF, and some of the 
components of the score may not be associated with an increased stroke risk in the 
HF population. Therefore, we would not expect the score to perform perfectly in 
this population[33]. However, we found that the CHA2DS2-VASc score modestly 
predicted the risk of ischemic stroke and similarly to findings in studies of the AF 
population for which the score was originally designed[75,77]. This is not 
surprising, as many of the components of the CHA2DS2-VASc score are well-
known risk factors of stroke in the general population[78] and, thus, most likely 
also stroke risk factors in the HF population.  
Currently, the components of the CHA2DS2-VASc score are dichotomized with the 
exception of age. This approach may be simplistic, as some of the components may 
provide better risk stratification if subdivided. However, for a risk score to be 
clinically applicable it must not be too complicated or time-consuming to use. In the 
AF setting, few studies have looked at the opportunities to subdivide the 
components of the CHA2DS2-VASc score[79,80], but future studies are necessary. 
Similarly, studies examining this in the HF setting are warranted. 
A new risk score specifically derived from data of patients with HF will possibly 
better predict ischemic stroke risk. However, in a recent study[15], a novel 
prognostic scoring model to predict stroke or death in patients with systolic HF and 
sinus rhythm including eight clinical characteristics (age, gender, hemoglobin, 
blood urea nitrogen, ejection fraction, diastolic blood pressure, diabetes status, and 
prior stroke or TIA) performed similarly (C-statistic: 0.63) to the CHA2DS2-VASc 
score in our study. Additionally, as seen in other cardiovascular diseases, it is more 
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likely that a well-performing, previously established risk score accepted by 
clinicians will have broader impact in clinical practice. Thus, based on our findings, 
the CHA2DS2-VASc score could turn out as a useful tool for stroke risk 
stratification of patients with HF and without AF and aid the clinician in 
identification of low- and high-risk subgroups. 
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4.3. PAPER 2: SEX AND ISCHEMIC STROKE RISK ACCORDING 
TO AGE 
An important but somewhat controversial risk factor for stroke in the AF setting is 
that of female sex[55,81]. This risk factor has been widely discussed during the last 
years due to conflicting results[82,83]. In the AF population, the stroke risk 
attributable to female sex interacts with age, as female sex is not an independent 
predictor of stroke in AF patients aged <65 years and as the (low) absolute rates in 
this age group are similar between males and females[55,81,84]. It is of interest to 
elucidate the relevance of this simple and very inclusive risk factor in a HF setting 
of patients without AF. In particular, it is unknown whether the association between 
sex and stroke risk in HF is also influenced by the presence of well-known 
cardiovascular risk factors of stroke, such as age[28,36,75]. Previous studies have 
described the association between sex and the risk of stroke in HF; however, many 
studies did not exclude patients with AF[23,85,86]. One study of patients with HF 
and without AF found that being female did not add any excess risk of TE 
compared with being male, when simply comparing these groups without any 
adjustment for age or other variables[69]. Similarly, another study of patients with 
HF and without AF found an association between female sex and lower risk of the 
combined end point stroke or death[15]. However, inconsistent results have 
generally been reported[87–89], which may in part be explained by differences in 
the severity and etiology of HF. The etiology of HF is different in females 
compared with males because HF in males are more often caused by ischemic heart 
disease, which may have a great influence on the subsequent risk of stroke[90,91].  
Increasing age has been associated with an increased risk of ischemic stroke both in 
the general population and in specific patient groups[92,93]. In the context of the 
CHA2DS2-VASc score in patients with AF, age is divided into three separate 
components; age ≥75 years, age 65-74 years, and age <65 years, where age ≥75 
years and age 65-74 years are strong risk factors of ischemic stroke[20]. In the HF 
population without AF, the association between age and ischemic stroke risk has 
not been comprehensively investigated. One study of patients with HF and without 
AF identified age >60 years as a predictor of stroke or mortality[15]. Another study 
looked at several different risk factors for all strokes (ischemic or hemorrhagic) 
including age ≥75 years[28]. In this latter study, age ≥75 years was not associated 
with an increased risk of all strokes; however, a very wide confidence interval 
existed due to a very low event number in this patient group. In another study of 
patients with HF and without AF, age 65-74 years was a strong predictor of TE[69].  
In substudy 2[94], female sex was associated with a lower risk of ischemic stroke 
compared with male sex at 1-year follow-up, as shown in Table 1. This seems to be 
a reversed association compared with findings from the AF population. The 
observed lower risks of ischemic stroke in females were not present in the older age 
groups, where the competing risk of death was substantial among males in 
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particular; males may die before they are diagnosed with stroke. However, the 
competing risk of death would only introduce selection bias if the males who die 
were also those who would have been more likely to experience a stroke than the 
surviving males, which is likely to be a reasonable assumption. Males and females 
may also die due to undiagnosed stroke, which could lead to misclassification of the 
outcome. When considering a more broadly defined thromboembolic end point, a 
decreased risk among females persisted across nearly all age groups after 5 years of 
follow-up. 
 
Table 1. Results of ischemic stroke in substudy 2 after 1 year of follow-up. 
Exposure\Outcome Ischemic stroke 
 Patient 
number 
* 
Event 
number
* 
Absolute 
risk (%) 
* 
Crude  
relative risk 
(95% CI) 
Adjusted 
relative risk 
(95% CI)† 
Male sex (reference) 44,196 1,542 3.7 1.00 1.00 
Female sex (overall) 39,946 1,284 3.3 0.90 (0.84-0.97) 0.91 (0.83-1.00) 
Age 50-59 years 
(females vs. males) 
2,859 48 2.3 0.70 (0.51-0.96) 0.85 (0.59-1.23) 
Age 60-69 years 
(females vs. males) 
6,040 154 3.3 0.73 (0.61-0.88) 0.86 (0.69-1.07) 
Age 70-79 years 
(females vs. males) 
11,421 416 4.1 0.86 (0.76-0.97) 0.93 (0.80-1.08) 
Age 80-89 years 
(females vs. males) 
14,690 525 3.7 0.97 (0.85-1.10) 0.93 (0.80-1.09) 
Age 90+ years 
(females vs. males) 
4,939 141 2.7 1.25 (0.89-1.76) 1.38 (0.89-2.15) 
 
* In the age-divided analysis, patient number, event number, and absolute risk are only shown for the 
female exposure group. 
†Adjusted for hypertension (binary), diabetes (binary), prior stroke/transient ischemic attack (binary), 
vascular disease (binary), and age (continuous).  
 
Study-specific limitations 
Our finding of a lower risk of ischemic stroke in females with HF compared with 
males may have prognostic value for clinicians in daily practice: even if the same 
comorbidities are present, males are at a higher risk of ischemic stroke. The 
difference in risk may partly be explained by the etiology of HF in males and 
females, as males more often have HF due to ischemic cardiac disease and females 
more often have preserved ejection fraction[95]. Unfortunately, we did not have 
information about the etiology of HF. Similarly, the etiology of HF may be closely 
related to the ejection fraction which we did not have access to due to lack of 
echocardiographic findings in the registries. Nonetheless, our results indicate a sex 
difference in ischemic stroke risk even when taking into account the components of 
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the CHA2DS2-VASc score. This finding may change when additional information 
such as detailed biochemical data is taken into account; indeed, it is possible that a 
suitably large collection of physiological parameters or lifestyle differences would 
explain the sex differences. However, our prognostic study does not aim for nor 
permit causal inferences; therefore, other studies are needed to elucidate the 
underlying mechanism for the difference in ischemic stroke risk between male and 
female HF patients.  
 
Female sex as a risk factor in the CHA2DS2-VASc score 
In substudy 1, we applied the CHA2DS2-VASc score to the HF population, as the 
clinician would do in clinical practice. Consequently, patients with a score of 1 are 
all males, because female sex gives one additional point besides HF. As male sex 
may be associated with an increased risk of stroke in the HF population compared 
with female sex[28,69,94], this may explain why a score of 1 (including only 
males) was related to a higher or equivalent absolute risk of ischemic stroke and TE 
than a score of 2 (including both females and males).  
Readily available risk factors, such as sex, are important in order to have successful 
implementation and use of risk stratification in a clinical environment. Substudy 2 
indicates that female sex is not a predictor of ischemic stroke and TE in the HF 
population and for the purpose of stroke risk stratification using e.g., a risk score, 
male sex would perhaps serve valuable as a risk component. 
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4.4. PAPER 3: VASCULAR DISEASE AND ISCHEMIC STROKE 
RISK 
Vascular disease is an established risk factor for stroke and TE[96,97] and included 
in the CHA2DS2-VASc score[36]. Vascular disease is a broad term, including two 
common and severe diseases, that is, PAD and MI. HF is known to be complicated 
by comorbidities such as PAD and prior MI[98,99]. In a study of patients with HF 
and without AF, no difference in the risk of all strokes (ischemic or hemorrhagic) 
was found between the presence and absence of vascular disease during the study 
period[28]. Oppositely, another study found vascular disease to be a predictor of TE 
in patients with HF and without AF[69]. These conflicting results may be due to the 
observation that PAD and prior MI do not confer the same risk of TE which has 
been observed in a previous study of a non-HF population[100]. Accordingly, 
evaluation of the association between vascular disease and ischemic stroke risk in 
the HF population requires investigating PAD and prior MI separately, as 
previously done in other settings[100,101].  
In substudy 3, PAD was associated with a higher 1-year rate of ischemic stroke and 
all-cause death when compared with HF patients with no vascular disease, whereas 
prior MI was not associated with a higher rate, as shown in Table 2. When 
comparing patients with PAD to patients with prior MI, PAD was associated with a 
higher rate of both outcomes. In our study, patients with PAD had more often 
experienced a previous stroke/TIA compared with both patients with prior MI or no 
vascular disease, and the prevalence of diabetes, hypertension, and renal disease 
was higher in patients with PAD. Thus, patients with PAD in general had more 
comorbidity predisposing for stroke. However, with risk stratification in focus our 
results indicate that patients with HF and PAD represent a subgroup of HF patients 
with increased risk of ischemic stroke, also when taking into account other common 
cardiovascular comorbidities. Therefore, in clinical practice, this subgroup of HF 
patients should receive specific attention regarding thromboprophylaxis. 
Oppositely, patients with prior MI were not a high-risk subgroup in our study which 
may be because these patients are already well treated with thromboprophylactic 
therapies, such as platelet inhibitors, statins, and changes in lifestyle (an issue 
which will be discussed later).  
Unfortunately, strong differential competing mortality across exposure levels can 
lead to counterintuitive findings on a risk scale, which is a real concern for vascular 
disease as an exposure. As emphasized in the discussion of the methodological 
concerns when assessing stroke risk in a high-mortality population, this is an 
example of a situation where statements about event rates cannot be directly 
translated to statements about absolute risks. Therefore, in substudy 3 we reported 
associations in terms of (Cox model) hazard rate ratios after 1 year of follow-up and 
repeated this analysis on a risk (ratio) scale in the supplemental material. In our 
study, associations were attenuated when viewed on a risk scale. This provides 
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important information from a clinical perspective as the absolute potential of 
prevention strategies among a high-risk subgroup, such as PAD patients, might be 
smaller than suggested by the associations seen in the rate assessments. 
 
Study-specific limitations 
The rate and risk calculations in our study may be overestimated, as the definition 
of PAD was based on diagnosis codes from the Danish National Patient Registry, 
and thus, we may have only included patients with more severe PAD requiring 
hospitalization or treatment (as PAD is known to be asymptomatic in almost 50% 
of cases)[102]. We cannot reject that these aspects may partially explain our 
findings. It would have been beneficial to have information, for example, about the 
ankle-brachial index and use this measurement in the definition of PAD, but due to 
the nature of our data this was not possible. 
 
Table 2. Results of ischemic stroke in substudy 3 after 1 year of follow-up. 
Exposure\Outcome Ischemic stroke 
 
Patient 
number 
Event 
number 
Absolute 
risk (%) 
Crude  
hazard ratios 
(95% CI) 
Adjusted  
hazard ratios  
(95% CI)† 
No vascular disease 
(reference) 
27,242 705 2.7 1.00 1.00 
PAD  2,274 101 4.7 1.82 (1.47-2.24) 1.34 (1.08-1.65) 
Prior MI  8,556 250 3.0 1.09 (0.94-1.26) 1.00 (0.86-1.15) 
 
†Adjusted for sex (binary), hypertension (binary), diabetes (binary), prior stroke/transient ischemic 
attack (binary), COPD (binary), renal disease (binary), and age (continuous). 
 
The need for future studies  
Our work in this study focuses on the basic issue to establish whether patients with 
HF and vascular disease, especially PAD, are indeed a subgroup at high ischemic 
stroke risk. We did not examine vascular disease as a potential cause of ischemic 
stroke, and accordingly, causal relations and confounding by possible stroke risk 
factors are not an issue of concern. Therefore, statements about the causal 
relationship in this subgroup of patients with HF are not justifiable with our data.  
As vascular disease is a well-recognized ischemic stroke risk factor in the general 
population, it is not surprising that PAD is also a risk factor in the HF population. 
Strokes in patients with vascular disease are often atherosclerotic by nature and, 
therefore, the next step will be to elucidate whether strokes in the HF population 
with vascular disease are also atherosclerotic, as this information is important when 
determining how to manage the increased risk. Additionally, as studies examining 
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vascular disease and stroke risk in the HF population have demonstrated conflicting 
results, future studies are warranted. 
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4.5. PAPER 4: DIABETES MELLITUS AND ISCHEMIC STROKE 
RISK 
Diabetes mellitus is common in patients with HF[103], and patients with diabetes 
have been demonstrated to have altered hemostasis, platelet activity, and vascular 
endothelial function contributing to a prothrombotic state[104]. In previous studies 
of patients with HF, diabetes has been associated with a higher risk of stroke and 
TE[15,87,88]. A recent study identified insulin-treated diabetes as a predictor of 
stroke in patients with HF and without AF[50]. In addition, other studies of patients 
with HF and without AF found an association between diabetes and increased risk 
of stroke and TE[69,105]. Previous non-HF studies have demonstrated that a longer 
duration of diabetes influences the risk of ischemic stroke in the form of a dose-
response relationship[79,106,107]. In addition, duration of diabetes has been 
associated with an increased risk of other cardiovascular diseases and cardio-
vascular mortality[108,109]. Whether duration of diabetes influences the stroke risk 
in patients with HF has not previously been investigated. 
In substudy 4[110], we examined diabetes as a risk factor in the context of stroke 
risk stratification in the HF population. Patients with diabetes had an increased risk 
of ischemic stroke compared to HF patients without diabetes, as shown in Table 3. 
Furthermore, a secondary analysis suggested that a longer duration of diabetes is 
associated with higher cumulative incidences of ischemic stroke, TE, and all-cause 
death. However, these associations were not as clear as expected and as seen in 
previous non-HF studies, especially not for the outcome of ischemic 
stroke[79,106,107]. Although these previous studies were not performed in HF 
populations, we would expect to find a similar association in patients with HF. 
 
Table 3. Results of ischemic stroke in substudy 4 after 1 year of follow-up. 
Exposure\Outcome Ischemic stroke 
 
Patient 
number 
Event 
number 
Absolute 
risk (%) 
Crude  
relative risk 
(95% CI) 
Adjusted 
relative risk 
(95% CI)† 
No diabetes (reference) 32,249 839 2.8 1.00 1.00 
Diabetes 7,108 277 4.1 1.49 (1.30-1.70) 1.27 (1.07-1.23) 
 
†Adjusted for sex (binary), hypertension (binary), vascular disease (binary), previous stroke/transient 
ischemic attack (binary), COPD (binary), renal disease (binary), and age (continuous). 
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Study-specific limitations 
We included only diabetes patients diagnosed in a hospital setting or treated 
pharmacologically; thus, patients treated only non-pharmacologically with no 
history of a hospital admission were not included in our study. Therefore, our study 
may not include patients with diabetes who are treated solely in general practice 
and are well controlled on diet and lifestyle. Moreover, we were not able to 
distinguish between type 1 and type 2 diabetes, two etiologically distinct diseases 
which could influence our results, but previous studies have found an increased risk 
of stroke in both subtypes[111,112]. Despite these limitations, diabetes is most 
likely associated with an increased risk of ischemic stroke and TE in the HF 
population without AF, as suggested in our and previous studies[28,87].  
The association between time since diabetes diagnosis and risk of ischemic stroke 
and TE was examined only in a secondary exploratory investigation in our study 
due to the limitations of register-based studies. The register-based proxy for the 
duration of diabetes used in our study has important limitations; it can be affected 
by delayed diagnosis, changes over time in diagnostic criteria, and changes over 
time in medical treatment. These limitations make it difficult to estimate the precise 
duration of diabetes, and thus, we might not find the correct relationship between 
the duration of diabetes and the outcomes. However, our study provides a good 
approximation of this relationship and to our knowledge is the first study examining 
this in the HF setting.  
 
Clinical considerations  
Diabetes is included as a component in the CHA2DS2-VASc score[36] and will 
possibly be useful for stroke risk stratification in HF patients. However, patients 
with diabetes are a very heterogeneous group with varying degrees of diabetes 
duration, glycemic control, and diabetic complications; thus, it may be beneficial to 
subdivide these patients according to severity of diabetes to optimize risk 
stratification. Whether duration of diabetes will further enhance the identification of 
high-risk HF patients needs to be assessed in addition to substudy 4. Additionally, 
future studies are still necessary to comprehensively examine whether longer 
duration of diabetes may further refine stroke risk stratification in the HF 
population, as we did not find a clear association in our study, perhaps due to the 
limitations of our study.   
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4.6. OTHER PUTATIVE ISCHEMIC STROKE RISK FACTORS 
Besides the risk factors evaluated in the substudies of this thesis, other possible 
stroke risk factors in the HF setting exist. As previously mentioned, the focus of this 
PhD project was to identify risk factors of ischemic stroke useful for stroke risk 
stratification in the HF population and not to examine or interpret causal 
relationships. Therefore, the following sections will present and discuss the limited 
existing literature on other possible risk factors of stroke in the HF population 
without AF, not causal associations. Components of the CHA2DS2-VASc score, not 
discussed in the four substudies, have already been evaluated in previous studies in 
relation to a HF setting. These components will be discussed in the following 
sections. Additionally, few other clinically available and HF-related risk factors will 
be deliberated.  
 
Prior thromboembolism 
Generally, ischemic stroke has a high recurrence rate both at short- and long-term 
follow-up[113,114]. In the AF population, prior stroke is associated with an 
increased risk of a new stroke event[20,115] and included as a risk factor in the 
CHA2DS2-VASc score[36]. Among patients with HF, several comorbidities are 
often present including prior stroke or TE. A few studies have reported that a prior 
stroke, TIA, or TE is a strong predictor of a recurrent stroke in patients with HF and 
without AF[28,50]. In a Danish study of patients with HF and without AF, previous 
TE appeared to be a very strong predictor of future TE; however, the end point of 
ischemic stroke alone was not evaluated[69]. In an exploratory analysis of the 
WARCEF trial (the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction 
trial), prior stroke was a risk factor for ischemic stroke in patients with HF and 
without AF[116]. Additionally, prior stroke/TIA was included as a strong predictor 
of stroke or mortality in a recent published scoring algorithm for HF patients[15]. 
As prior stroke is an accepted and well-known predictor of recurrent stroke in the 
general population, it is not surprising that this variable is also a strong predictor of 
recurrent stroke in the HF population. Thus, a history of prior stroke should be 
taken into account when assessing the stroke risk in a HF patient in clinical 
practice. Future studies examining the etiology of prior stroke in relation to 
recurrent stroke in the HF population without AF is warranted. 
 
Hypertension 
Hypertension is an established risk factor for stroke and TE in several 
cardiovascular diseases[117,118], and possibly also in the HF population. 
Additionally, hypertension is included in the CHA2DS2-VASc score[36]. Hyper-
tension and HF are common disorders seen in everyday clinical practice, and both 
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diseases are increasing in incidence and prevalence. The risk of ischemic stroke and 
TE in patients with both hypertension and HF have been evaluated in a few 
studies[21,28,69,119]. Among patients with incident HF and without AF, higher 
baseline systolic and diastolic pressure levels were associated with a higher rate of 
stroke[119]. In other studies, hypertension has been identified as a predictor of 
stroke and TE among patients with HF and without AF[21,28,69,105]. 
Additionally, a history of hypertension has been associated with an increased risk of 
hospitalization due to stroke in patients with HF and normal sinus rhythm[120]. 
Thus, the previous studies in the literature suggest that hypertension is associated 
with an increased risk of TE in HF patients and if included in a risk score would 
possibly improve the identification of high-risk subgroups in the HF population. 
 
Miscellaneous putative risk factors beyond the CHA2DS2-VASc score  
In the HF population, several other possible stroke risk factors exist, such as 
symptom severity, lifestyle factors, echocardiographic findings, laboratory 
biomarkers, etc[50,121]. Some of these risk factors have previously been identified 
as predictors of stroke in patients with HF and without AF[50]. However, future 
studies are necessary to confirm these findings. 
Today, HF is often subdivided into HF with reduced ejection fraction (HFrEF) or 
HF with preserved ejection fraction (HFpEF)[2]. An interesting question is whether 
the etiology and prevalence of stroke differ in patients with HFrEF and HFpEF, and 
thus, whether ejection fraction provides useful prognostic information regarding 
stroke risk. This issue is under debate due to inconsistent results[88,122–124]. No 
difference in embolic risk (risk of stroke, TIA, or systemic embolism) was found in 
a recent study of non-anticoagulated patients with HFrEF and HFpEF[122]. 
Similarly, in a post-hoc analysis of a study of patients with AF with HFrEF or 
HFpEF, no difference in ischemic stroke risk was found between the groups[123]. 
Oppositely, in other studies ejection fraction appeared to be independently 
associated with TE risk[15,125], and a study including women only indicated that 
the TE risk potentially differs in HFrEF and HFpEF[88]. Furthermore, an 18% 
increase in the risk of stroke for every 5% decline in ejection fraction was observed 
in another study[124]. However, both of these latter studies included patients with 
AF. The etiology of stroke in HFrEF and HFpEF without AF is still an unclear 
topic, but most likely, the etiology is closely associated with the underlying cause 
of HF[31]. With the available data in our study, we did not have information about 
ejection fraction and could not evaluate this information in relation to stroke risk. 
Thus, whether ejection fraction should be included in the assessment of a HF 
patient’s risk of ischemic stroke and TE remains to be determined.  
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HF can also be subdivided according to the functional level. The New York Heart 
Association (NYHA) functional classification is often used to grade patients with 
HF according to their symptom severity (NYHA class I-IV; where class IV is 
severe symptoms)[126]. One study of patients with HF and without AF identified 
higher NYHA class as a predictor of ischemic stroke, as they found a higher HR of 
ischemic stroke among patients with NYHA class III/IV compared with patients 
with NYHA class II[50]. We were not able to evaluate the functional classification 
with our data; thus, future studies need to comprehensively evaluate this possible 
risk factor. It would be practical to use this predictor, as HF patients are already 
assessed using the NYHA class to estimate their functional level. However, the 
functional classification may change over time and with treatments, and therefore, 
may be a challenging variable to include in risk stratification of HF patients.  
Renal disease is a frequent comorbidity in patients with HF[127,128]. Renal disease 
has been associated with an increased stroke risk in patients with AF [129,130] and  
recent investigations have examined whether it adds predictive value to the 
CHA2DS2-VASc score in the AF setting[131]. Whether this risk factor is associated 
with an increased risk of stroke and TE in HF patients without AF still needs to be 
elucidated, but this was beyond the scope of this PhD project. Before further 
evaluation has been performed, it is not possible to comment on whether renal 
disease will provide clinically useful stroke risk stratification in the HF population. 
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4.7. POTENTIAL OF STROKE RISK STRATIFICATION IN HEART 
FAILURE 
Stroke risk stratification can complement clinical reasoning, inform patients about 
their stroke risk, and guide healthcare professionals in their decision making 
regarding further management[34,35]. In the HF population, there exists a great 
potential for routine clinical stroke risk stratification to help clinicians in identifying 
high-risk subgroups. As seen in the review of the literature in the previous sections, 
the components of the CHA2DS2-VASc score may be a good starting point when 
trying to identify subgroups in the HF population with a high stroke risk. Nearly all 
the components of the CHA2DS2-VASc score are risk factors of ischemic stroke 
and TE in the HF population, with the possible exception of female sex. 
Specifically in our studies, we identified male sex, PAD, and diabetes as risk factors 
of ischemic stroke. Several other clinically available risk factors may exist beyond 
those included in the CHA2DS2-VASc score, and the impact of these additional risk 
factors on stroke risk would need further investigation, as the existing literature on 
these risk factors is sparse. Identification of high-risk subgroups is an important 
first step towards providing a basis for evidence-based clinical risk stratification for 
preventing stroke and TE among HF patients without AF. 
Compared to the CHA2DS2-VASc score, a risk score derived from data of patients 
with HF will possibly better identify high-risk subgroups, e.g., including male sex 
as a risk factor instead of female sex. However, as previously mentioned, it is more 
likely that a well-performing, formerly established risk score accepted by clinicians 
will have broader impact in clinical practice. Thus, based on our findings, the 
CHA2DS2-VASc score may have a role as a useful tool for stroke risk stratification 
of patients with HF and without AF. However, the clinical usefulness of a stroke 
risk score, such as the CHA2DS2-VASc score, in the HF population will need to be 
determined in a future well-designed randomized study, before it can be 
implemented in clinical practice. Additionally, future studies would need to 
examine how to handle patients who are categorized in a high-risk subgroup.  
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4.8. METHODOLOGICAL CONSIDERATIONS 
The four substudies described in the previous sections were designed as prospective 
population-based cohort studies using historical data. All study populations of the 
four substudies were drawn from the same Danish HF population. Figure 2 shows a 
combined flowchart of all four substudies with the number of patients excluded in 
each substudy and the final study populations. The major strengths of these register-
based nationwide studies were the large sample size, population-based coverage, 
and virtually complete follow-up of all patients, which reduce the risk of selection 
bias. 
The study population in the four substudies consisted of patients with an incident 
diagnosis of HF. It is known that the stroke risk is higher in the first six months 
after diagnosis of HF[28] and, therefore, our results may demonstrate higher risks 
than found in other studies of HF patients. Furthermore, we investigated a real-life 
population using nationwide registries where we did not exclude the severely ill 
patients (as typically done in clinical trials); thus, our study population includes HF 
patients with several comorbidities predisposing for stroke events and again our 
event rates may be higher than those seen in clinical trials.  
We only included patients aged >50 years, as HF in persons aged <50 years might 
represent a different group of patients, for example patients with congenital heart 
disease. Accordingly, our findings might not apply to younger HF patients. 
Additionally, our study population was ethnically non-diverse, since we 
investigated a Danish HF population which has a relatively stable and homo-
geneous demography[53], and therefore, our study results might not be 
generalizable to more diverse HF populations. 
Patients with any diagnosis of cancer (ICD-10: C00-C97) within 5 years before HF 
diagnosis were excluded from the study population, since cancer patients represent 
a subgroup with high stroke risk and specialized thromboprophylactic treatment 
regimens[132]. You could argue that not all cancer types should prompt exclusion 
(e.g., patients who had a total prostatectomy done or patients with curative skin 
cancer); however, this distinction would be debatable. For the purpose of our study, 
we chose to exclude all patients with any cancer diagnosis within 5 years before HF 
diagnosis. 
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Limitations of Danish nationwide registries for studies in heart failure 
The use of the Danish nationwide registries in research entails some limitations. 
The following factors affect the value of register-based data in research: 1) 
completeness of registration of individuals, 2) the accuracy and degree of 
completeness of the registered data, 3) data accessibility and availability, and 4) 
possibilities of linkage with other data sources (record linkage)[54].  
The diagnoses in the registries may not be complete or accurate. The diagnosis of 
HF in the Danish National Patient Registry has previously been validated with a 
sensitivity of 29%, a specificity of 99%, and a positive predictive value (PPV) of 
81-84%[133,134]; thus, we did not capture all patients with HF and also cannot be 
certain that all patients identified as having HF had definite HF which could lead to 
imprecision in the risk estimates. However, as the specificity of the HF diagnosis 
was 99%, a more strict definition of HF will most likely not be necessary. The low 
sensitivity of 29% may reflect the inclusion of patients mainly with more severe 
HF. In this case, risk estimates obtained in this population may not apply to patients 
with less severe HF.  
When using ischemic stroke as a primary outcome in a Danish register-based study, 
the outcome will be estimated using codes (ICD-10: I63, I64) in the Danish 
Patients diagnosed 
with heart failure 
(2000-2012) 
Study 1: 68,463 
Study 2: 151,415 
Study 3: 72,618 
Study 4: 72,618 
Excluded: 
- Invalid data: Study 1: 516; Study 2: 1,050; Study 3+4: 560  
- Date of death equal to date of heart failure diagnosis:  
                       Study 1: 604; Study 2: 1,331; Study 3+4: 580 
- Age<50 years: Study 1+2: NA; Study 3+4: 4,186  
- Atrial fibrillation or atrial flutter:  
                       Study 1: Included; Study 2: 46,256; Study 3+4: 18,136 
- Cancer prior to heart failure diagnosis:  
                       Study 1: 5,171; Study 2: 10,579; Study 3+4: 4,272 
- Anticoagulant therapy within 6 months prior to diagnosis:  
                       Study 1: 10,667; Study 2: 6,752, Study 3+4: 5,527 
- Valvular disease or mechanical cardiac valve: Study 2: 1,303 
- Chronic obstructive pulmonary disease: Study 1: 8,518 
Study 4: 
39,357 heart 
failure patients 
defining the 
study 
population 
 
Study 3: 
39,357 heart 
failure patients 
defining the 
study 
population 
 
Study 2: 
84,142 heart 
failure patients 
defining the 
study 
population 
 
Study 1: 
42,987 heart 
failure patients 
defining the 
study 
population 
 
Figure 2. Combined flowchart of the four sub-studies. 
Figure 2. Combined flowchart of the four substudies. 
31 
National Patient Registry. As the end point depends on a diagnosis in the registry, it 
cannot be ruled out that some of the strokes might have been hemorrhagic strokes 
and thus, misclassified as ischemic strokes. In 2007, a validation study of the 
diagnosis of ischemic stroke in the Danish National Patient Registry found a PPV 
of approximately 97%[135]. Here, the number of subjects suffering from any stroke 
showed a tendency towards an overestimation in this registry, but the majority of 
the diagnoses of unspecified strokes were estimated to be of ischemic origin, 
indicating that the number of ischemic strokes seems to be underestimated. Thus, it 
may be reasonable to include unspecified stroke in the definition of ischemic stroke, 
as we did in our studies. In a review of the validity of diagnostic stroke codes in 
administrative databases from different countries[136], the diagnosis of ischemic 
stroke had a PPV of ≥82%. Thus, when using the registries the number of stroke 
events must be interpreted with caution, as it may be overestimated. Oppositely, 
some patients have fatal strokes and are therefore never admitted to a hospital, 
which underestimates the number of stroke events. One option to take into account 
the possible missing stroke events is to include deaths due to a TE in the outcome 
definitions, for example by using data from the Danish Register of Causes of 
Death[137–139]. However, in Denmark less than 10% of deceased have an autopsy 
performed, which impedes the usefulness of these data[138]. 
In studies of patients with HF and without AF, it is possible to exclude patients with 
a diagnosis of AF at baseline in the registries. A small validation study of the AF 
diagnosis in the Danish National Patient Registry found a positive predictive value 
of 99%[140]. However, not all patients with diagnosed AF are coded in the 
National Patient Register, as some patients are managed solely in general practice. 
Thus, some patients may be misclassified as non-AF patients in our study. Although 
not as important in the setting of our studies, it cannot be ruled out that some 
patients might have undiagnosed AF, since heart disease is associated with an 
increased risk of developing AF[141]. Among patients with HF who have 
experienced a stroke, about one-half have been reported to have AF[31]. To take 
into account the possibility that some patients would not be diagnosed with AF until 
weeks after the diagnosis of HF, we repeated the absolute and relative risk 
calculations after extending the definition of concomitant AF in substudy 1 and 4 
and found very similar results as in the main analyses. Patients may also develop 
AF during follow-up. This is not really a concern when examining the possibility of 
risk stratification, as in clinical practice we do not know whether or not a patient 
will develop AF in the future. Nonetheless, in substudy 1, 3, and 4 we did a 
sensitivity analysis censoring patients with HF who were diagnosed with AF during 
follow-up and found similar results as in the main analysis of each substudy. 
However, inclusion of patients with AF in the assumed HF without AF population 
may overestimate the absolute risk of stroke in such patients, as AF is a well-known 
risk factor of stroke[142]. The diagnoses of PAD, prior MI and diabetes mellitus 
were also found to be reasonably valid in the Danish National Patient 
Registry[140,143,144]. 
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Data availability and accessibility may also be a problem when using register-based 
data, as the data collection has already been performed. For example, the Danish 
nationwide registries do not contain information about echocardiographic findings, 
and thus, it is not possible to distinguish between HF with preserved or reduced 
ejection fraction or to estimate the functional level (or NYHA class). Lifestyle 
factors, such as smoking habit, alcohol intake, physical activity, and BMI, are also 
inaccessible information, which could be an important limitation when investigating 
different risk factors and ischemic stroke risk. However, if the focus of a study is on 
the prognostic value of a risk factor in relation to ischemic stroke in the context of 
the CHA2DS2-VASc score (as in our studies), and not its causal role, confounding 
by other known stroke risk factors is not an issue of concern. We investigated 
whether different exposures were associated with ischemic stroke in patients with 
HF. Therefore, we adjusted for components of the CHA2DS2-VASc score, COPD 
(as some COPD patients may be misclassified as HF patients, possibly due to 
undistinguishable symptoms, which could potentially distort the investigated 
associations), and renal disease (as renal disease has been associated with an 
increased stroke risk in other patient groups[129,130] and, possibly, is also a risk 
factor of stroke in the HF population). This was not an attempt to adjust for 
confounding and hereby explore the potential causal relationship between the 
exposure and ischemic stroke, but to elucidate the potential predictive ability of the 
exposure for risk stratification in patients with HF, after adjustment for other 
possible risk factors. Careful considerations of how to deal with potential 
differences between exposed and non-exposed during follow-up are necessary to 
avoid distortions of the association in focus. 
Baseline medications in Danish register-based studies are based on claimed 
prescriptions in the Danish National Prescription Registry. Therefore, it is unknown 
whether each patient will actually take the medication, and compliance is an 
important factor. With our register-based data, information about individual over-
the-counter medications is not available. However, the potential for identifying, for 
example, aspirin use from prescription registries in Denmark is high, and only a 
very low proportion is sold over-the-counter[145]. Differences in antithrombotic 
treatment between exposed and non-exposed may distort the ‘natural’ associations 
if not taken into account; therefore we adjusted for antiplatelet therapy in substudy 
3, as antiplatelet therapy may especially warp the association between vascular 
disease and stroke risk. 
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CHAPTER 5. REFLECTIONS ON THE 
FUTURE MANAGEMENT OF HIGH-
RISK HEART FAILURE PATIENTS 
After having identified high-risk subgroups within the HF population without AF, 
the next obvious question is how to handle these high-risk patients. It is tempting to 
direct the attention towards antithrombotic therapy; however, regarding stroke 
prevention in the HF population the relevance of antithrombotic therapy is 
controversial[17,19,29,146]. Today, cardiovascular international guidelines only 
recommend anticoagulant therapy in HF patients with concomitant AF, unless 
contraindicated[2,12,147]. Some guidelines also recommend anticoagulation in HF 
patients who have previously experienced a TE[12,147] or in the setting of a left 
ventricular thrombus[147,148]. A summary of recommendations for anticoagulant 
therapy in patients with HF is shown in Table 4. In HF patients without AF, 
antiplatelet therapy is only recommended in patients known to have coronary artery 
disease or prior MI[12]. Whether high-risk HF patients without AF or prior TE 
stand to gain from antiplatelet or anticoagulant therapy with either a vitamin K 
antagonist or one of the non-vitamin K antagonist oral anticoagulants (NOACs) is 
still unsettled.  
 
Thromboprophylaxis in subgroups of patients with heart failure 
Recently, the benefit of thromboprophylactic therapy in subgroups of patients with 
HF and without AF has been discussed[87,149]. We have identified subgroups in 
the HF population with an increased risk of ischemic stroke. However, we did not 
examine whether the identified high-risk subgroups would benefit from 
thromboprophylaxis or which thromboprophylaxis is most relevant in each 
subgroup of patients with HF and without AF. Therefore, the identified high-risk 
subgroups may provide new avenues for future randomized trials studying the 
effect of, for example, antithrombotic therapy in the HF population. However, the 
etiology of ischemic stroke may vary in HF patients with different co-
morbidities[31], and thus, the effect of antithrombotic therapy, lipid-lowering 
drugs, or other thromboprophylactic strategies may differ across these subgroups of 
HF patients – an important aspect to take into consideration. 
Patients with HF often have concomitant artery disease and, thus, are at high risk of 
atherothrombotic events. As described in the literature, these patients should receive 
appropriate antiplatelet therapy, as around 50% of cases of sudden cardiac death in 
HF are related to coronary atherothrombosis[16]. However, this patient group 
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possibly still has an increased risk of ischemic stroke and TE due to 
cardioembolism. As suggested by our results, a large proportion of patients with 
PAD were treated with an antiplatelet agent, but still had a moderately high 1-year 
absolute ischemic stroke risk, suggesting that this patient group may benefit from 
more thromboprophylaxis[149]. We did not see a similar increased rate of ischemic 
stroke among patients with prior MI, where an even greater proportion was treated 
with an antiplatelet agent. Our findings in the subpopulation of patients on 
antiplatelet therapy were consistent with the hypothesis of more intensified 
treatment and prophylaxis among MI patients, since patients on antiplatelet therapy 
with prior MI or no vascular disease had essentially the same rate of ischemic 
stroke. However, it was not the aim of the study to test this hypothesis; hence, 
future studies need to examine this. We did not examine which thromboprophylaxis 
is most relevant in patients with HF and vascular disease; therefore, statements 
about drug effects and preventive strategies in this subgroup of patients with HF are 
not justifiable with our data and the next step will be to elucidate the causal 
relations and the relevance of different treatment options in future studies.  
The ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases from 
2013 recommend antiplatelet therapy as secondary prevention in patients with 
diabetes at high risk of cardiovascular events[150]. In our study, we found a high 
absolute risk of TE, even though a large proportion of the study population was on 
antiplatelet therapy, indicating that more prophylaxis may be necessary. Previous 
studies of HF patients without AF and with concomitant diabetes only found a 
stroke risk high enough to possibly justify anticoagulation if other comorbidities 
were present simultaneously[28,87]. In our study population of HF patients with 
diabetes, other comorbidities were commonly present. This may indicate that in HF 
patients without AF but with concomitant diabetes in combination with other 
comorbidities, oral anticoagulation could be justifiable[87]. However, this 
speculation would need confirmation in prospective randomized trials. 
As previously mentioned, patients with HF and without AF who have formerly 
experienced a TE or have a left ventricular thrombus are recommended anti-
coagulant therapy in many guidelines[12,147,148,151]. For other subgroups in the 
HF population without AF, such as patients with hypertension or advanced age, the 
potential benefit from antithrombotic therapy is unknown. Regarding age, one 
explorative subgroup analysis has been performed in a post hoc analysis of patients 
younger and older than 60 years of age[152]. Younger patients benefited from 
warfarin over aspirin on the primary outcome (time to ischemic stroke, intracerebral 
hemorrhage, or death), whereas in older patients the different therapies did not 
differ with respect to the outcome. However, for the end point of ischemic stroke 
alone, both patients below and above 60 years of age demonstrated lower event 
rates when assigned to receive warfarin compared with aspirin. Additionally, the 
risk of stroke has been demonstrated to be highest during the first six months after 
the HF diagnosis and then attenuates over time[22,28], thus, short-term 
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anticoagulant therapy may be a solution[153]. Still, future trials are necessary 
before recommendations about antithrombotic therapy in subgroups of HF patients 
can be implemented in international guidelines. Furthermore, as AF is a common 
comorbidity among patients with HF and a strong risk factor for stroke, some 
events may be due to undiagnosed AF. Therefore, an important approach in the HF 
population without AF is to be aware of silent AF, e.g., by introducing AF 
screening programs in this population[153].  
 
Table 4. Recommendations for anticoagulant therapy in heart failure from selected guidelines. 
Guideline Recommendations 
Level of 
evidence 
HF patients 
without AF 
Level of 
evidence 
ACC/AHA 
[12] 
Anticoagulation is 
recommended for patients 
with chronic HF and AF 
(permanent/persistent/ 
paroxysmal) and an additional 
risk factor for cardioembolic 
stroke (history of 
hypertension, diabetes 
mellitus, previous stroke or 
TIA, or age ≥75 years). 
Chronic anticoagulation is 
reasonable for patients with 
chronic HF who have AF 
(permanent/persistent/ 
paroxysmal) but do not have 
any additional risk factor for 
cardioembolic stroke. 
A 
 
 
 
 
B 
Anticoagulation is not 
recommended in 
patients with chronic 
HF with reduced EF 
without AF, a prior TE, 
or a cardioembolic 
source. 
B 
ESC 
[2] 
Anticoagulation is 
recommended for all patients 
with HF and AF 
(permanent/persistent/ 
paroxysmal) and a CHA2DS2-
VASc score ≥1, without 
contraindications, and 
irrespective of whether a rate- 
or rhythm-management 
strategy is used. 
A Other than in patients 
with HF with AF (both 
HF with reduced and 
preserved EF), there is 
no evidence that an oral 
anticoagulant reduces 
mortality-morbidity 
compared with placebo 
or aspirin. 
NA 
HFSA 
[147] 
Anticoagulation is 
recommended for all patients 
with HF and chronic or 
documented AF 
(permanent/persistent/ 
paroxysmal), unless 
contraindicated. 
Anticoagulation is 
recommended for all patients 
with HF and a history of 
systemic or pulmonary 
emboli, including stroke or 
TIA, unless contraindicated. 
A 
 
 
C 
HF patients with a 
recent large anterior MI 
with symptomatic or 
asymptomatic ischemic 
cardiomyopathy is 
recommended 
anticoagulation for a 3-
month period post-MI. 
B 
Abbreviations: ACC = American College of Cardiology; AF = Atrial fibrillation; AHA = American Heart Association; EF = Ejection 
fraction; ESC = European Society of Cardiology; HF = Heart failure; HFSA = Heart Failure Society of America; MI = Myocardial 
infarction; TE = Thromboembolic event; TIA = Transient ischemic attack. 
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Considerations for routine use of antithrombotic drugs in heart failure 
Looking at the possibilities of antithrombotic therapy in a more critical aspect; 
would it be well worth to even consider starting anticoagulant therapy in a 
population with a very high mortality rate? This is a difficult question to answer. 
Some deaths are likely to be attributable to undiagnosed stroke. A previous study 
suggested that anticoagulation may reduce mortality in patients with impaired left 
ventricular function[154]. Here, the reduction in all-cause mortality was suggested 
to be mainly driven by a reduction in cardiac mortality[154]. However, in another 
recent study, anticoagulation did not reduce mortality in patients with HF and in 
sinus rhythm[155]. Likewise, in other trials of patients with HF and without AF the 
rates of death were similar with warfarin and aspirin, a finding that is consistent 
with the lack of an effect of anticoagulants on mortality in patients with HF[156–
158]. The lack of an effect of warfarin on mortality may suggest that most deaths in 
patients with HF who had severe impairment of left ventricular function are 
unrelated to TE and, instead, are most likely due to pump failure or ventricular 
arrhythmias[149]. Additionally, the risk of stroke in the HF population is modest, 
unless comorbidity is present, and therefore, the absolute stroke risk reduction with 
anticoagulation may also be modest. Thus, together with the probable lack of 
mortality benefit the absolute gain of anticoagulant therapy may only be justifiable 
in subgroups of HF patients who have a high stroke risk, such as in those with one 
or several comorbidities predisposing for stroke. However, it would be interesting 
to investigate the proportion of patients with HF who die from an ischemic stroke or 
TE or due to consequences of these events.  
Another important issue to take into account is the risks and adverse effects of 
antithrombotic therapy[159]. Besides a number of factors influencing quality of life 
in patients using anticoagulant therapy, bleeding is a major adverse effect of 
anticoagulation. Although anticoagulant therapy was found to reduce the risk of 
ischemic stroke in previous trials of HF populations, it also caused increased risk of 
major bleeding, possibly since many risk factors are shared by both of these adverse 
outcomes[155,160]. In a recent randomized trial, however, the rate of the most 
feared type of bleeding, intracranial bleeding, did not differ between patients treated 
with warfarin and patients treated with aspirin, but the rate of major gastrointestinal 
bleedings was almost doubled in the warfarin group compared with the aspirin 
group[155]. Among anticoagulated patients with AF, use of the HAS-BLED score 
(Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or 
Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly, based on 9 
possible points) is recommended to assess the bleeding risk[20,159]. If a patient has 
a HAS-BLED score ≥3, then the risks and benefits of anticoagulant therapy should 
be individually considered, and therapy will require regular monitoring to ensure 
effectiveness[161]. The HAS-BLED score is not meant to establish contra-
indications for anticoagulation, but is rather used to estimate the bleeding risk in 
anticoagulated patients. Whether the HAS-BLED score can predict bleeding risk 
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among anticoagulated patients with HF and without AF has recently been 
investigated[162]. The authors found that the HAS-BLED score predicts bleeding 
risk in anticoagulated patients with HFrEF in sinus rhythm. These findings in 
combination with our findings in substudy 1 suggest that the CHA2DS2-VASc score 
together with the HAS-BLED score could possibly be used to identify HF patients 
with a low or high stroke risk and a possibly favorable risk/benefit profile for 
anticoagulant therapy. However, this would need confirmation in future randomized 
trials.  
If anticoagulation is not the optimal choice of antithrombotic therapy, antiplatelet 
therapy may be considered. Currently no data exist to support routine use of aspirin 
or other antiplatelet therapies in all patients with HF[2,12,147,151,158]. 
Antiplatelet therapy should in most cases be used in patients with atherosclerotic 
vascular disease[27,147]. However, in some studies of patients with HF, aspirin use 
has been associated with adverse outcomes, such as hospitalization for worsening 
HF[158,160], bleedings[158,160], serious gastrointestinal events[158], and 
pharmacological attenuation of the cardiovascular protective effect of angiotensin-
converting enzyme inhibitor[163,164], an important agent in HF therapy. 
Additionally, aspirin resistance may occur more often in patients with HF[165]. 
Nonetheless, aspirin use has also been associated with a lower mortality in patients 
with left ventricular dysfunction and HF[163,166]. It is not the scope of this section 
to go into the discussion of possible adverse and beneficial effects of antiplatelet 
therapy in HF patients, but just to emphasize that antiplatelet therapy is also 
associated with clinical problems and the benefit of this thromboprophylactic 
therapy in patients with HF is controversial. 
 
Non-vitamin K antagonist oral anticoagulants in heart failure 
To overcome some of the limitations of standard anticoagulant therapy with 
warfarin such as food and drug interactions, frequent laboratory monitoring, and 
dose adjustments, the NOACs have been developed[167,168]. Yet, the role of the 
NOACs in patients with HF and without AF is unclear. An ongoing trial 
(COMMANDER HF)[169] explores the efficacy and safety of one of the NOACs, 
rivaroxaban, compared with placebo (standard care) after an exacerbation of HF in 
non-AF patients with HFrEF and documented coronary artery disease. This trial is 
expected to conclude in April 2017. However, additional trials examining the net 
clinical benefit of the NOACs in the HF population without AF is warranted, 
especially in specific high-risk subgroups within the HF population. 
Even though these newer anticoagulants overcome some of the limitations of 
warfarin, one important limitation of the NOACs may particularly influence the 
potential use in HF patients. Several NOACs are predominantly eliminated renally, 
and therefore, their use is limited in patients with renal insufficiency[170,171]. 
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Since renal and liver dysfunctions are common in patients with HF, the 
pharmacokinetic properties of the NOACs may impact the possibilities of these 
agents in a large proportion of patients with HF. A recent study has demonstrated 
that dose adjustment may be necessary when using NOACs in patients with AF and 
HF and concomitant renal impairment[172]. Future clinical trials, besides the 
COMMANDER HF trial, are warranted to elucidate the possibilities and safety of 
the NOACs in HF patients without AF.  
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CHAPTER 6. PERSPECTIVES AND 
CONCLUDING REMARKS  
The research contained in this PhD thesis has contributed to the identification of the 
individual and collective importance of a number of risk factors for ischemic stroke 
and TE in patients with HF and without AF. The identification of high-risk 
subgroups is an important first step towards providing a basis for evidence-based 
clinical risk stratification for preventing stroke and TE among HF patients without 
AF.  
We used the components of the CHA2DS2-VASc score as a starting point and 
identified male sex, PAD, and diabetes as risk factors of ischemic stroke. 
Previously, age, hypertension, and prior stroke have also been identified as stroke 
risk factors in the HF population without AF. We focused on the risk factors 
included in the CHA2DS2-VASc score, which are available for the clinician in daily 
clinical practice. These risk factors may provide the basis for a simple and 
recognizable approach to stroke risk stratification in the HF population, since the 
CHA2DS2-VASc score has been almost globally endorsed for use in AF patients. 
However, not all the individual components of the CHA2DS2-VASc score have 
been identified as established risk factors for ischemic stroke in the HF population 
without AF. Previous studies have even showed that some of these components are 
associated with a decreased ischemic stroke risk. Therefore, future studies are still 
necessary to confirm the results of our studies. Also, several other clinically 
available risk factors may exist beyond those included in the CHA2DS2-VASc 
score, and the impact of these additional risk factors would also be an area of 
interest for future research; for example, whether the stroke risk differs in patients 
with HFrEF and HFpEF, and whether the stroke risk increases with reduction in 
ejection fraction, which we were not able to investigate with our data. Similarly, as 
we excluded patients under 50 years of age, because the prevalence and 
contribution of the various stroke risk factors in this small subgroup are likely to be 
different from the typical elderly HF patient, our findings might not be 
generalizable to younger HF patients. Thus, future studies will need to examine this 
patient group separately.  
We found that the CHA2DS2-VASc score was able to modestly predict patients with 
a high and low risk of ischemic stroke and TE. Whether a modified CHA2DS2-
VASc score, including or substituting with other risk factors, will perform better 
than the original score still needs to be explored in future studies. Additionally, the 
clinical usefulness of a stroke risk score, e.g., the opportunity to identify subgroups 
of HF patients suitable for antithrombotic treatment using the CHA2DS2-VASc 
score, remains to be determined in a randomized controlled study. 
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Currently, the choice of antithrombotic medication in the HF population without AF 
should be made on a patient-by-patient basis and depends on a careful risk/benefit 
discussion between the patient and the clinician, especially among high-risk 
patients. Anticoagulant therapy prevents strokes, most likely embolic strokes, in 
patients with HF and without AF who have severe systolic dysfunction; but the 
general stroke rate is too low to justify the routine clinical use of anticoagulation in 
all patients with HF in the light of the increased risk of bleeding. Preventative 
strategies may be particularly relevant among high-risk subgroups, but whether full 
anticoagulant therapy would be beneficial in reducing the risk without increasing 
the risk of bleeding, that is, to yield a net clinical benefit in these patients, needs to 
be tested in an appropriately designed randomized controlled trial including high-
risk patients potentially defined by a high CHA2DS2-VASc score. 
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Assessment of the CHA2DS2-VASc Score in Predicting
Ischemic Stroke, Thromboembolism, and Death in Patients
With Heart FailureWith andWithout Atrial Fibrillation
Line Melgaard, MSc; Anders Gorst-Rasmussen, MSc, PhD; Deirdre A. Lane, PhD;
Lars Hvilsted Rasmussen, MD, PhD; Torben Bjerregaard Larsen, MD, PhD; Gregory Y. H. Lip, MD
IMPORTANCE The CHA2DS2-VASc score (congestive heart failure, hypertension, age$75
years [doubled], diabetes, stroke/transient ischemic attack/thromboembolism [doubled],
vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age
65-75 years, sex category [female]) is used clinically for stroke risk stratification in atrial
fibrillation (AF). Its usefulness in a population of patients with heart failure (HF) is unclear.
OBJECTIVE To investigate whether CHA2DS2-VASc predicts ischemic stroke,
thromboembolism, and death in a cohort of patients with HF with and without AF.
DESIGN, SETTING, AND POPULATION Nationwide prospective cohort study using Danish
registries, including 42 987 patients (21.9%with concomitant AF) not receiving
anticoagulation whowere diagnosed as having incident HF during 2000-2012. End of
follow-up was December 31, 2012.
EXPOSURES Levels of the CHA2DS2-VASc score (based on 10 possible points, with higher
scores indicating higher risk), stratified by concomitant AF at baseline. Analyses took into
account the competing risk of death.
MAIN OUTCOMES ANDMEASURES Ischemic stroke, thromboembolism, and deathwithin 1 year
after HF diagnosis.
RESULTS In patients without AF, the risks of ischemic stroke, thromboembolism, and death
were 3.1% (n = 977), 9.9% (n = 3187), and 21.8% (n = 6956), respectively; risks were greater
with increasing CHA2DS2-VASc scores as follows, for scores of 1 through 6, respectively:
(1) ischemic stroke with concomitant AF: 4.5%, 3.7%, 3.2%, 4.3%, 5.6%, and 8.4%; without
concomitant AF: 1.5%, 1.5%, 2.0%, 3.0%, 3.7%, and 7% and (2) all-cause death with
concomitant AF: 19.8%, 19.5%, 26.1%, 35.1%, 37.7%, and 45.5%; without concomitant AF:
7.6%, 8.3%, 17.8%, 25.6%, 27.9%, and 35.0%. At high CHA2DS2-VASc scores ($4), the
absolute risk of thromboembolismwas high regardless of presence of AF (for a score of 4,
9.7% vs 8.2% for patients without and with concomitant AF, respectively; overall P<.001 for
interaction). C statistics and negative predictive values indicate that the CHA2DS2-VASc score
performedmodestly in this HF population with and without AF (for ischemic stroke, 1-year
C statistics, 0.67 [95% CI, 0.65-0.68] and 0.64 [95% CI, 0.61-0.67], respectively; 1-year
negative predictive values, 92% [95% CI, 91%-93%] and 91% [95% CI, 88%-95%],
respectively).
CONCLUSIONS AND RELEVANCE Among patients with incident HFwith or without AF, the
CHA2DS2-VASc score was associated with risk of ischemic stroke, thromboembolism, and
death. The absolute risk of thromboembolic complications was higher among patients
without AF compared with patients with concomitant AF at high CHA2DS2-VASc scores.
However, predictive accuracy wasmodest, and the clinical utility of the CHA2DS2-VASc score
in patients with HF remains to be determined.
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H
eart failure (HF) is associated with an increased risk
of ischemic stroke and mortality, whether in sinus
rhythmor atrial fibrillation (AF).1-5Risk stratification
using readily available clinical variablesmayhelp identify sub-
groups at low and high risk of ischemic stroke and thrombo-
embolic events (TE) in an HF population.
Simple clinical risk scores have been useful in other
settings such as in patients with AF, for example, the
CHA2DS2-VASc score (congestive heart failure, hypertension,
age ≥75 years [doubled], diabetes, stroke/transient ischemic
attack/thromboembo-
lism [doubled], vascular
disease [prior myocardial
infarction, peripheral ar-
tery disease, or aortic
plaque], age 65-74 years,
sex category [female]),
which is recommended in
current guidelines (based
on10possiblepoints,with
higher scores indicating higher risk).6,7 In recent years, use of
the CHA2DS2-VASc score in predicting ischemic stroke, TE,
and death has extended beyond the original disease state for
which itwas proposed.8,9 In addition, it is recognized that the
cluster of multiple stroke risk factors included within the
CHA2DS2-VASc score increases the risk of ischemic stroke, TE,
and death,whether or not AF is present. Thus, there is a need
to study theextent towhich concomitantAFmodifies thepat-
tern of the association between CHA2DS2-VASc score and the
risk of ischemic stroke, TE, and death in patients with HF.
Evaluating an ischemic stroke andTE risk score in apopu-
lation with a high mortality rate such as the HF population
(5-yearmortality of 45%-60%)10,11 is not trivial because a com-
peting-risks setting taking careful consideration of the inter-
play betweenmortality and ischemic stroke/TE risk is needed
to provide meaningful risk assessments.12,13
Wehypothesized that theCHA2DS2-VASc score couldpre-
dict ischemic stroke, TE, and death in patients with HFwith-
out AF in amanner comparablewith that evident inAFpopu-
lations. We hypothesized that at high CHA2DS2-VASc scores,
the riskwouldbecomparablebetweenpatientswithandwith-
out AF.
Methods
Registry Data Sources
We used 3 nationwide registries in this study: (1) the Danish
National Patient Register,14 which has registered all hospital
admissions alongwith diagnoses since 1977 andhas coded all
diagnoses according to the International Statistical Classifica-
tion of Diseases and Related Health Problems, Tenth Revision
(ICD-10) since 1994; (2) the Danish National Prescription
Registry,15 which contains data on all prescriptions dis-
pensed fromDanish pharmacies since 1994, coded according
to the Anatomical Therapeutic Chemical (ATC) Classification
System; and (3) the Danish Civil Registration System, which
holds informationondateofbirth,migration, vital status, date
of death, and sexof all persons living inDenmark.16Datawere
linkedvia a uniquepersonal identificationnumber used in all
Danish national registries. All 3 registrieswere used up toDe-
cember 31, 2012 (end of follow-up). These registries have pre-
viouslybeenwell validated,14,15,17and thediagnosesofHF,AF,
and ischemic stroke have been found to be valid.17-19
No ethical approval is required for anonymous register
studies in Denmark. The study was approved by the Danish
Data Protection Agency.
Study Population
The studypopulationwas identified as patients aged 50years
or older discharged with a primary diagnosis of incident HF
(ICD-10 codes I50, I42.0, I11.0, I13.0, and I13.2) in the period
January 1, 2000, toDecember 31, 2012. PatientswithAFwere
identifiedby ahospital diagnosis ofAFor atrial flutter (ICD-10
code I48) between 1994 and baseline. We excluded patients
treatedwith a vitamin K antagonist (ATC codes B01AA03 and
B01AA04) within 6 months prior to the HF diagnosis. More-
over, patients with a diagnosis of cancer (ICD-10 codes
C00-C97) within 5 years before HF diagnosis or with a prior
diagnosis of chronic obstructive pulmonary disease (COPD
[ICD-10 code J44]) were excluded.
Comorbidities at baselinewere identifiedusing theDanish
National Patient Register and the Danish National Prescrip-
tionRegistry.Ascertainmentofbaselinemedicationstatuswas
based on medication purchase in a 45-day window before or
after thedateofHFdiagnosis. ICD-10codesandATCcodeswere
used to define comorbidities andmedical therapies (eTable 1
in the Supplement).
Risk Stratification Using CHA2DS2-VASc Score
Basedon theCHA2DS2-VASc score, patientswere given 1 point
for congestive HF, hypertension, age 65 to 74 years, diabetes
mellitus, vascular disease, and female sex and2points for age
75 years or older and previous TE.20 Accordingly, a score of 1
in our analyses corresponds to patients with HF only and no
additional stroke risk factors.
Outcomes
The primary end point was defined as a hospital diagnosis
(according to the Danish National Patient Register) of ische-
mic stroke (ICD-10 codes I63 and I64.9) or TE (ischemic stroke
[ICD-10 codes I63and I64.9], transient ischemicattack [ICD-10
code G45], systemic embolism [ICD-10 code I74], pulmonary
embolism [ICD-10 code I26], or acute myocardial infarction
[ICD-10 codes I21 and I23]). All-cause death (according to the
Danish Civil Registration System) was included as a second-
ary end point.
Statistical Analysis
Baseline characteristics at the time of HF diagnosis were de-
scribed using means and standard deviations for continuous
measures and percentages for categoricalmeasures (Table 1).
Time-to-event analysis was used to describe the associa-
tion between the CHA2DS2-VASc score and the risk of ische-
mic stroke, TE, and death, separately within the strata of pa-
tients withHFwith andwithout a prior diagnosis of AF. Time
AF atrial fibrillation
COPD chronic obstructive pulmonary
disease
HF heart failure
ICD-10 International Statistical
Classification of Diseases and Related
Health Problems, Tenth Revision
NPV negative predictive value
TE thromboembolism
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at risk was measured from the date of HF diagnosis until an
event of ischemic stroke or TE, date of death, emigration, or
end of study (December 31, 2012), whichever came first. Pa-
tientswere censored if theybegan anticoagulant therapydur-
ing the follow-up period.
To enable comparison with other studies, we first calcu-
lated crude incidence rates of end points, stratified accord-
ing to presence of concomitant AF. However, for the purpose
of risk stratification, particularly in the context of competing
risks, absolute risks (cumulative incidences/probabilities)
are more relevant.12,13 We calculated absolute risks for all
end points using the Aalen-Johansen estimator21 to take into
account competing risks of death. Relative risks according to
CHA2DS2-VASc score (relative to a CHA2DS2-VASc score of 1)
were also calculated using the pseudovalue method to take
into account competing risks of death.22,23 The pseudovalue
method reduces to simple regression with a log-link func-
tion on the event status indicator in the absence of censor-
ing, whereas censored observations (for which the event sta-
tus is not observed) are replaced with pseudo-observations
based on Aalen-Johansen cumulative incidence estimates
using the jackknife method. These methods have not been
validated but are described in previous literature.24,25
Wald P values for interactions on a risk ratio scale were used
to quantify whether the overall association between
CHA2DS2-VASc score and outcome risk differed between
patients with and without AF.
To quantify the discriminatory properties of the
CHA2DS2-VASc score, we used C statistics for each end
point. This well-known measure of discrimination can be
interpreted as the probability that a randomly selected
patient who experiences the event of interest before a given
time has a higher risk score than a control patient who does
not experience an event before a given time. Because of com-
peting risks of death, there are several valid definitions of
control patients (alive and event free; alive and event free or
dead) leading to different interpretations.24,25 We used as
controls patients who were alive and event free at 1- and
5-year follow-up and used the inverse-probability-of-
censoring weighted estimator (assuming censoring and event
times to be independent given CHA2DS2-VASc score).
24,25
Bootstrap confidence intervals for the C statistics were calcu-
lated using 1000 bootstrap samples. Furthermore, with the
same definition of controls, we estimated for each end point
the negative predictive value (NPV) of the CHA2DS2-VASc
score with 1 as the cutoff; ie, the proportion of patients with
CHA2DS2-VASc score = 1 who were alive and without the end
point of interest at 1- and 5-year follow-up.
Sensitivity analysiswas performed by repeating the abso-
lute and relative risk calculations when extending the defini-
tion of concomitant AF at baseline to presence of a prior diag-
nosisofAFatbaselineorwithin30daysafterHFdiagnosis.This
sensitivityanalysiswasperformedbecausesomepatientsmight
have a diagnosis of AF shortly after the HF diagnosis. Addi-
tionally, approximately 14% had a diagnosis of AF during 5
years of follow-up; thus, we performed another sensitivity
analysis by repeating the absolute and relative risk calcula-
tions in the non-AF group after censoring patients who were
diagnosed as having AF during follow-up. Moreover, a split
sampleanalysisaccording toearly (2000-2005)and late (2006-
2012) studyperiodwasperformed.Finally,weperformedasen-
sitivity analysis in whichwe included patients with COPD. All
sensitivity analyses were compared with themain analysis.
Table 1. Baseline Characteristics of the Heart Failure Study Population,
Stratified According to Prior Diagnosis of Atrial Fibrillationa
Clinical Characteristics
No. (%) of Patients
Without Atrial
Fibrillation
(n=33 592)
With Atrial
Fibrillation
(n=9395)
Female 14 817 (44.1) 4420 (47.1)
Age at baseline, mean (SD), y 74 (11.6) 78 (11.1)
Age group, y
50-64 8284 (24.7) 1390 (14.8)
65-74 8334 (24.8) 1850 (19.7)
≥75 16 974 (50.5) 6155 (65.5)
Baseline comorbidity
Hypertension 14 444 (43.0) 4082 (43.5)
Previous thromboembolismb 9559 (28.5) 2504 (26.7)
Vascular disease 8746 (26.0) 1884 (20.1)
Previous myocardial infarction 6650 (19.8) 1263 (13.4)
Diabetes 5769 (17.2) 1403 (14.9)
Peripheral arterial disease 2918 (8.7) 794 (8.5)
Previous ischemic stroke 2675 (8.0) 1085 (11.6)
Renal disease 1686 (5.0) 491 (5.2)
Hyperthyroidism 630 (1.9) 360 (3.8)
Liver disease 121 (0.4) 38 (0.4)
Baseline medications
Loop diuretics 21 949 (65.3) 7131 (75.9)
Angiotensin-converting
enzyme inhibitors
17 724 (52.8) 4625 (49.2)
Aspirin 16 457 (49.0) 4453 (47.4)
β-Blockers 15 365 (45.7) 5155 (54.9)
Nonloop diuretics 13 197 (39.3) 3763 (40.1)
Statins 10 394 (31.0) 1907 (20.3)
Aldosterone antagonists 7701 (22.9) 2408 (25.6)
Calcium channel antagonists 5674 (16.9) 1822 (19.4)
NSAIDs 4761 (14.2) 1223 (13.0)
Antidiabetics 4551 (13.6) 1016 (10.8)
Digoxin 3667 (10.9) 4862 (51.8)
Thienopyridines 3610 (10.8) 521 (5.6)
Angiotensin receptor blockers 3490 (10.4) 889 (9.5)
Vasodilators 640 (1.9) 221 (2.4)
Pacemaker/ICD 1169 (3.5) 628 (6.7)
Percutaneous coronary intervention 3107 (9.3) 394 (4.2)
Coronary artery bypass graft surgery 1691 (5.0) 447 (4.8)
Rehospitalization for heart failure
during full follow-up
1 event 13 172 (39.2) 3445 (36.7)
2-4 events 13 873 (41.3) 4140 (44.1)
≥5 events 6547 (19.5) 1810 (19.3)
Abbreviations: ICD, implantable cardioverter-defibrillator; NSAIDs, nonsteroidal
anti-inflammatory drugs.
a All study patients had heart failure at baseline.
bComposite end point of ischemic stroke, transient ischemic attack, systemic
embolism, pulmonary embolism, or acute myocardial infarction.
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Because fewprior studies have found that individual risk
factors of the CHA2DS2-VASc score are associated with lower
risk, not higher risk, of stroke in the HF population,4,26,27we
performed a supplemental analysis of the association be-
tweeneach individual component of theCHA2DS2-VASc score
and the risk of ischemic stroke.
The analyses were performed using Stata version 13
(Stata Corp) and R version 3.0.2 (R Foundation for Statistical
Computing) with the package timeROC.25 A 2-sided P<.05
was considered statistically significant.
Results
Thestudypopulationcomprised42 987patientswithHFaged
50 years or older, among whom 21.9% had a diagnosis of AF
at baseline (Figure 1). The median follow-up period with re-
spect to ischemic stroke was 1.84 years (interquartile range,
0.22-4.59 years). The distribution of CHA2DS2-VASc scores in
the study population according to presence of an AF diagno-
sis are shown in Table 2.
Incidence rates during the first year are shown in Table 2;
overall, they exhibited the same fundamental characteristics
as the absolute risks, which are presented in detail below. In-
cidence rates were generally attenuated after 5 years of
follow-up (eTable 2 in the Supplement), indicating that most
eventsoccurred relatively shortlyafter theHFdiagnosis.Num-
bersofeventsandperson-yearsareshowninTable2andeTable
2 for 1 and 5 years of follow-up, respectively.
For patients with HF with and without a diagnosis of AF,
Figure 2 shows the absolute risks according to CHA2DS2-VASc
during the first year after HF diagnosis, alongside the corre-
sponding relative risks, comparing patients with a score
higher than 1 with those with a score of 1 (no additional
stroke risk factors). In both strata, the 1-year absolute risk
generally increased with increasing CHA2DS2-VASc score but
exhibited a less clear association for ischemic stroke among
patients with HF and AF. For ischemic stroke and death,
absolute risks were consistently higher among patients with
HF and AF compared with those without AF (for ischemic
stroke, with concomitant AF, 4.5%, 3.7%, 3.2%, 4.3%, 5.6%,
and 8.4% and without concomitant AF, 1.5%, 1.5%, 2.0%,
3.0%, 3.7%, and 7% for scores 1-6, respectively; overall
P = .001 for interaction; for all-cause death, with concomi-
tant AF, 19.8%, 19.5%, 26.1%, 35.1%, 37.7%, and 45.5% and
without concomitant AF, 7.6%, 8.3%, 17.8%, 25.6%, 27.9%,
and 35.0%, for scores 1-6, respectively; overall P<.001 for
interaction), but this pattern was not observed for the end
point of TE at low CHA2DS2-VASc scores (for a score of 1,
9.0% vs 5.3%; for a score of 2, 8.3% vs 6.6%; for a score of 3,
7.9% vs 7.7%; overall P<.001 for interaction). The absolute
risk of TE was higher among patients without AF compared
with patients with concomitant AF at high CHA2DS2-VASc
scores (for a score of 4, 9.7% vs 8.2%; for a score of 5, 11.9%
vs 11.2%; for a score of 6, 18.0% vs 14.9%; overall P<.001 for
interaction) (see eTable 3 in the Supplement for more results
on the test for interaction). The absolute risk increased in a
comparable manner at high CHA2DS2-VASc scores (≥4),
exhibiting a clear dose-response relationship. Similar pat-
terns were observed after 5 years of follow-up (eFigure 1 in
the Supplement).
The discriminatory properties of the CHA2DS2-VASc
score depended on the choice of end point and the dur-
ation of follow-up (Table 3). In patients without AF, the
CHA2DS2-VASc score showed moderate predictive ability for
the end point of ischemic stroke (C statistics at 1- and 5-year
follow-up, 0.67 [95% CI, 0.65-0.68] and 0.69 [95% CI,
0.67-0.69], respectively). In patients with AF, the predictive
ability for the end point of ischemic stroke was also modest
(C statistics at 1- and 5-year follow-up, 0.64 [95% CI, 0.61-
0.67] and 0.71 [95% CI, 0.68-0.73], respectively). When
using NPV to identify patients at low risk of ischemic stroke,
TE, and death, the CHA2DS2-VASc score yielded NPVs
around 90% at 1-year follow-up for patients with HF with-
out AF (NPVs, 92% [95% CI, 91%-93%] for ischemic stroke,
88% [95% CI, 87%-89%] for TE, and 93% [95% CI, 92%-
94%] for death). At 5-year follow-up, NPVs were strongly
attenuated.
Figure 1. Selection of Study PopulationWith Heart FailureWith andWithout Atrial Fibrillation
68 463 Patients diagnosed as having
 heart failure in 2000-2012
42 987 Patients with heart failure
included in study population
25 476 Excluded
10 667 Anticoagulation therapy within
6 mo prior to heart failure diagnosis
604 Date of death equal to date of heart
failure diagnosis
516 Invalid data
8518 Chronic obstructive pulmonary disease
5171 Cancer prior to heart failure diagnosis
33 592 Patients with heart failure
and sinus rhythm
9395 Patients with heart failure
and atrial fibrillation
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In the sensitivity analysis, repeating theabsolute and rela-
tive risk calculations after extending the definition of con-
comitantAF,we foundverysimilar results as in themainanaly-
sis (eFigure 2 in the Supplement). When censoring patients
withHFwhowere diagnosedwithAFduring follow-up, simi-
lar resultswere foundand the conclusions remained the same
as in the main analysis (eFigure 3 in the Supplement). In the
split sampleanalysis,we foundsimilar results for all endpoints
in both the early and late study period as in themain analysis
forpatientswithoutAF (eFigure4andeFigure5 in theSupple-
ment). However, for patients with AF, we found higher rela-
tive risks of all end points in the early study period compared
with themainanalysisbut similar results for theabsolute risks.
The C statistics were similar in both the early and late study
period and comparable with the main analysis as follows:
(1) in the early study period, for patients without AF, 0.66
(95% CI, 0.64-0.67) for ischemic stroke, 0.64 (95% CI, 0.63-
0.64) forTE, and0.63 (95%CI,0.62-0.63) fordeathand forpa-
tients with AF, 0.62 (95% CI, 0.58-0.65), 0.61 (95% CI, 0.58-
0.63), and0.62 (95%CI,0.60-0.64), respectively; (2) in the late
study period, for patients without AF, 0.68 (95% CI, 0.66-70)
for ischemic stroke, 0.63 (95%CI, 0.61-0.64) for TE, and 0.66
(95% CI, 0.65-0.67) for death and for patients with AF, 0.67
(95% CI, 0.63-0.72), 0.64 (95% CI, 0.61-0.68), and 0.64 (95%
CI, 0.63-0.68), respectively.
In the sensitivity analysis,whenwe includedpatientswith
COPD, the resultswere qualitatively similar for patientswith-
out AF, but the absolute risks for patients with AFwere lower
and the relative risks were higher compared with the main
analysis. Thus, the conclusions remained the same (eFigure
6 in the Supplement).
Supplemental analysis of theassociationbetweeneach in-
dividual component of the CHA2DS2-VASc score and the risk
of ischemic stroke is shown in eTable 4 in the Supplement. In
patients both with and without AF, female sex was not asso-
ciated with an increased risk of ischemic stroke.
Table 2. Crude Incidence Rates at 1 Year of Follow-up in the Heart Failure Study Population, Stratified According to Prior Diagnosis
of Atrial Fibrillationa
End Points Overall
No. of Additional Risk Factors on CHA2DS2-VASc Score
1 (HF Only) 2 3 4 5 ≥6
Patients Without Atrial Fibrillation
Patients, No. (%) 33 592 2366 (7.0) 4503 (13.4) 7462 (22.2) 9183 (27.3) 5958 (17.7) 4120 (12.3)
Ischemic stroke
Events, No. 977 29 62 141 258 212 275
Person-years, No. 9 448 812 711 473 1 393 807 2 180 746 2 529 593 1 599 137 707 004
Incidence rate, % (95% CI) 1.0 (1.0-1.1) 0.4 (0.3-0.6) 0.4 (0.3-0.6) 0.6 (0.5-0.8) 1.0 (0.9-1.2) 1.3 (1.2-1.5) 2.6 (2.4-3.0)
Thromboembolismb
Events, No. 3187 110 276 548 853 683 717
Person-years, No. 9 040 950 696 366 1 348 456 2 104 494 2 421 856 1 518 482 652 067
Incidence rate, % (95% CI) 3.5 (3.4-3.6) 1.6 (1.3-1.9) 2.0 (1.8-2.3) 2.6 (2.4-2.8) 3.5 (3.3-3.8) 4.5 (4.2-4.8) 7.5 (7.0-8.1)
Death
Events, No. 6956 149 332 1256 2239 1596 1384
Person-years, No. 9 596 399 715 795 1 404 213 2 201 781 2 566 123 1 632 315 731 311
Incidence rate, % (95% CI) 7.2 (7.1-7.4) 2.1 (1.8-2.4) 2.4 (2.1-2.6) 5.7 (5.4-6.0) 8.7 (8.4-9.1) 9.8 (9.3-10.3) 12.9 (12.2-13.6)
Patients With Atrial Fibrillation
Patients, No. (%) 9395 606 (6.5) 931 (9.9) 1752 (18.7) 2571 (27.4) 137 (20.6) 1598 (17.0)
Ischemic stroke
Events, No. 318 8 11 32 82 80 105
Person-years, No. 1 592 497 55 019 110 265 294 757 477 528 365 633 180 083
Incidence rate, % (95% CI) 2.0 (1.8-2.2) 1.5 (0.7-2.9) 1.0 (0.6-1.8) 1.1 (0.8-1.5) 1.7 (1.4-2.1) 2.2 (1.8-2.7) 3.6 (3.0-4.4)
Thromboembolismb
Events, No. 651 18 31 85 158 169 190
Person-years, No. 1 551 095 54 425 107 277 287 648 468 813 357 479 172 156
Incidence rate, % (95% CI) 4.2 (3.9-4.5) 3.3 (2.1-5.2) 2.9 (2.0-4.1) 3.0 (2.4-3.7) 3.4 (2.9-3.9) 4.7 (4.1-5.5) 6.9 (6.0-8.0)
Death
Events, No. 2153 11 47 282 677 561 575
Person-years, No. 1 630 977 55 347 111 192 297 304 489 042 373 574 186 490
Incidence rate, % (95% CI) 13.2 (12.7-13.8) 2.0 (1.1-3.6) 4.2 (3.2-5.6) 9.5 (8.4-10.7) 13.8 (12.8-14.9) 15.0 (13.8-16.3) 18.9 (17.4-20.5)
a CHA2DS2-VASc score is calculated as congestive heart failure (1 point),
hypertension (1 point), age 75 years or older (2 points), diabetes (1 point),
stroke/transient ischemic attack/thromboembolism (2 points), vascular
disease (prior myocardial infarction, peripheral artery disease, or aortic plaque;
1 point), age 65 to 75 years (1 point), female sex (1 point). All study patients had
heart failure at baseline.
bComposite end point of ischemic stroke, transient ischemic attack, systemic
embolism, pulmonary embolism, or acute myocardial infarction.
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Discussion
In this cohort study, our principal findings were that (1) pa-
tients with HF had a high risk of ischemic stroke, TE, and
death whether or not AF was present; (2) the CHA2DS2-VASc
scorewas able tomodestly predict these endpoints andhad a
moderately high NPV at 1-year follow-up; and (3) at high
CHA2DS2-VASc scores (≥4), patients with HF without AF had
high absolute risk of ischemic stroke, TE, and death, and the
absolute risk increased inacomparablemanner inpatientswith
HFwith and without AF, exhibiting a clear dose-response re-
lationship. Indeed, the absolute risk of thromboembolic com-
plications was higher among patients without AF compared
with patients with concomitant AF at high CHA2DS2-VASc
scores (≥4). To our knowledge, this is the first study to evalu-
ate the predictive ability of the CHA2DS2-VASc score in esti-
mating the risk of ischemic stroke, TE, and death in a popula-
tion of patients with incident HF with and without AF.
Patients with HF and without AF are at increased risk of
ischemic stroke andTE, and in recent randomized trials, these
end points (which were secondary trial end points) were re-
ducedbywarfarin therapy.28-30 In theDanishDiet, Cancer and
Health cohort, we previously demonstrated the high risk of
strokeandmortalityamongpatientswithHFwithoutAF,which
was lower if warfarin therapy was prescribed.4
PatientswithHFhavean increased riskof ischemic stroke,
TE, and death regardless of whether AF is present.28 In our
study, one of our principal findingswas that the absolute risk
of ischemic stroke amongpatientswithoutAFwas about 1.5%
per year or higher with CHA2DS2-VASc scores of 2 or higher,
with associated 5-year absolute ischemic stroke risks in ex-
cess of 4% or more. Risks were even higher among the pa-
tientswithHFwithAF inour study. Similar absolute riskswere
found when stratifying analyses according to early and late
studyperiod, indicatinga robustnessofour findings tochanges
in standardHFdiagnostic and treatmentmodesbetween2000
and2012. In the generalAFpopulation, a stroke risk of greater
Figure 2. Absolute Risks and Relative Risks by CHA2DS2-VASc Score Components During the First Year
of Follow-up, Stratified According to Prior Diagnosis of Atrial Fibrillation
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Error bars indicate 95% CIs. Numbers
of patients contributing data in each
group for CHA2DS2-VASc scores from
1 to 6, respectively, were as follows:
without atrial fibrillation, 2366, 4503,
7462, 9183, 5958, and 2733; with
atrial fibrillation, 606, 931, 1752, 2571,
1937, and 980.
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than 1% per year is often used as a cut point to identify pa-
tients inwhom the benefits of long-termoral anticoagulation
mayoutweigh the risks of bleeding.31 In the presentHFpopu-
lation, patientswithoutAFwith aCHA2DS2-VASc score of 2 or
higher had a stroke risk greater than 1% per year. Although it
is not clear whether this cut point would apply directly to the
HF population without AF, our results may suggest that sub-
groupsofpatientswithHFwithoutAFandwith2ormorecom-
ponents of the CHA2DS2-VASc score besides HF are at high
enough risk of ischemic stroke to benefit from anticoagula-
tion therapy; especially with availability of the non–vitamin
K antagonist oral anticoagulants.
Ourotherprincipal finding is that inpatientswithHFwith
elevatedCHA2DS2-VASc scores (≥4), the absolute risk of ische-
mic stroke, TE, and death was very high. At these high
CHA2DS2-VASc scores, the absolute risk increased in a com-
parablemanner in patients with HFwith andwithout AF, ex-
hibiting a clear dose-response relationship, so that the abso-
lute risk of TE was even greater among patients without AF
comparedwith thosewith concomitant AF. The poor progno-
sis ofAF for ischemic stroke anddeath inpatientswithHFwas
evident in our study, but the observation that additional risk
factors in patients with HF are particularly significant among
those without AF is an important result. Indeed, preventa-
tivestrategies to reduce ischemicstrokeandTErisk in this large
patient population require further investigation.
The C statistics demonstrated that the performance of
the CHA2DS2-VASc score was dependent on the type of end
point and the length of follow-up. In patients with HF with-
out AF, the CHA2DS2-VASc score performed moderately in
discriminating patients experiencing an ischemic stroke
from stroke-free survivors. The C statistics for predicting
“events” in this study are also comparable with other com-
monly used risk scores based on clinical risk factors (for
example, the CHADS2 score in AF). Although these initial
results demonstrate a potential use of the score, the direct
clinical utility of stroke risk stratification in patients with HF
is an open question. In this high-risk population, all-cause
mortality remains the key concern, as indicated by the very
high mortality rates and the corresponding relatively poorer
performance of the risk score for predicting events after 5
years of follow-up. On the other hand, CHA2DS2-VASc
yielded a moderately high 1-year NPV for identifying
patients at “low risk” of stroke or death (approximately
90%). This is consistent with the CHA2DS2-VASc score as a
useful tool for identifying “low-risk” patients, as evident in
various studies examining risks in AF patients.32,33 In our
study, we found a less clear association between ischemic
stroke risk and increasing CHA2DS2-VASc score among
patients with HF and AF, exhibiting a possible J-shaped asso-
ciation or possibly no meaningful association, which could
be due to the low event numbers with some of the scores.
Furthermore, not all the individual components of the
CHA2DS2-VASc score have been identified as established
risk factors of ischemic stroke in the HF population with-
out AF. Previous studies have even showed that some of
these components are associated with a decreased ischemic
stroke risk,4,26,27 which our supplemental analysis also
demonstrates. In spite of these previous findings, the
CHA2DS2-VASc score was able to modestly predict the risk of
ischemic stroke in our study. Future studies examining the
individual drivers of risk derived from the CHA2DS2-VASc
score are still needed.
The major strengths of this study are the validated out-
comes and large sample size uniquely possible with this type
of cohort study. Selection into the study was not an issue be-
causewe investigatedanationwidepopulationofpatientswith
incident HFwith andwithout AF, with limited loss to follow-
up.We also accounted for competing risk of death, an impor-
tant issue when investigating the performance of risk scores
in populations with a high mortality.13,24
The study has some limitations. We were unable to dis-
tinguishbetweenHFwithpreservedvs reduced ejection frac-
tionor to estimate the functional classification/symptoms se-
verity becausewedid not have access to echocardiograms. In
a previous systematic review, whether a clinical diagnosis of
Table 3. Assessment of the CHA2DS2-VASc Score at 1- and 5-Year Follow-up in the Heart Failure Study Population According to Prior Diagnosis
of Atrial Fibrillationa
Without Atrial Fibrillation With Atrial Fibrillation
C Statistic (95% CI) NPV, % (95% CI)b C Statistic (95% CI) NPV, % (95% CI)b
Ischemic stroke
At 1 y 0.67 (0.65-0.68) 92 (91-93) 0.64 (0.61-0.67) 91 (88-95)
At 5 y 0.69 (0.67-0.69) 78 (77-80) 0.71 (0.68-0.73) 69 (60-77)
Thromboembolismc
At 1 y 0.63 (0.62-0.64) 88 (87-89) 0.62 (0.60-0.64) 88 (84-92)
At 5 y 0.67 (0.67-0.68) 73 (71-74) 0.69 (0.67-0.71) 61 (51-69)
Death
At 1 y 0.64 (0.63-0.64) 93 (92-94) 0.63 (0.62-0.65) 94 (91-97)
At 5 y 0.68 (0.67-0.68) 81 (79-82) 0.70 (0.69-0.72) 76 (67-84)
Abbreviation: NPV, negative predictive value.
a CHA2DS2-VASc score is calculated as congestive heart failure (1 point),
hypertension (1 point), age 75 years or older (2 points), diabetes (1 point),
stroke/transient ischemic attack/thromboembolism (2 points), vascular
disease (prior myocardial infarction, peripheral artery disease, or aortic plaque;
1 point), age 65 to 75 years (1 point), female sex (1 point). All study patients had
heart failure at baseline.
bUsing a cutoff value of 1.
c Composite end point of ischemic stroke, transient ischemic attack, systemic
embolism, pulmonary embolism, or acute myocardial infarction.
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HF is a significant risk factor remained inconclusive, although
when the diagnosis is certain (recent decompensation requir-
inghospitalization, as inDanish registries), it does seemtobea
significant risk factor irrespective of left ventricular systolic
function.5 However, functional classification among patients
withHFwould also vary over time andwith treatments. In ad-
dition,we investigatedtherisk inpatientswith incidentHF,and
our resultsmaynot relate to the general populationof patients
withHF.However,wealso reported risksafter5yearsof follow-
up, andwe believe these results are comparable with the gen-
eralHFpopulation.Becauseof thehighmortality rate in theHF
population (andtherefore, theshort follow-up inthis study),we
focusedonthe1-yearrisks.TheHFdiagnosishaspreviouslybeen
validatedwith a sensitivity of 29%, a specificity of 99%, and a
positive predictive value of 81%,18 and based on the validation
study we did not capture all patients with HF and also cannot
be certain that all patients identified as havingHFhaddefinite
HF,whichcould lead to imprecision in the riskestimates.How-
ever,we included only patientswith a primary discharge diag-
nosis of HF to optimize the probability of including only cor-
rectly identified patients with HF.
We investigated a real-life population using nationwide
registries in which we did not exclude severely ill patients
(astypicallydoneinclinical trials); thus,ourstudypopulationin-
cludespatientswithHFwithseveralcomorbiditiespredisposing
forstrokeevents,andoureventratesmaybehigherthanthatseen
inclinical trials. Indeed,NielsenandChao13discussed the issue
withdifferent event ratesobserved fromdifferentpopulations.
We cannot rule out that some patients without AFmight
have hadundiagnosedAFbecause heart disease is associated
with an increased risk of developing AF and AF is silent in up
to a quarter of patients. In our sensitivity analyses, extending
the AF definition and censoring if development of AF oc-
curredduring follow-up,wefoundsimilar resultsas in themain
analysis.Additionally,our studypopulationwasethnicallyand
socially nondiverse. Thus, our study resultsmight not be gen-
eralizable to more diverse HF populations. Furthermore, we
excluded patients with HF younger than 50 years; accord-
ingly, our findingsmaynot apply to younger patientswithHF.
We did not have information about smoking habits; how-
ever, we excluded patients with a diagnosis of COPD, which
are primarily patients with an intensive smoking habit or his-
tory, and therefore, our resultsmight not be valid for patients
with COPD. However, in our sensitivity analysis, whenwe in-
cludedpatientswithCOPD, theconclusionsremainedthesame.
Because of the nature of our nationwide registry study,
follow-up depended on the National Civil Registration Sys-
tem, in which some deaths are likely to be attributable to an
undiagnosed stroke. Finally, the diagnosis of ischemic stroke
wasdefinedby theDanishHospitalDischargeRegister, andnot
all stroke end points have been defined by cerebral imaging;
thus, the data did not allow classification of ischemic stroke
types.However, the ischemic stroke diagnosis has previously
been validated.17
Conclusions
Among patients with incident HF with or without AF, the
CHA2DS2-VASc score was associated with risk of ischemic
stroke, thromboembolism, and death. The absolute risk of
thromboembolic complications was higher among patients
without AF compared with patients with concomitant AF at
highCHA2DS2-VASc scores.However, predictive accuracywas
modest, and the clinical utility of the CHA2DS2-VASc score in
patients with HF remains to be determined.
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eTable 1. ICD-10 Codes and ATC-Codes Used in the Study 
 
ICD 10-Codes and ATC-Codes used in the Study 
 Main diagnosis ICD 10-codes 
Congestive heart failure I50.0-I50.9, I11.0, I13.0, I13.2 
Atrial fibrillation I48.0-I48.9 
Endpoints  
Stroke (ischemic) I63.0-I63.9, I64.9  
Ischemic stroke (Thromboembolic 
event) I63.0-I63.9, I64.9 
Transient ischemic attack 
(Thromboembolic event) G45.0-G45.9* 
Systemic embolism 
(Thromboembolic event) I74.0-I74.9 
Pulmonary embolism 
(Thromboembolic event) I26.0-I26.9 
Acute myocardial infarction 
(Thromboembolic event) I21.0-I21.9, I23.0-I23.9 
Comorbidities ICD 10-codes 
Prior stroke (ischemic or 
hemorrhagic) I60.0-I60.9, I61.0-I61.9, I62.0-I62.9, I63.0-I63.9, I64.9 
Acute myocardial infarction I21.0-I21.9, I23.0-I23.9 
Peripheral ischemic disease† I70.2-I70.9, I71.0-I71.9, I73.9 
Vascular disease I21.0-I21.9, I23.0-I23.9, I70.0, I70.2-I70.9, I71.0-I71.9, I73.9 
Diabetes mellitus E10.0-E10.9, E11.0-E11.9 
Hypertension I10.0-I10.9, I11.0-I11.9, I12.0-I12.9, I13.0-I13.9, I15.0–I15.9 
Renal disease I12.0-I12.9, I13.0-I13.9, N00-N07, N11.0-N11.9, N14.0-N14.4, N17.0-N17.9, N18.0-N18.9, N19, Q61.0-Q61.9 
Liver disease B15.0-B15.9, B16.0-B16.9, B17.0-B17.9, B18.0-B18.9, B19.0-B19.9, K70.4, K72.0-K72.9, K76.6 
Hyperthyroidisme E05.0-E05.9, E06.0-E06.9 
Chronic obstructive pulmonary 
disease (COPD) J44.0-J44.9 
Valvular disease (exclusion criteria) I05.0-I05.9, I06.0-I06.9, I34.0-I34.9, I35.0-I35.9 
Mechanical cardiac valve 
(exclusion criteria) Z95.2, Z95.3, Z95.4 
Cancer any type (exclusion criteria) C00-C97 
Concomitant medication ATC-codes 
Warfarin (exclusion criteria) B01AA03 
Phenprocoumon (exclusion criteria) B01AA04 
ACE-inhibitors C09AA 
Angiotensin receptor blockers C09CA 
Beta-blockers C07 
Non-loop diuretics C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G,C09BA, C09DA, C09XA52  
Aldosterone antagonists C03DA 
Loop diuretics C03C 
  Statins C10 
© 2015 American Medical Association. All rights reserved. 
Downloaded From: http://jama.jamanetwork.com/ by a AALBORG UNIVERSITY HOSPITAL User  on 01/28/2016
Concomitant medication ATC-codes 
Non steroidal anti-inflammatory 
drugs (NSAIDs) M01A 
Aspirin B01AC06 
Thienopyridines B01AC04, B01AC22, B01AC24 
Antidiabetics A10 
Calcium chanel antagonists C07F C08 C09BB C09DB 
Digoxin C01AA05 
Vasodilators C02DB C02DD C02DG C04 C05 
Interventions Procedure codes (SKS code) 
Pacemakr/ICD FPG FPE 
Percutaneous coronary 
intervention(PCI) FNG 
Coronary artery bypass graft 
(CABG) FNA FNC FND FNE 
* Not inclusive G45.3 (Amaurosis fugax) 
† Peripheral arterial disease, refers to the obstruction of large arteries not within the coronary, aortic arch vasculature, or brain  
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eTable 2. Crude Incidence Rates at 5-Year Follow-up in the Heart Failure Study Population, 
Stratified According to Prior Diagnosis of Atrial Fibrillation 
 
Endpoint  CHA2DS2-VASc score  - Additional risk factor 
 Overall 1 (HF only) 2 3 4 5 6+ 
Non-AF        
Patients in each score, No. 
(%) 
33,592 2,366  
(7.0) 
4,503 (13.4) 7,462 
(22.2) 
9,183  
(27.3) 
5,958  
(17.7) 
4,120  
(12.3) 
        
Ischemic stroke        
Events, No. 2,080 64 151 395 548 455 467 
Person-years 3.14e+07 2.723.598 5.204.536 7.478.778 8.172.942 4.930.078 2.058.004 
Incidence rate (95% CI) 0.7  
(0.6-0.7) 
0.2 
(0.2-0.3) 
0.3 
(0.2-0.3) 
0.5 
(0.5-0.6) 
0.7 
(0.6-0.7) 
0.9 
(0.8-1.0) 
1.6 
(1.5-1.8) 
        
Thromboembolism†        
Events, No. 5,572 202 506 1,073 1,501 1,224 1,066 
Person-years 2.93e+07 2.632.036 4.941.719 7.057.264 7.607.543 4.532.796 1.824.215 
Incidence rate (95% CI) 1.9 
(1.8-1.9) 
0.7 
(0.7-0.9) 
1.0 
(0.9-1.1) 
1.5 
(1.4-1.6) 
2.0 
(1.9-2.1) 
2.7 
(2.6-2.9) 
4.1 
(3.9-4.4) 
        
Death        
Events, No. 13,836 354 818 2,633 4,444 3,144 2,443 
Person-years 3.25e+07 2.765.491 5.305.327 7.686.298 8.450.027 5.161.519 2.206.065 
Incidence rate (95% CI) 4.3 
(4.3-4.3) 
1.3 
(1.2-1.4) 
1.5 
(1.4-1.7) 
3.4 
(3.3-3.6) 
5.3 
(5.1-5.4) 
6.1 
(5.9-6.3) 
7.7 
(7.4-8.0) 
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AF        
Patients in each score, No. 
(%) 
9,395 606  
(6.5) 
931  
(9.9) 
1,752 
(18.7) 
2,571  
(27.4) 
1,937  
(20.6) 
1,598  
(17.0) 
        
Ischemic stroke        
Events, No. 590 14 19 69 159 158 171 
Person-years 4.092.929 145.003 305.795 789.468 1.265.106 918.162 423.061 
Incidence rate (95% CI) 1.4 
(1.3-1.6) 
1.0 
(0.6-1.6) 
0.6 
(0.4-1.0) 
0.9 
(0.7-1.1) 
1.3 
(1.1-1.5) 
1.7 
(1.5-2.0) 
2.6 
(2.2-3.0) 
        
Thromboembolism†        
Events, No. 1,124 31 49 152 294 296 302 
Person-years 3.897.488 139.425 291.140 756.390 1.225.451 877.400 386.309 
Incidence rate (95% CI) 2.9 
(2.7-3.1) 
2.2 
(1.6-3.2) 
1.7 
(1.3-2.2) 
2.0 
(1.7-2.4) 
2.4 
(2.1-2.7) 
3.4 
(3.0-3.8) 
5.0 
(4.4-5.6) 
        
Death        
Events, No. 3,766 26 90 561 1,190 963 936 
Person-years 4.301.442 147.071 310.708 809.780 1.332.492 975.518 453.103 
Incidence rate (95% CI) 8.8 
(8.5-9.0) 
1.8 
(1.2-2.6) 
2.9 
(2.4-3.6) 
6.9 
(6.4-7.5) 
8.9 
(8.4-9.5) 
9.9 
(9.3-10.5) 
12.9 
(12.1-13.7) 
All study patients had heart failure at baseline 
Incidence rates are reported as % per year over 5 years of follow-up 
Abbreviations: HF=heart failure; CHA2DS2-VASc score=congestive heart failure, hypertension, age ≥75 years (doubled), diabetes, stroke/TIA/thromboembolism 
(doubled), vascular disease (prior myocardial infarction, peripheral artery disease, or aortic plaque), age 65–75 years, sex category (female); CI=confidence interval 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, pulmonary embolism, acute myocardial infarction 
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eTable 3. Crude Relative Risks at 1-Year Follow-up in the Heart Failure Population, When 
Comparing Patients With and Without Atrial Fibrillation 
 
Non-AF patients vs AF patients (reference: AF patients) 
ENDPOINT Risk score  RR after 1 year 
(95% CI) 
Test for interaction, 
overall 
ISCHEMIC 
STROKE 
CHA2DS2-VASc score P=0.001 
1 (HF only) Ref.  
 2 additional risk factor 2.21 (1.53-3.19)  
 3 additional risk factors 1.60 (1.20-2.15)  
 4 additional risk factors 1.42 (1.13-1.78)  
 5 additional risk factors 1.37 (1.08-1.75)  
 6+ additional risk factors 1.05 (0.85-1.30)  
THROMBO-
EMBOLISM† 
CHA2DS2-VASc score P=0.000 
1 (HF only)  Ref.  
 2 additional risk factor 1.32 (1.09-1.60)  
 3 additional risk factors 1.07 (0.91-1.26)  
 4 additional risk factors 0.86 (0.75-1.00)  
 5 additional risk factors 0.90 (0.78-1.04)  
 6+ additional risk factors 0.75 (0.65-0.86)  
DEATH CHA2DS2-VASc score P=0.000 
 1 (HF only) Ref.  
 2 additional risk factor 2.32 (2.01-2.69)  
 3 additional risk factors 1.41 (1.28-1.54)  
 4 additional risk factors 1.28 (1.20-1.37)  
 5 additional risk factors 1.25 (1.16-1.35)  
 6+ additional risk factors 1.17 (1.09-1.27)  
All study patients had heart failure at baseline  
Abbreviations: AF=atrial fibrillation; CHA2DS2-VASc score=congestive heart failure, hypertension, age ≥75 years 
(doubled), diabetes, stroke/TIA/thromboembolism (doubled), vascular disease (prior myocardial infarction, peripheral 
artery disease, or aortic plaque), age 65–75 years, sex category (female) 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, pulmonary embolism, acute 
myocardial infarction 
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eTable 4. Association Between Each Individual Component of the CHA2DS2-VASc Score and 
Ischemic Stroke Risk 
 
Individual components of the CHA2DS2-VASc score 
Non-AF 
Crude RR (95% CI) 
AF 
Crude RR (95% CI) 
Hypertension 1.30 (1.13-1.51) 1.24 (1.09-1.40) 
Age ≥75 years 1.33 (1.17-1.51) 1.34 (1.20-1.49) 
Diabetes 1.50 (1.29-1.73) 1.42 (1.25-1.62) 
Stroke/TIA/thromboembolism 4.92 (4.34-5.58) 4.40 (3.94-4.90) 
Vascular disease 1.32 (1.16-1.51) 1.24 (1.10-1.40) 
Age 65-75 years 1.57 (1.34-1.85) 1.64 (1.41-1.90) 
Female sex 0.84 (0.74-0.95) 0.96 (0.86-1.07) 
All study patients had heart failure at baseline  
Abbreviations: AF: atrial fibrillation; CHA2DS2-VASc score=congestive heart failure, hypertension, age ≥75 years (doubled), 
diabetes, stroke/TIA/thromboembolism (doubled), vascular disease (prior myocardial infarction, peripheral artery disease, or aortic 
plaque), age 65–75 years, sex category (female); CI: confidence interval; RR: relative risk; TIA: transient ischemic attack 
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eFigure 1. Absolute Risks and Relative Risks by CHA2DS2-VASc Score Components During 5-
Year of Follow-up, Stratified According to Prior Diagnosis of Atrial Fibrillation 
 
 
A) Absolute risk of ischemic stroke; B) Relative risk of ischemic stroke; C) Absolute risk of thromboembolism; D) 
Relative risk of thromboembolism; E) Absolute risk of death; F) Relative risk of death. Number of patients contributing 
data in each group for each CHA2DS2-VASc score (non-AF: 2,366, 4,503, 7,462, 9,183, 5,958, and 2,733; AF: 606, 
931, 1,752, 2,571, 1,937, and 980, for score 1-6).  
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eFigure 2. Sensitivity Analysis (Extending the Definition of Concomitant AF at Baseline): 
Absolute Risks and Relative Risks by CHA2DS2-VASc Score Components During the First Year of 
Follow-up, Stratified According to Prior Diagnosis of Atrial Fibrillation 
 
 
A) Absolute risk of ischemic stroke; B) Relative risk of ischemic stroke; C) Absolute risk of thromboembolism; D) 
Relative risk of thromboembolism; E) Absolute risk of death; F) Relative risk of death. Number of patients contributing 
data in each group for each CHA2DS2-VASc score (non-AF: 2,277, 4,377, 7,267, 8,941, 5,817, and 2,671; AF: 695, 
1,057, 1,947, 2,813, 2,078, and 1,042, for score 1-6). 
  
© 2015 American Medical Association. All rights reserved. 
Downloaded From: http://jama.jamanetwork.com/ by a AALBORG UNIVERSITY HOSPITAL User  on 01/28/2016
eFigure 3. Sensitivity Analysis (Censoring Patients Who Get a Diagnosis of AF During Follow-
up): Absolute Risks and Relative Risks by CHA2DS2-VASc Score Components During the First 
Year of Follow-up, Stratified According to Prior Diagnosis of Atrial Fibrillation 
 
 
A) Absolute risk of ischemic stroke; B) Relative risk of ischemic stroke; C) Absolute risk of thromboembolism; D) 
Relative risk of thromboembolism; E) Absolute risk of death; F) Relative risk of death. Number of patients contributing 
data in each group for each CHA2DS2-VASc score (non-AF: 2,366, 4,503, 7,462, 9,183, 5,958, and 2,733; AF: 606, 
931, 1,752, 2,571, 1,937, and 980, for score 1-6). 
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eFigure 4. Sensitivity Analysis (Split Sample Analysis – Early Study Period (2000-2005)): 
Absolute Risks and Relative Risks by CHA2DS2-VASc Score Components During the First Year of 
Follow-up, Stratified According to Prior Diagnosis of Atrial Fibrillation 
 
 
A) Absolute risk of ischemic stroke; B) Relative risk of ischemic stroke; C) Absolute risk of thromboembolism; D) 
Relative risk of thromboembolism; E) Absolute risk of death; F) Relative risk of death. Number of patients contributing 
data in each group for each CHA2DS2-VASc score (non-AF: 1,281, 2,398, 4,334, 5,526, 3,280, and 1,429; AF: 267, 
419, 1,005, 1,539, 1,063, and 493, for score 1-6). 
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eFigure 5. Sensitivity Analysis (Split Sample Analysis – Late Study Period (2006-2012)): Absolute 
Risks and Relative Risks by CHA2DS2-VASc Score Components During the First Year of Follow-
up, Stratified According to Prior Diagnosis of Atrial Fibrillation 
 
 
A) Absolute risk of ischemic stroke; B) Relative risk of ischemic stroke; C) Absolute risk of thromboembolism; D) 
Relative risk of thromboembolism; E) Absolute risk of death; F) Relative risk of death.  Number of patients 
contributing data in each group for each CHA2DS2-VASc score (non-AF: 1,096, 2,124, 3,175, 3,710, 2,726, and 1,322; 
AF: 349, 550, 878, 1,211, 1,046, and 596, for score 1-6). 
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eFigure 6. Sensitivity Analysis (Including Patients With COPD): Absolute Risks and Relative 
Risks by CHA2DS2-VASc Score Components During the First Year of Follow-up, Stratified 
According to Prior Diagnosis of Atrial Fibrillation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) Absolute risk of ischemic stroke; B) Relative risk of ischemic stroke; C) Absolute risk of thromboembolism; D) 
Relative risk of thromboembolism; E) Absolute risk of death; F) Relative risk of death.  Number of patients 
contributing data in each group for each CHA2DS2-VASc score (non-AF: 2,605, 5,269, 8,784, 10,670, 6,935, and 4,816; 
AF: 664, 1,095, 2,238, 3,204, 2,474, and 2,076, for score 1-6). 
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Heart Failure
Female sex is associated with a lower risk of
stroke in patients with heart failure
LineMelgaard,MSc, aAndersGorst-Rasmussen,MSc,PhD,a,bGregoryY.H.Lip,MD,b,c LarsHvilstedRasmussen,MD,PhD,b
and Torben Bjerregaard Larsen, MD, PhDa,b Aalborg, Denmark and Birmingham, United Kingdom
Background Stroke in patients with heart failure is associated with poor outcomes. Risk stratification schemes may
improve clinical decision making in this patient population. This study investigated whether female sex is a risk factor for stroke
in patients with heart failure in sinus rhythm.
Methods This is a population-based cohort study of patients diagnosed with heart failure during 2000 to 2012, identified by
record linkage between nationwide Danish registries. Our primary outcomewas stroke, and secondary outcomewas thromboembolic
event.Weused relative risks (RRs) after 1 and5 years to comparemaleswith femaleswithin each of the following age groups: 50 to59
years, 60 to 69 years, 70 to 79 years, 80 to 89 years, and 90+ years. Analyses took into account the competing risks of death.
Results During the study period, 84,142 patients were diagnosed with heart failure, of which 39,946 (47.5%) were
females. At 5-year follow-up, female sex was associated with a lower risk of stroke compared with males (adjusted overall
hazard ratio 0.91, 95% CI 0.85-0.96). The observed lower risks of stroke in females were not present in the older age groups,
where the competing risk of death was substantial among males in particular. When considering a more broadly defined
thromboembolic end point, a decreased risk among females persisted across nearly all age groups after 5-year follow-up
(adjusted overall hazard ratio 0.93, 95% CI 0.91-0.96).
Conclusions We found an association between female sex and decreased stroke risk in patients with heart failure,
which persisted after adjustment for concomitant cardiovascular risk factors. The association was attenuated with increasing
age, possibly because of competing risks of death. (Am Heart J 2015;169:396-403.e2.)
Heart failure (HF) is associated with an increased risk
of stroke, also in patients without concomitant atrial
fibrillation (AF).1 Recent prospective randomized con-
trolled trials of antithrombotic therapy in HF revealed that
the benefit of warfarin in reducing stroke was counter-
balanced by an increased risk of bleeding.2–5 However,
the extent to which subgroups within the HF population
would benefit from anticoagulation was not investigated.
Risk stratification using readily available clinical variables
mayhelp identifying subgroups at lowandhigh risk of stroke
in a population of patients with HF without concomitant
AF. An important but somewhat controversial risk factor
for stroke in the AF setting is that of female sex,6,7 and it is
of interest to elucidate the relevance of this simple risk
factor in anHF setting. In particular, it is unknownwhether
the association between sex and stroke risk in HF is
influenced by the presence of well-known cardiovascular
risk factors of stroke.1,8,9
Examining risk factors for stroke in a population of
patients with HF poses important methodological chal-
lenges. Specifically, the high all-cause mortality among
patients with HF (5-year mortality of 45%-60%)10,11 leads to
a competing risks setting in which careful consideration of
the interplay betweenmortality and stroke risk is needed to
provide meaningful stroke risk assessments. In addition,
careful accounting for the effects of age heterogeneity is
neededwhen investigating sex as a risk factor because high
age, in itself, is a key risk factor for stroke.12
We hypothesized that, in a population of patients with
incident HF, female sex would be associated with a
higher risk of stroke compared with male sex, also when
taking into account sex differences in age and other
known risk factors of stroke. To investigate this
hypothesis, we used data from Danish nationwide
registries to identify a population of patients with
incident HF with no concomitant AF or anticoagulant
therapy. Within this population, we compared the male
and female 1- and 5-year stroke risk in a setting
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incorporating competing risks because of death, while also
taking into account age and other established cardiovascu-
lar risk factors of stroke.
Methods
Registry data sources
We used 3 different nationwide registries in this study:
(1) Danish National Patient Registry,13 which has registered
all hospital admissions along with diagnoses since 1977 and
codes all diagnoses according to the International Classi-
fication of Diseases, 10th Revision (ICD-10), since 1994;
(2) The National Prescription Registry,14 which contains
data on all prescriptions dispensed fromDanish pharmacies
since 1994, coded according to the Anatomical Therapeutic
Chemical (ATC) Classification System; (3) The Danish Civil
Registration System, which holds information on date of
birth, migration, vital status, date of death, and sex of all
persons living in Denmark.15 Data were linked via unique
personal identification number used in all Danish national
registries. All 3 registries were up to December 31, 2012.
These registries have previously been validated,13,14,16
and the diagnoses of HF and stroke were found to have
high validity.16,17
Study population
The study population was identified as patients aged
N50 years, discharged with an incident diagnosis of HF in
sinus rhythm in the period January 1, 2000, to December
31, 2012 (ICD-10: I50, I11.0, I13.0, I13.2). To restrict to
patients without AF, we excluded those who had a prior
diagnosis of AF (I48), valvular disease (I05, I06, I34, I35),
or mechanical cardiac valve (Z95.2, Z95.3, Z95.4). We
moreover excluded patients treated with anticoagulant
medication (ATC: B01AA03, B01AA04) within 6 months
before the HF diagnosis. Lastly, patients with a diagnosis
of cancer (ICD-10: C00-C97) within 5 years before HF
diagnosis were excluded (Figure 1).
Comorbidities were assessed at time of HF diagnosis
identified using the Danish National Patient Registry and the
Danish National Prescription Registry. Ascertainment of
baselinemedication statuswas based onmedication purchase
in a 30-day window before or after the date of HF diagnosis.
ICD-10codes andATCcodesused todefinecomorbidities and
medical therapy are provided in the online-only material (see
online Appendix Supplementary Table I).
Outcomes
The primary end point was defined as a stroke
diagnosis resulting in an ICD-10 code of ischemic stroke
(ICD-10: I63, I64.9). As a broader secondary end point,
we defined a thromboembolic event to be a diagnosis of
ischemic stroke (ICD-10: I63, I64.9), transient ischemic
attack (ICD-10: G45), systemic embolism (ICD-10: I74),
pulmonary embolism (ICD-10: I26.0, I26.9), or acute
myocardial infarction (ICD-10: I21, I23). Because of the
high mortality in the HF population, all-cause death was
also included as an end point in a competing risks setting
to enable correct risk assessment.
Statistical methods
Baseline characteristics were described separately for
each sex stratum with means and SD for continuous
measures and proportions for categorical measures.
Figure 1
Flowchart of patients included in the final study population.
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Time-to-event analysis was used to estimate the
association between female sex and the risk of stroke.
Time at risk was measured from baseline date (date of HF
diagnosis) and until the relevant event (stroke, all-cause
death, or thromboembolic event), emigration, initiation
of anticoagulant therapy, or end of study (December 31,
2012), whichever came first.
Crude cumulative incidence curves of stroke (Figure 2)
and death (Figure 3) according to sex were constructed
based on Aalen-Johansen estimator18 for competing risks
data. We proceeded to perform regression analyses to
calculate 1-year and 5-year RR of an end point according
to sex, stratifying analyses by age at time of diagnosis (50-
59 years, 60-69 years , 70-79 years, 80-89 years, and 90+
years). To this end, we used generalized linear regression
alongside the pseudovalue method to take into account
the competing risks of death.19,20 The pseudovalue
regression technique reduces to simple regression (with
a log-link function) on the event status indicator at 1 and 5
years in the absence of censoring. Concomitant baseline
comorbidities such as hypertension, diabetes, prior
thromboembolism, prior myocardial infarction, and
peripheral artery disease are well-known risk factors of
stroke in other heart diseases.8,9 Accordingly, to assess
the independent prognostic value of sex among estab-
lished cardiovascular risk factors, we also fitted the
regression models after adjustment for these risk factors.
Sensitivity analyses were performed by repeating the
RR calculations when treating initiation of antiplatelet
therapy as a censoring event. An additional end point,
deep venous thrombosis, and a broad end point,
composite of “stroke/thromboembolic event or death”,
were also analyzed in sensitivity analyses and compared
with the main analysis.
The analyses were performed using Stata version 13
(Stata Corporation; College Station, TX). A 2-sided P b .05
was considered statistically significant. The study was
conducted and reported in accordance with Strengthen-
ing the Reporting of Observational Studies in Epidemiol-
ogy (STROBE) recommendations.
Ethical considerations
No ethical approval is required for anonymous register
studies inDenmark. The studywas approved by theDanish
Data Protection Agency (J. No. File No. 2012-41-0633).
Sources of funding
No extramural funding was used to support this work.
This study was conducted independently of any industry
or other grant support. The authors are solely responsible
for the design and conduct of this study, all study
analyses, the drafting and editing of the manuscript, and
its final contents.
Results
The study population comprised 84,142 patients
with HF aged N50 years, of which 39,946 (47.5%) were
females. The median follow-up time for stroke or death
was 2.1 years (interquartile range 0.3-4.8).
Figure 2
Cumulative incidence of stroke for males and females.
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Baseline characteristics of the study population are
shown in Table I. The mean ages of the cohort were 78
(SD 10.9) and 73 (SD 10.7) years for females and males,
respectively. Females were in general older, with 49.2%
aged N80 years at study start, compared with 28.6%
of the males. Males more often had a history of previous
myocardial infarction and vascular disease plus a minor
higher prevalence of peripheral ischemic disease and
diabetes. In addition, more males than females were
prescribed angiotensin-converting enzyme inhibitors, β-
blockers, statins, and aspirin.
In the study population, the 1- and 5-year absolute risks
of stroke were 3.5% and 7.6%, and the absolute risks of
death were 26.4% and 54.8%, respectively (the absolute
risks of composite end point “stroke or death” were
30.0% and 60.6%, respectively).
The RRs of stroke comparing females with males within
each age group are shown in Table II. Within 5 years after
HF diagnosis, female sex was associated with an overall
9% (RR 0.91, 95% CI 0.85-0.96) lower risk of stroke
compared with males, after adjusting for concomitant
risk factors. Formal statistical tests for interactions
suggested an age-by-sex interaction after 5 years of
follow-up (stroke P = .03, death P = .02, thromboembolic
event P = .07). Turning to effect size estimates, a lower
risk among females was observed in most age groups;
except in the age group of 90+ years where the 5-year
adjusted RR was 1.33 (95% CI 0.98-1.79) indicating a
nonsignificant risk increase among females. Older age
attenuated the RRs toward 1.00 indicating a modifying
effect of age on the association between sex and stroke.
Findings for the 1-year risks were qualitatively similar to
those for the 5-year risks, although formal statistical tests
for age-by-sex interaction were generally nonsignificant.
For the competing event of all-cause death, female sex
was associated with a significantly decreased 5-year risk
of death compared with males (adjusted RR 0.93, 95% CI
0.92-0.94). When stratifying on age groups, females had a
lower RR of death after adjusting for cardiovascular risk
factors compared with males both after 1- and 5-year
follow-up in all age groups, except those aged 60 to 69
years at 1-year follow-up.
For the broader secondary end point of “any thrombo-
embolic event”, the 1- and 5-year absolute risks were
16.3% and 31.0%, respectively. Females still had an overall
lower risk of events after 5 years of follow-up, which
persisted after adjusting for concomitant risk factors
(adjusted RR 0.93, 95% CI 0.91-0.96), but in contrast to
the findings for the end point of stroke, the lower female
risk was observed in the crude results for all age groups,
including the older age groups.
Sensitivity analyses
Around 40% of patients were taking antiplatelet therapy
at baseline. In the sensitivity analysis that excluded
patients on antiplatelet therapy at baseline and censored
patients starting on antiplatelet therapy during follow-up,
we found similar results as in the main analyses
Figure 3
Cumulative incidence of death for males and females.
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(see online Appendix Supplementary Table II, online-only
material). The sensitivity analysis of deep venous thrombosis
as an outcome showed an adjusted overall lower risk in
females compared with males (see online Appendix
Supplementary Table III, online-only material). When
investigating the composite end point of stroke/thrombo-
embolic event or all-cause death, female sex was associated
with a lower risk of the composite end point in most age
groups; however, the association was weaker than in the
main analysis (see online Appendix Supplementary Table IV,
online-only material).
Discussion
In this large cohort study, we found an association
between female sex and decreased stroke risk in patients
with HF older than 50 years, which persisted after
adjustment for concomitant risk factors. In the older age
groups, where the competing risk of death was
substantial among males in particular, the association
between female sex and stroke risk was attenuated and
even reversed. When considering a more broadly defined
thromboembolic end point, our findings were consistent
with those for stroke, indicating a decreased risk among
females across nearly all age groups.
Previous studies have described the association between
sex and the risk of stroke in HF; however, many studies did
not exclude patients with HF with AF.21–23 Inconsistent
results have been reported,24–26 which may in part be
explained by the severity and type of HF because HF with
preserved ejection fraction is more common in females
than males.27 The etiology of HF is also different in females
compared with males because HF in males are more often
caused by ischemic heart disease, which may have a great
influence on the risk of stroke.28,29
In studies involving patients with AF, some but not all
studies report female sex to be associated with an increased
risk of stroke.30–33 This association appears to be reversed in
the presentHFpopulation. However,we emphasize that our
prognostic findings do not permit etiologic conclusions;
other studies are needed to elucidate biologic reasons for the
differences in male and female patients with HF.
In the HF population, females were generally older than
males, leading to a higher risk of death when age was not
taken into account. However, upon stratification by age
groups, females generally had a lower risk of death.
Females had a lower risk of stroke compared with males,
but this association was attenuated with increasing age.
Considering the 1-year RRs, this phenomenon could be
attributed to the competing risks of death; males die
before they are diagnosed with a stroke. An alternative
explanation could be that HF with an ischemic etiology
may develop at a later age among women.
We took into account competing risks in our analyses, an
issue that has received limited attention in prior literature
on cardiovascular risk stratification. For HF populations
such as the present, where around 60% of participants died
during the first 5 years of follow-up, not accounting for
competing risk of death could lead to overestimation of risk
and inappropriate risk stratification.34,35
Clinical importance
Our finding of a lower risk of stroke in females with HF
compared with males may have prognostic value for
clinicians in daily practice; even if the same comorbidities
are present, males are at a higher risk of stroke. This may
warrant focus on modifiable risk factors in male patients
with HF compared with female patients with HF to
reduce the risk of stroke, especially if the etiology of HF is
due to ischemic heart disease.
Strengths and limitations
This study investigated a contemporary population of
patients with incident HF in sinus rhythm followed up in
nationwide registers, which has limited loss to follow-up,
and therefore, the study is unlikely to be subject to
serious selection bias. The major strengths of this study
Table I. Baseline characteristics of study population, stratified
according to sex
Clinical characteristics Males Females
n (%) 44,196 (52.5) 39,946 (47.5)
Average age at baseline, y (SD) 73 (10.9) 78 (10.7)
Age 50-59 y, % (n) 15.1 (6,652) 7.2 (2,859)
Age 60-69 y, % (n) 25.3 (11,170) 15.1 (6,040)
Age 70-79 y, % (n) 31.2 (13,768) 28,6 (11,421)
Age 80-89 y, % (n) 24.0 (10,598) 36.8 (14,690)
Age 90+ y, % (n) 4.6 (2,008) 12.4 (4,936)
Baseline comorbidity, % (n)
Previous stroke
(ischemic or hemorrhagic)
11.1 (4,913) 10.2 (4,064)
Previous thromboembolism⁎ 40.1 (17,699) 31.6 (12,627)
Previous myocardial infarction 30.0 (13,277) 20.8 (8,316)
Peripheral ischemic disease 11.6 (5,130) 8.8 (3,527)
Vascular disease 37.5 (16,575) 27.1 (10,832)
Diabetes 15.6 (6,896) 12.8 (5,125)
Hypertension 30.3 (13,406) 32.9 (13,124)
Renal disease 6.8 (3,014) 4.9 (1,974)
Liver disease 0.6 (261) 0.4 (145)
Hyperthyroidism 0.9 (378) 3.7 (1,488)
COPD 17.4 (7,668) 19.3 (7,694)
Baseline medication, % (n)
ACE inhibitors 44.9 (19,849) 32.8 (13,092)
Aldosterone antagonists 6.9 (3,036) 8.0 (3,199)
β-Blockers 38.8 (17,161) 29.7 (11,842)
Non–loop diuretics 29.7 (13,117) 31.0 (12,370)
Loop diuretics 55.0 (24,288) 57.1 (22,798)
Statins 29.0 (12,839) 18.7 (7,477)
NSAIDs 10.9 (4,824) 13.6 (5,412)
Aspirin 40.3 (17,828) 34.6 (13,816)
Thienopyridines 13.7 (6,067) 8.6 (3,430)
Abbreviations: COPD, Chronic obstructive pulmonary disease; ACE, angiotensin-
converting enzyme; NSAIDs, nonsteroidal antiinflammatory drugs.
⁎Combined ischemic stroke, transient ischemic attack, systemic embolism, pulmonary
embolism, and acute myocardial infarction.
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are the high validity of the major outcomes and the large
sample size uniquely possible with this type of cohort study.
The study also has several limitations. Because of the
nature of our nationwide registry study, follow-up
depended on the National Civil Registration System,
where some deaths are likely to be attributable to an
undiagnosed stroke. The diagnosis of stroke was defined
by the Danish Hospital Discharge Register, and not all
stroke end points have been defined by cerebral imaging.
Furthermore, we cannot rule out that some patients
might have had undiagnosed AF.
In our study, we were unable to distinguish between HF
with preserved and reduced ejection fraction or estimate the
functional classification, which we recognize as a major
limitation. On the other hand, stroke and thromboembolism
rates are broadly similar in hospitalized patients with HF,
whetherwith preserved or reduced ejection fraction.22,36–38
Around 18% of the study population had a prior diagnosis
of chronic obstructive pulmonary disease; therefore, some
patients might have been misclassified as patients with HF
because of symptoms that were actually related to their
diagnosis of chronic obstructive pulmonary disease.
However, the diagnosis of HF in the Danish National
Patient Registry has been validated as very specific.17
Lastly, the present study only provides information
on the prognostic value of sex, with respect to stroke
risk, when taking into account standard cardiovascular
comorbidities. Other studies are needed to elucidate
biologic reasons for differences in prognosis between
males and females.
In conclusion, we found an association between female
sex and decreased stroke risk in patients with HF, which
persisted after adjustment for concomitant cardiovascular
risk factors. The association was attenuated with increas-
ing age, possibly because of competing risks of death.
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Table II. Relative risks of stroke, all-cause death, and thromboembolic event after 1 year and 5 years of follow-up according to sex and age
group (reference males, RR 1.00)
Primary end point 1 year after HF diagnosis 5 years after HF diagnosis
Stroke Crude RR 95% CI Adjusted RR⁎ 95% CI Crude RR 95% CI Adjusted RR⁎ 95% CI
Overall 0.90 0.84-0.97 0.91 0.83-1.00 0.92 0.87-0.97 0.91 0.85-0.96
Age (y), 50-59 0.70 0.51-0.96 0.85 0.59-1.23 0.95 0.77-1.17 1.00 0.80-1.25
Age (y), 60-69 0.73 0.61-0.88 0.86 0.69-1.07 0.72 0.64-0.82 0.81 0.70-0.92
Age (y), 70-79 0.86 0.76-0.97 0.93 0.80-1.08 0.89 0.81-0.97 0.89 0.81-0.98
Age (y), 80-89 0.97 0.85-1.10 0.93 0.80-1.09 1.02 0.93-1.12 0.96 0.87-1.07
Age (y), 90+ 1.25 0.89-1.76 1.38 0.89-2.15 1.23 0.94-1.61 1.33 0.98-1.79
Death Crude RR 95% CI Adjusted RR⁎ 95% CI Crude RR 95% CI Adjusted RR⁎ 95% CI
Overall 1.18 1.15-1.21 0.90 0.88-0.93 1.13 1.11-1.14 0.93 0.92-0.94
Age (y), 50-59 0.95 0.81-1.10 0.97 0.83-1.14 0.85 0.76-0.95 0.85 0.76-0.94
Age (y), 60-69 1.07 0.99-1.16 1.09 1.01-1.18 0.95 0.91-1.00 0.95 0.90-1.00
Age (y), 70-79 0.97 0.93-1.02 0.98 0.93-1.02 0.94 0.92-0.97 0.94 0.91-0.97
Age (y), 80-89 0.90 0.87-0.93 0.90 0.87-0.93 0.92 0.90-0.94 0.92 0.90-0.93
Age (y), 90+ 0.82 0.78-0.86 0.83 0.79-0.87 0.95 0.93-0.98 0.95 0.93-0.97
Secondary end point 1 year after HF diagnosis 5 years after HF diagnosis
Thromboembolic event† Crude RR 95% CI Adjusted RR⁎ 95% CI Crude RR 95% CI Adjusted RR⁎ 95% CI
Overall 0.86 0.83-0.89 1.00 0.96– 1.04 0.91 0.88-0.94 0.93 0.91-0.96
Age (y), 50-59 0.74 0.64-0.86 1.01 0.88-1.16 0.69 0.59-0.82 0.86 0.74-0.99
Age (y), 60-69 0.78 0.71-0.85 1.00 0.91-1.08 0.75 0.68-0.81 0.87 0.81-0.94
Age (y), 70-79 0.88 0.83-0.94 1.03 0.97-1.10 0.89 0.84-0.93 0.96 0.92-1.01
Age (y), 80-89 0.86 0.80-0.91 0.97 0.91-1.03 0.88 0.85-0.92 0.94 0.90-0.98
Age (y), 90+ 0.91 0.80-1.04 1.07 0.92-1.24 0.93 0.86-1.00 1.01 0.93-1.10
Wald test for age-by-sex interaction in the adjusted analyses according to end point: stroke 1 year, P = .43; stroke 5 years, P = .03; death 1 year, P = .00; death 5 years, P = .02;
thromboembolism 1 year, P = .60; thromboembolism 5 years, P = .07.
⁎Adjusted for hypertension (binary), diabetes (binary), prior thromboembolism (binary), vascular disease (binary), and age (continuous).
†Combined ischemic stroke, transient ischemic attack, systemic embolism, pulmonary embolism, and acute myocardial infarction.
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Appendix
Supplementary Table I. ICD-10 codes and ATC codes used in the cohort study
ICD-10 codes and ATC codes used in the study
Main diagnosis ICD-10 codes
Congestive HF I50.0-I50.9, I11.0, I13.0, I13.2
End points
Stroke (ischemic) I63.0-I63.9, I64.9
Ischemic stroke (thromboembolic event) I63.0-I63.9, I64.9
Transient ischemic attack (thromboembolic event) G45.0-G45.9⁎
Systemic embolism (thromboembolic event) I74.0-I74.9
Pulmonary embolism (thromboembolic event) I26.0-I26.9
Acute myocardial infarction (thromboembolic event) I21.0-I21.9, I23.0-I23.9
Deep venous thrombosis I80.1-I80.9, I81.9, I63.6, I67.6, I82.2, I82.3, I82.8, I82.9
Comorbidities
Prior stroke (ischemic or hemorrhagic) I60.0-I60.9, I61.0-I61.9, I62.0-I62.9, I63.0-I63.9, I64.9
Acute myocardial infarction I21.0-I21.9, I23.0-I23.9
Peripheral ischemic disease† I70.2-I70.9, I71.0-I71.9, I73.9
Vascular disease I21.0-I21.9, I23.0-I23.9, I70.0, I70.2-I70.9, I71.0-I71.9, I73.9
Diabetes mellitus E10.0-E10.9, E11.0-E11.9
Hypertension I10.0-I10.9, I11.0-I11.9, I12.0-I12.9, I13.0-I13.9, I15.0–I15.9
Renal disease I12.0-I12.9, I13.0-I13.9, N00-N07, N11.0-N11.9, N14.0-N14.4,
N17.0-N17.9, N18.0-N18.9, N19, Q61.0-Q61.9
Liver disease B15.0-B15.9, B16.0-B16.9, B17.0-B17.9, B18.0-B18.9, B19.0-B19.9, K70.4,
K72.0-K72.9, K76.6
Hyperthyroidisme E05.0-E05.9, E06.0-E06.9
Chronic obstructive pulmonary disease (COPD) J44.0-J44.9
AF and flutter (exclusion criteria) I48
Valvular disease (exclusion criteria) I05.0-I05.9, I06.0-I06.9, I34.0-I34.9, I35.0-I35.9
Mechanical cardiac valve (exclusion criteria) Z95.2, Z95.3, Z95.4
Cancer any type (exclusion criteria) C00-C97
Concomitant medication ATC codes
Warfarin (exclusion criteria) B01AA03
Phenprocoumon (exclusion criteria) B01AA04
ACE-inhibitors C09AA
Angiotension receptor blockers C09CA
Beta-blockers C07
Non-loop diuretics C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D,
C08G,C09BA, C09DA, C09XA52
Aldosterone antagonists C03DA
Concomitant medication
Loop diuretics C03C
Statins C10
Non steroidal anti-inflammatory drugs (NSAIDs) M01A
Aspirin B01AC06
Thienopyridines B01AC04, B01AC22, B01AC24
⁎Not inclusive G45.3 (Amaurosis fugax).
† Peripheral arterial disease refers to the obstruction of large arteries not within the coronary, aortic arch vasculature, or brain.
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Supplementary Table II. Sensitivity analysis after excluding patients on antiplatelet therapy at baseline and censoring during follow-up: RRs of
stroke, all-cause death, and thromboembolic event after 1 year and 5 years of follow-up according to sex and age group (reference: males, RR 1.00)
Primary end point 1 year after HF diagnosis 5 years after HF diagnosis
Stroke Crude RR 95% CI Adjusted RR⁎ 95% CI Crude RR 95% CI Adjusted RR⁎ 95% CI
Overall 0.79 0.71-0.89 0.92 0.80-1.06 0.90 0.82-1.00 0.96 0.87-1.06
Age (y), 50-59 0.40 0.21-0.75 0.63 0.35-1.14 0.43 0.21-0.87 0.56 0.34-0.94
Age (y), 60-69 0.70 0.53-0.93 0.95 0.69-1.31 0.77 0.60-0.98 0.94 0.74-1.19
Age (y), 70-79 0.78 0.64-0.94 1.03 0.82-1.28 0.89 0.75-1.04 0.96 0.82-1.12
Age (y), 80-89 0.92 0.75-1.13 0.91 0.72-1.16 1.11 0.94-1.32 1.11 0.93-1.31
Age (y), 90+ 0.97 0.57-1.64 0.98 0.51-1.86 1.11 0.68-1.82 1.28 0.78-2.08
Death Crude RR 95% CI Adjusted RR⁎ 95% CI Crude RR 95% CI Adjusted RR⁎ 95% CI
Overall 1.05 1.02-1.09 0.89 0.87-0.92 1.04 1.01-1.06 0.92 0.90-0.94
Age (y), 50-59 0.73 0.58-0.92 0.77 0.62-0.96 0.45 0.33-0.62 0.48 0.36-0.65
Age (y), 60-69 0.86 0.77-0.96 0.90 0.82-1.00 0.76 0.70-0.83 0.77 0.71-0.84
Age (y), 70-79 0.91 0.86-0.97 0.95 0.89-1.00 0.90 0.86-0.94 0.90 0.87-0.94
Age (y), 80-89 0.88 0.84-0.92 0.90 0.86-0.94 0.94 0.91-0.97 0.95 0.92-0.98
Age (y), 90+ 0.82 0.77-0.87 0.84 0.79-0.90 0.99 0.95-1.04 1.00 0.96-1.04
Secondary end point 1 year after HF diagnosis 5 years after HF diagnosis
Thromboembolic event† Crude RR 95% CI Adjusted RR⁎ 95% CI Crude RR 95% CI Adjusted RR⁎ 95% CI
Overall 0.82 0.77-0.88 0.98 0.91-1.04 0.89 0.83-0.94 0.91 0.86-0.96
Age (y), 50-59 0.57 0.40-0.83 0.86 0.64-1.15 0.30 0.09-0.96 0.50 0.28-0.87
Age (y), 60-69 0.67 0.56-0.80 0.95 0.81-1.12 0.58 0.46-0.72 0.74 0.62-0.88
Age (y), 70-79 0.81 0.73-0.91 1.00 0.90-1.11 0.89 0.80-0.99 0.96 0.88-1.06
Age (y), 80-89 0.88 0.79-0.99 1.00 0.90-1.12 0.92 0.84-1.01 0.98 0.90-1.07
Age (y), 90+ 0.95 0.75-1.21 1.08 0.85-1.38 0.92 0.78-1.09 1.00 0.85-1.17
⁎Adjusted for hypertension (binary), diabetes (binary), prior thromboembolism (binary), prior myocardial infarction (binary), peripheral artery disease (binary), and age (continuous).
†Combined ischemic stroke, transient ischemic attack, systemic embolism, pulmonary embolism, and acute myocardial infarction.
Supplementary Table III. Relative risks of deep venous thrombosis after 1 year and 5 years of follow-up according to sex and age group
(reference: males, RR 1.00)
End point 1 year after HF diagnosis 5 years after HF diagnosis
Deep venous thrombosis Crude RR 95% CI Adjusted RR⁎ 95% CI Crude RR 95% CI Adjusted RR⁎ 95% CI
Overall 1.18 0.98-1.41 0.85 0.61-1.18 1.16 1.03-1.30 0.95 0.79-1.14
Age (y), 50-59 1.78 1.00-3.18 1.26 0.31-5.11 1.12 0.77-1.63 0.78 0.43-1.40
Age (y), 60-69 1.03 0.66-1.59 0.94 0.42-2.09 1.18 0.91-1.53 0.96 0.66-1.38
Age (y), 70-79 1.15 0.84-1.58 0.79 0.40-1.59 1.20 0.98-1.48 0.98 0.71-1.35
Age (y), 80-89 1.01 0.72-1.40 0.76 0.42-1.37 1.24 0.99-1.56 1.04 0.75-1.44
Age (y), 90+ 2.60 0.95-7.10 1.90 0.25-14.18 3.12 1.20-8.12 2.29 0.59-8.94
⁎Adjusted for hypertension (binary), diabetes (binary), prior thromboembolism (binary), prior deep venous thrombosis (binary), prior myocardial infarction (binary), peripheral artery
disease (binary), and age (continuous).
Supplementary Table IV. Relative risks of stroke/thromboembolism or all-cause death after 1 year and 5 years of follow-up according to sex
and age group (reference: males, RR 1.00)
End point 1 year after HF diagnosis 5 years after HF diagnosis
Composite end point Crude RR 95% CI Adjusted RR⁎ 95% CI Crude RR 95% CI Adjusted RR⁎ 95% CI
Overall 1.05 1.05-1.07 0.94 0.93-0.96 1.06 1.04-1.07 0.94 0.93-0.95
Age (y), 50-59 0.86 0.78-0.94 0.93 0.85-1.02 0.84 0.78-0.89 0.86 0.80-0.91
Age (y), 60-69 0.93 0.88-0.98 0.99 0.94-1.04 0.91 0.88-0.95 0.93 0.90-0.96
Age (y), 70-79 0.95 0.91-0.98 1.00 0.96-1.03 0.94 0.92-0.96 0.95 0.94-0.97
Age (y), 80-89 0.90 0.87-0.92 0.93 0.90-0.95 0.94 0.92-0.95 0.94 0.93-0.95
Age (y), 90+ 0.84 0.80-0.87 0.87 0.84-0.91 0.96 0.94-0.98 0.97 0.95-0.98
⁎Adjusted for hypertension (binary), diabetes (binary), prior thromboembolism (binary), prior myocardial infarction (binary), peripheral artery disease (binary), and age (continuous).
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Abstract 
Background: Stroke and mortality risk among heart failure patients previously diagnosed with different manifestations 
of vascular disease is poorly described. We conducted an observational study to evaluate the stroke and mortality risk 
among heart failure patients without diagnosed atrial fibrillation and with peripheral artery disease (PAD) or prior 
myocardial infarction (MI). 
Methods: Population-based cohort study of patients diagnosed with incident heart failure during 2000-2012 and 
without atrial fibrillation, identified by record linkage between nationwide registries in Denmark. Hazard rate ratios of 
ischemic stroke and all-cause death after 1 year of follow-up were used to compare patients with either: a PAD 
diagnosis; a prior MI diagnosis; or no vascular disease.  
Results: 39,357 heart failure patients were included. When compared to heart failure patients with no vascular disease, 
PAD was associated with a higher 1-year rate of ischemic stroke (adjusted hazard rate ratio [HR]: 1.34, 95% confidence 
interval [CI]: 1.08-1.65) and all-cause death (adjusted HR: 1.47, 95% CI: 1.35-1.59), whereas prior MI was not 
(adjusted HR: 1.00, 95% CI: 0.86-1.15 and 0.94, 95% CI: 0.89-1.00, for ischemic stroke and all-cause death, 
respectively). When comparing patients with PAD to patients with prior MI, PAD was associated with a higher rate of 
both outcomes. 
Conclusions: Among incident heart failure patients without diagnosed atrial fibrillation, a previous diagnosis of PAD 
was associated with a significantly higher rate of the ischemic stroke and all-cause death compared to patients with no 
vascular disease or prior MI. Prevention strategies may be particularly relevant among HF patients with PAD. 
 
Introduction 
Heart failure (HF) is associated with an increased risk 
of ischemic stroke and mortality[1], for which vascular 
disease is also an established risk factor[2,3]. In the 
general population, vascular disease is associated with 
an increased risk of cardiovascular events[4,5]. 
However, currently there is a lack of research on risk of 
ischemic stroke and mortality among incident HF 
patients in sinus rhythm previously diagnosed with 
different manifestations of vascular disease. Estimating 
the risk of ischemic stroke and all-cause death among 
HF patients in sinus rhythm with vascular disease is an 
important step towards finding subgroups of HF 
patients who might benefit from thromboprophylaxis, 
as suggested in a recent study[6] which found a high 
risk of ischemic stroke and thromboembolism among 
HF patients without AF.  
 
Vascular disease is a broad term, including two 
common and severe diseases, that is, peripheral artery 
disease (PAD) and myocardial infarction (MI). HF is 
known to be complicated by comorbidities such as 
PAD and prior MI[7,8], and assessment of these two 
comorbidities in relation to ischemic stroke, mortality, 
and prevention is important in a HF setting. However, 
PAD and prior MI may not confer the same risk of 
ischemic stroke[9]. Accordingly, evaluation of the 
association between vascular disease and ischemic 
stroke risk in the HF population requires investigating 
PAD and prior MI separately, as previously done in 
other settings[9,10]. The task of identifying subgroups 
of patients with HF who are at a high risk of stroke is 
clinically highly relevant because many such strokes 
may be preventable, for example, by pharmacological 
thromboprophylaxis. 
 
 
The objective of the present observational cohort study 
was to assess the prognostic value of a prior diagnosis 
of PAD or MI in relation to the risk of ischemic stroke 
and all-cause death in HF patients, using Danish 
nationwide administrative registry data. We 
hypothesized that in a population of incident HF 
patients without AF (and not taking a vitamin K 
antagonist (VKA) to avoid issues with effect 
modification by anticoagulation therapy), a prior 
diagnosis of either PAD or MI would be associated 
with a higher risk of ischemic stroke and all-cause 
death, when compared to no vascular disease, also 
when taking into account concomitant cardiovascular 
risk factors of ischemic stroke. Second, we 
hypothesized that PAD and prior MI would not 
contribute equally to this risk, since a difference in risk 
of ischemic stroke and all-cause death has been 
observed in other cardiovascular settings[9]. 
 
Methods 
Registry Data Sources 
We used three different nationwide registries in this 
study: i) The Danish National Patient Registry[11] 
which has registered all hospital admissions along with 
diagnoses since 1977 and codes all diagnoses 
according to the 10
th
 revision of the International 
Classification of Diseases (ICD-10) since 1994; ii) The 
National Prescription Registry[12] which contains data 
on all prescriptions dispensed from Danish pharmacies 
since 1994, coded according to the Anatomical 
Therapeutic Chemical (ATC) Classification System; 
iii) The Danish Civil Registration System which holds 
information on date of birth, migration, vital status, 
date of death, and sex of all persons living in 
Denmark[13]. Data were linked via unique personal 
identification number used in all Danish national 
registries. All three registries were up to December 31
st
 
2012. These registries have previously been 
validated[11,12,14], and the diagnosis of HF, ischemic 
stroke, PAD and MI was found to be valid[14–16]. 
Study Population 
The study population was identified as in- or 
outpatients aged>50 years, diagnosed with a primary 
discharge diagnosis of incident (first-time diagnosis) 
HF in the period January 1
st
 2000 - December 31
st
 2012 
(ICD-10: I50, I42.0, I11.0, I13.0, I13.2). “Vascular 
disease” was defined as a diagnosis of either PAD 
(ICD-10: I70.2-I70.9, I73.9) or MI (ICD-10: I21.0-
I21.9, I23.0-I23.9) between 1994 and time of HF 
diagnosis. Patients with prior diagnoses of both PAD 
and MI were not included in the analyses: this is a 
small and seriously ill patient group, against which 
direct comparisons would have both limited statistical 
power and clinical use. To restrict to patients without 
AF, we excluded those who had a prior diagnosis of 
AF or atrial flutter (I48) between 1994 and time of HF 
diagnosis. We moreover excluded patients treated with 
a vitamin K antagonist (ATC: B01AA03, B01AA04) 
within six months prior to the HF diagnosis to avoid 
considering effect modification by anticoagulation 
therapy. Lastly, patients with a diagnosis of cancer 
(ICD-10: C00-C97) within 5 years before HF diagnosis 
were excluded, since cancer patients represent a 
subgroup with high stroke risk[17] and specialized 
thromboprophylactic treatment regimens. 
Additional comorbidities were assessed at time of HF 
diagnosis identified using the Danish National Patient 
Registry and the Danish National Prescription Registry 
which have registered diagnoses (using ICD-10) and 
prescriptions since 1994. Ascertainment of baseline 
medication status was based on medication purchase in 
a 45-day window before or after the date of HF 
diagnosis. ICD-codes and ATC-codes used to define 
comorbidities and medical therapy are provided in the 
Supplementary material [please see S1 Table in the 
supporting materials]. 
Outcomes 
The primary endpoint was defined as an ischemic 
stroke diagnosis (ICD-10: I63, I64). Because of the 
high mortality in the HF population and the fact that in 
registries some deaths may be due to undiagnosed 
stroke, especially since postmortems and cerebral 
scanning are not mandated, all-cause death was also 
included as a primary endpoint.  
Statistical Methods  
Baseline characteristics were described separately for 
patients with no vascular disease, PAD, and prior MI; 
using means and standard deviation for continuous 
variables, and proportions for categorical variables.  
Time-to-event analysis was used to describe the 
association with the three-level vascular disease 
exposure (no vascular disease; prior PAD; prior MI) 
and risk of ischemic stroke or all-cause death. Time at 
risk was measured from baseline date (date of HF 
diagnosis) and until an event of ischemic stroke, all-
cause death, emigration, or end of study (December 
31
st
 2012), whichever came first. Additionally, patients 
were censored if they initiated anticoagulant therapy 
during the follow-up period. 
We have previously advocated risks (probabilities) 
rather than rates for assessing associations in a HF 
population, since risks lead to statements which are 
more clinically and prognostically relevant when faced 
with a high competing mortality risk[18]. However, 
strong differential competing mortality across exposure 
levels can lead to counterintuitive findings on a risk 
scale. This is a real concern for vascular disease as an 
exposure. Accordingly, we reported associations in 
terms of (Cox model) hazard rate ratios after 1 year of 
 
 
follow-up. Following the suggestions of Andersen et 
al.[19] to consider both risk and rate assessments, we 
repeated this analysis on a risk (ratio) scale; see the 
Supplementary material for methodological details.  
Specifically, for the primary analysis, Cox regression 
was used to calculate 1-year hazard rate ratios of the 
endpoints according to the presence of PAD or prior 
MI (5-year hazard ratios are reported in the 
Supplementary material). Concomitant baseline 
comorbidities such as hypertension, diabetes, renal 
disease, and prior ischemic stroke are well-known risk 
factors of ischemic stroke in other heart 
diseases[20,21]. Thus, in order to assess the 
independent prognostic value of PAD and prior MI, we 
also fitted Cox models after adjusting for these risk 
factors; alongside with chronic obstructive pulmonary 
disease (COPD), age and sex. Antiplatelet therapy may 
modify the association between vascular disease and 
ischemic stroke risk; therefore, we calculated 1-year 
hazard rate ratios of the endpoints according to the 
presence of PAD or prior MI, and stratified by 
antiplatelet therapy at baseline (5-year hazard ratios are 
reported in the Supplementary material). 
We performed a sensitivity analysis in which we 
censored patients receiving a diagnosis of AF during 
follow-up. We also performed a sensitivity analysis in 
which patients with a history of stroke were excluded 
(since a prior stroke diagnosis is a strong risk factor for 
a subsequent stroke)[22].  
The analyses were performed using Stata version 13 
(Stata Corporation, College Station, TX, USA). A two-
sided p-value of <0.05 was considered statistically 
significant. The study was conducted and reported in 
accordance with the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) 
recommendations. 
Ethical Considerations 
No ethical approval is required for anonymous register 
studies in Denmark. The study was approved by the 
Danish Data Protection Agency (J. No. File No. 2012-
41-0633). 
 
Results 
The study population comprised 39,357 HF patients 
aged>50 years, among which 69.2% had no vascular 
disease, 5.8% had PAD and 21.7% had prior MI (3.3% 
had both) [please see Figure 1 at the end of the 
manuscript]. The median follow-up time for ischemic 
stroke or all-cause death was 2.5 years (interquartile 
range 0.6-5.3).  
Baseline patient characteristics are summarized in 
Table 1 at the end of the manuscript. The mean age 
among patients with no vascular disease was 74.3 years 
(standard deviation (SD): 11.7) compared to 74.9 years 
(SD: 9.9) and 73.1 years (SD: 10.9) years for patients 
with PAD and prior MI, respectively. Patients with 
PAD had more often experienced a previous stroke or 
transient ischemic attack compared to both patients 
with prior MI or no vascular disease, and the 
prevalence of diabetes, hypertension, renal disease, and 
COPD was higher in patients with PAD. More patients 
with prior MI were taking medical therapy with ACE-
inhibitors, beta-blockers and statins. Furthermore, 
almost 75% of the patients with prior MI were on 
antiplatelet therapy, compared to around 50% of the 
patients with PAD.  
The number of ischemic strokes and deaths in each 
patient group after 1 year of follow-up are shown in 
Table 2 at the end of the manuscript. For patients with 
no vascular disease, PAD, or prior MI, the absolute 
risks of both endpoints are shown in Table 2. The 1-
year absolute risks of ischemic stroke and all-cause 
death were highest in patients with PAD (4.7% and 
30.8%, respectively). For the 5-year event numbers and 
absolute risks please see e-Table 2 in the 
Supplementary material.  
In the Cox regression analysis, when compared to HF 
patients with no vascular disease, PAD was associated 
with a higher 1-year rate of ischemic stroke (adjusted 
hazard rate ratio [HR]: 1.34, 95% confidence interval 
[CI]: 1.08-1.65) and all-cause death (adjusted HR: 
1.47, 95% CI: 1.35-1.59), whereas prior MI was not 
(adjusted HR: 1.00, 95% CI: 0.86-1.15 and 0.94, 95% 
CI: 0.89-1.00, for ischemic stroke and all-cause death, 
respectively), as shown in Table 3 at the end of the 
manuscript. When comparing patients with PAD to 
patients with prior MI, PAD was associated with a 
higher rate of both endpoints (adjusted HR: 1.36, 95% 
CI: 1.07-1.72 and 1.53, 95% CI: 1.40-1.68, for 
ischemic stroke and all-cause death, respectively). 
Similar results were obtained after 5-years follow-up 
[please see e-Table 3 in the Supplementary material]. 
The stratified HRs of ischemic stroke and all-cause 
death after 1-year follow-up, according to antiplatelet 
therapy at baseline, are shown in Table 4 at the end of 
the manuscript. Regardless of antiplatelet therapy 
status at baseline, PAD was associated with a higher 1-
year rate of ischemic stroke and all-cause death when 
compared to HF patients with no vascular disease or 
prior MI. In patients on antiplatelet therapy, we found 
similar rates of ischemic stroke and all-cause death 
among patients with prior MI compared to those with 
no vascular disease. In patients not on antiplatelet 
therapy, prior MI was associated with an increased rate 
of all-cause death, when compared to no vascular 
disease. Similar results were obtained after 5-years 
 
 
follow-up [please see e-Table 4 in the Supplementary 
material]. 
The 1- and 5-year relative risks of ischemic stroke and 
all-cause death, comparing patients with PAD or prior 
MI to patients with no vascular disease are shown in e-
Table 7 and e-Table 8 in the Supplementary material. 
We found similar crude associations as in the rate-
based calculations, but the associations attenuated after 
adjustment for cardiovascular risk factors, especially 
for the endpoint of ischemic stroke.   
Sensitivity analyses 
In the sensitivity analysis in which patients were 
censored when they were diagnosed with AF during 
follow-up, findings were similar to the main analysis 
[please see e-Table 5 in the Supplementary material]. 
When excluding patients with a history of stroke, PAD 
was associated with an even higher rate of ischemic 
stroke in the adjusted analyses compared to patients 
with no vascular disease and prior MI [please see e-
Table 6 in the Supplementary material].  
 
Discussion 
In this large nationwide cohort study of HF patients 
without AF, we found a significantly higher rate of 
ischemic stroke and all-cause death amongst HF 
patients with PAD compared to patients with no 
vascular disease or prior MI, even after extensive 
adjustment for concomitant cardiovascular risk factors. 
Similar results were obtained in the stratified analysis, 
regardless of antiplatelet therapy. However, for the risk 
(probability) based calculations, the picture was less 
consistent. 
 
 To our knowledge, this is the first study to 
comprehensively evaluate the association between 
PAD and prior MI and ischemic stroke and all-
cause death in a HF population without diagnosed 
AF. The current evidence on the risk of ischemic 
stroke in subgroups of HF patients without diagnosed 
AF is very limited[23–25]. In our population, PAD was 
associated with a roughly 30% higher rate of ischemic 
stroke compared to patients without vascular disease. 
We did not see a similar increased rate of ischemic 
stroke among patients with prior MI, as expected. 
Indeed, we found PAD to be associated with a higher 
rate of ischemic stroke compared to prior MI. 
 
Our findings for the rate of stroke and mortality are 
consistent with the possibility of less secondary 
prevention strategies in PAD patients compared to MI 
patients, as seen in other settings[26,27]. In our study, a 
larger proportion of patients with prior MI were taking 
medical therapy with ACE-inhibitors, beta-blockers, 
statins, and antiplatelet therapy compared to patients 
with PAD. This was despite patients with PAD having 
more comorbidities, such as prior stroke/transient 
ischemic attack, diabetes, and hypertension. The lower 
rate of ischemic stroke and all-cause death among prior 
MI patients compared to PAD patients may reflect a 
more ill patients group of those with PAD[28]. 
Alternatively, these findings may reflect a more 
intensified treatment and prophylaxis among patients 
with coronary artery disease[27]. For example, 
antiplatelet therapy is known to reduce the risk of 
ischemic stroke[29,30]. Our findings in the 
subpopulation of patients on antiplatelet therapy were 
consistent with the hypothesis of more intensified 
treatment and prophylaxis among MI patients, since 
patients on antiplatelet therapy with prior MI or no 
vascular disease had essentially the same rate of 
ischemic stroke.  
 
Clinical implications 
Reduced secondary prevention in PAD patients 
compared to patients with coronary artery disease has 
been observed in several studies[26,27]; not-
withstanding guideline recommendations that the same 
secondary prevention should be used in patients with 
PAD and prior MI[31,32]. Our results provide some 
indication that, in clinical practice, HF patients with 
PAD may represent a higher-risk subgroup in terms of 
ischemic stroke and all-cause death risk compared to 
prior MI patients. It is possible that more focus on 
secondary prevention could improve prognosis for this 
patient group. Currently, an ongoing trial 
(COMMANDER HF) is exploring the efficacy and 
safety of Rivaroxaban (one of the non-vitamin K 
antagonist oral anticoagulants) compared with placebo 
(standard care) after an exacerbation of HF in non-AF 
patients with HF with reduced ejection fraction and 
documented coronary artery disease. However, whether 
full anticoagulation therapy would be beneficial in HF 
patients with PAD is an open question in need of 
further investigation before recommendations about 
changes in management of these patients can be given, 
since recent prospective randomized controlled trials of 
antithrombotic therapy in HF have not investigated 
such subgroup issues[33–36]. 
 
We provided both risk/probability (risk ratio) and rate 
(hazard ratio) assessments of  associations[19]. While 
risk and rate assessments are traditionally thought of as 
being equivalent, they can be fundamentally different 
in the face of competing morality risk[37]. In the 
present study, associations were attenuated when 
viewed on a risk scale. This is important information 
from a clinical perspective, since it may indicate a 
smaller absolute potential (e.g. in terms of number of 
strokes prevented) of prevention strategies among PAD 
patients than otherwise suggested by the hazard ratios. 
 
 
 
 
Strengths and Limitations   
The major strengths of this study are the validated 
outcomes and large sample size uniquely possible 
with this type of cohort study. Selection into the 
study was not an issue, since we investigated a 
nationwide population cohort of incident HF 
patients without AF, with limited loss to follow-up. 
 
The study also has several important limitations. 
We were unable to distinguish between HF with 
preserved and reduced ejection fraction or estimate 
the functional classification, since we did not have 
access to echocardiograms. However, no difference 
in embolic risk (risk of stroke, transient ischemic 
attack, systemic embolism) was found in a recent 
study of non-anticoagulated patients with HF with 
reduced or preserved ejection fraction[38]. 
Similarly, in a post-hoc analysis of a study of AF 
patients with HF with reduced or preserved ejection 
fraction, no difference in ischemic stroke risk was 
found between the groups[39]. The diagnosis of HF 
has previously been validated and had a positive 
predictive value of 81-100%[16,40]. Based on the 
validation study, we did not capture all patients 
with HF and also cannot be certain that all patients 
identified as having HF had definite HF, which 
could lead to imprecision in the risk estimates. 
However, we included only patients with a primary 
discharge diagnosis of HF to optimize the 
probability of including only correctly identified 
patients with HF. We excluded HF patients younger 
than 50 years of age, and accordingly, our findings 
may not apply to younger HF patients. 
 
The exposure variable of vascular disease may also 
be subject to misclassification and incomplete 
ascertainment. Moreover, we did not have 
information about the ankle-brachial index, and 
were hence unable to use this measurement in the 
definition of PAD.  
 
We lacked information on smoking habits, which is 
a key concomitant risk factor for ischemic stroke; it 
is possible that some of the association between 
PAD and ischemic stroke risk is explained by 
smoking, but since the focus of the study was on 
the prognostic value of vascular disease in relation 
to ischemic stroke, not its causal role, confounding 
is not an issue. Similarly, we did not have 
information about the etiology of HF, which could 
influence the association between vascular disease 
and stroke risk; however, we were only interested 
in the prognostic importance of vascular disease, 
not the causal association. 
 
We included unspecified stroke (ICD-10: I64) in 
the definition of ischemic stroke, as most strokes 
are of ischemic origin. However, we cannot rule out 
that some of these strokes might have been 
hemorrhagic strokes and thus, misclassified as 
ischemic strokes. Also, we cannot rule out that 
some patients might have had undiagnosed AF, 
since heart disease is associated with an increased 
risk of developing AF, however, censoring for 
presence of AF during follow-up did not change the 
main conclusions.  
 
Last, the study was carried as a nationwide study in 
the Danish population, which both ethnically and 
socioeconomically is fairly homogeneous. Future 
studies are needed to evaluate if our findings hold 
in more diverse populations. 
 
Conclusion 
Among incident HF patients without AF, prior PAD 
was associated with a significantly higher rate of 
ischemic stroke and all-cause death compared to 
both patients with no vascular disease and with 
prior MI, even after adjustment for concomitant 
cardiovascular risk factors. 
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Table 1: Baseline characteristics of study population, stratified according to vascular disease. 
 
 
 
 
 
 
 
 
  
 
 
 
Clinical characteristics 
No vascular 
disease 
Peripheral 
artery disease 
Prior 
myocardial 
infarction 
 
N, % (n) 69.2 (27,242) 5.8 (2,274) 21.7 (8,556) 
 
 
Sex (females), % (n) 48.4 (13,191) 45.3 (1,030) 33.0 (2,824) 
 
Average age at baseline, years (SD) 74.3  (11.7)  74.9 (9.9)  73.1 (10.9) 
 
 
Baseline comorbidity, % (n)  
  
 
Previous stroke/transient ischemic attack 11.2 (3,060)  22.3 (507)  14.1 (1,203) 
 
Diabetes 12.0 (3,264) 23.1 (525) 16.1 (1,374) 
 
Hypertension 28.5 (7,752)  44.5 (1,012)  35.0 (2,991) 
 
Renal Disease 4.5 (1,215)  10.0 (228)  5.8 (495) 
 
Liver Disease 0.5 (136) 0.4 (9) 0.3 (29) 
 
Hyperthyroidism 2.7 (723) 3.7 (83) 2.1 (182) 
 
COPD 13.3 (3,632)  19.7 (447)  11.2 (959) 
 
  
Baseline medication, % (n)  
 
  
 
ACE-inhibitors 47.9 (13,040) 46.5 (1,058) 62.5 (5,345) 
 
Angiotensin receptor blocker 10.0 (2,721) 12.8 (292) 11.0 (941) 
 Beta-blockers 37.2 (10,138) 36.8 (837) 64.3 (5,497) 
 
Aldosterone antagonists 22.9 (6,225) 22.7 (516) 23.3 (1,990) 
 
Non-loop diuretics 40.0 (10,902) 40.0 (910) 35.5 (3,034) 
 
Loop diuretics 66.2 (18,041) 70.8 (1,609) 60.6 (5,185) 
 
Statins 21.0 (5,732) 34.0 (772) 57.1 (4,888) 
 
NSAIDs 14.6 (3,973) 14.4 (327) 12.3 (1,048) 
 
Aspirin 40.5 (11,032) 49.7 (1,129) 68.4 (5,851) 
 
Thienopyridines 3.8 (1,043) 6.4 (145) 31.6 (2,703) 
 
 
(Abbreviations: COPD=chronic obstructive pulmonary disease; NSAIDs=non-steroidal anti-
inflammatory drugs; SD=standard deviation; TIA=transient ischemic attack) 
 
 
 
 
Table 2: Event numbers and absolute risks of ischemic stroke and all-cause death after 1-year follow-up, 
according to vascular disease. 
 
  
ENDPOINT 
Event 
number 
Absolute 
risk*, % 
     
Ischemic stroke      
 No vascular disease   705  2.7 
 PAD   101  4.7 
 Prior MI   250  3.0 
All-cause death       
 No vascular disease   5486  21.5 
 PAD   661  30.8 
 Prior MI   1509  18.5 
       
(Abbreviations: HF: heart failure; MI: myocardial infarction; PAD: 
peripheral artery disease) 
*Taking into account competing risks of death (Aalen-Johansen 
estimator). 
 
 
 
Table 3: Hazard rate ratios of ischemic stroke and all-cause death after 1-year follow-up, according to vascular 
disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ENDPOINT PRIMARY EFFECT ESTIMATES 
Ischemic stroke 
Crude HR 
(95% CI) 
Adjusted HR* 
(95% CI) 
     
 PAD vs. no vascular disease 1.82 (1.47 – 2.24) 1.34 (1.08 – 1.65) 
 Prior MI vs. no vascular disease 1.09 (0.94 – 1.26) 1.00 (0.86 – 1.15) 
 PAD vs. prior MI 1.67 (1.32 – 2.10) 1.36 (1.07 – 1.72) 
      
All-cause death 
Crude HR 
(95% CI) 
Adjusted HR* 
(95% CI) 
     
 PAD vs. no vascular disease 1.51
 
(1.40 – 1.64) 1.47 (1.35 – 1.59) 
     Prior MI vs. no vascular disease 0.85 (0.80 – 0.90) 0.94 (0.89 – 1.00) 
      PAD vs. prior MI 1.78 (1.63 – 1.95) 1.53 (1.40 – 1.68) 
      
 
(Abbreviations: HF: heart failure; HR: hazard ratio; MI: myocardial infarction; PAD: 
peripheral artery disease;  95% CI: 95% confidence interval) 
 
*Adjusted for sex (binary), hypertension (binary), diabetes (binary), prior stroke/transient 
ischemic attack (binary), COPD (binary), renal disease (binary), and age (continuous) 
 
 
 
Table 4: Hazard rate ratios of ischemic stroke and all-cause death after 1-year follow-up, stratified by 
antiplatelet therapy at baseline. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
ENDPOINT STRATIFIED ADJUSTED ESTIMATES* 
Ischemic stroke 
No antiplatelet therapy 
HR (95% CI) 
Antiplatelet therapy 
HR (95% CI) 
     
 PAD vs. no vascular disease 1.49 (1.10 – 2.01) 1.23 (0.91 – 1.65) 
 Prior MI vs. no vascular disease 1.03 (0.79 – 1.34) 1.02 (0.85 – 1.22) 
 PAD vs. prior MI 1.45 (1.00 – 2.12) 1.23 (0.90 – 1.68) 
      
All-cause death 
No antiplatelet therapy 
HR (95% CI) 
Antiplatelet therapy 
HR (95% CI) 
     
 PAD vs. no vascular disease 1.43
 
(1.29 – 1.60) 1.65 (1.45 – 1.86) 
     Prior MI vs. no vascular disease 1.27 (1.17 – 1.38) 0.99 (0.91 – 1.07) 
      PAD vs. prior MI 1.11 (0.98 – 1.26) 1.64 (1.44 – 1.87) 
      
 
(Abbreviations: HF: heart failure; MI: myocardial infarction; PAD: peripheral artery disease;  
HR: hazard ratio; 95% CI: 95% confidence interval) 
 
*Adjusted for sex (binary), hypertension (binary), diabetes (binary), prior stroke/transient 
ischemic attack (binary), COPD (binary), renal disease (binary), and age (continuous) 
 
Figure 1: Flowchart of patients included in the final study population. 
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 e-Table 1. ICD-10 codes and ATC-codes used in the cohort study. 
 
ICD 10-Codes and ATC-Codes used in the Study 
 Main diagnosis ICD 10-Codes 
Congestive heart failure I50.0-I50.9, I11.0, I13.0, I13.2 
Acute myocardial infarction I21.0-I21.9, I23.0-I23.8 
Peripheral arterial disease*
 
I70.2-I70.9, I73.9 
Endpoint  
Stroke (ischemic) I63.0-I63.9, I64 
Comorbidities ICD 10-Codes 
Prior stroke (ischemic or 
hemorrhagic) / transient ischemic 
attack 
I60.0-I60.9, I61.0-I61.9, I62.0-I62.9, I63.0-I63.9, I64.9, G45† 
Vascular disease I21.0-I21.9, I23.0-I23.9, I70.0, I70.2-I70.9, I73.9 
Diabetes mellitus E10.0-E10.9, E11.0-E11.9 
Hypertension I10.0-I10.9, I11.0-I11.9, I12.0-I12.9, I13.0-I13.9, I15.0–I15.9 
Renal disease 
I12.0-I12.9, I13.0-I13.9, N00-N07, N11.0-N11.9, N14.0-N14.4, N17.0-N17.9, 
N18.0-N18.9, N19, Q61.0-Q61.9 
Liver disease 
B15.0-B15.9, B16.0-B16.9, B17.0-B17.9, B18.0-B18.9, B19.0-B19.9, K70.4, 
K72.0-K72.9, K76.6 
Hyperthyroidisme E05.0-E05.9, E06.0-E06.9 
Chronic obstructive pulmonary 
disease (COPD) 
J44.0-J44.9 
Atrial fibrillation and flutter 
(exclusion criteria) 
I48 
Cancer any type (exclusion criteria) C00-C97 
Concomitant medication ATC-Codes 
Warfarin (exclusion criteria) B01AA03 
Phenprocoumon (exclusion criteria) B01AA04 
ACE-inhibitors C09AA 
Angiotension receptor blockers C09CA 
Beta-blockers C07 
Non-loop diuretics 
C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, 
C08G,C09BA, C09DA, C09XA52  
Aldosterone antagonists C03DA 
Loop diuretics C03C 
Statins C10 
Non steroidal anti-inflammatory 
drugs (NSAIDs) 
M01A 
Aspirin B01AC06 
Thienopyridines B01AC04, B01AC22, B01AC24 
 
*Peripheral arterial disease, refers to the obstruction of large arteries not within the coronary, aortic arch 
vasculature, or brain  
†Not inclusive G45.3 (Amaurosis fugax) 
 
e-Table 2. Event numbers and absolute risks of ischemic stroke and all-cause death after 5-
years follow-up, according to vascular disease. 
 
 
  
ENDPOINT Event number Absolute risk*, % 
     
Ischemic stroke       
 No vascular disease   1559  6.8 
 PAD   185  9.2 
 Prior MI   569  7.9 
All-cause death      
 No vascular disease   10805  48.5 
 PAD   1239  66.1 
 Prior MI   2977  42.9 
       
(Abbreviations: MI: myocardial infarction; PAD: peripheral artery disease) 
* Taking into account competing risks of death (Aalen-Johansen estimator). 
 
 
e-Table 3. Hazard rate ratios of ischemic stroke and all-cause death after 5-years follow-up, 
according to vascular disease. 
ENDPOINT PRIMARY EFFECT ESTIMATES 
Ischemic stroke  
Crude HR 
(95% CI) 
Adjusted HR* 
(95% CI) 
     
 PAD vs. no vascular disease 1.68 (1.44 – 1.96) 1.32 (1.13 – 1.54) 
 Prior MI vs. no vascular disease 1.11 (1.01 – 1.22) 1.04 (0.94 – 1.15) 
 PAD vs. prior MI 1.56 (1.28 – 1.79) 1.23 (1.04 – 1.46) 
      
All-cause death  
Crude HR 
(95% CI) 
Adjusted HR* 
(95% CI) 
     
 PAD vs. no vascular disease 1.60 (1.51 – 1.70) 1.52 (1.43 – 1.61) 
 Prior MI vs. no vascular disease 0.84 (0.81 – 0.87) 0.91 (0.88 – 0.95) 
 PAD vs. prior MI 1.91 (1.79 – 2.04) 1.63 (1.53 – 1.75) 
      
 
(Abbreviations: HF: heart failure; HR: hazard rate ratio; MI: myocardial infarction; PAD: peripheral artery disease; 
95% CI: 95% confidence interval) 
 
*Adjusted for sex (binary), hypertension (binary), diabetes (binary), prior stroke/transient ischemic attack (binary), 
COPD (binary), renal disease (binary), and age (continuous) 
e-Table 4: Hazard rate ratios of ischemic stroke and all-cause death after 5-year follow-up, 
stratified by antiplatelet therapy at baseline. 
  
ENDPOINT STRATIFIED ADJUSTED ESTIMATES* 
Ischemic stroke 
No antiplatelet therapy 
HR (95% CI) 
Antiplatelet therapy 
HR (95% CI) 
     
 PAD vs. no vascular disease 1.51 (1.21 – 1.87) 1.18 (0.95 – 1.47) 
 Prior MI vs. no vascular disease 1.16 (0.98 – 1.38) 1.05 (0.93 – 1.18) 
 PAD vs. prior MI 1.25 (0.96 – 1.62) 1.11 (0.88 – 1.39) 
      
All-cause death 
No antiplatelet therapy 
HR (95% CI) 
Antiplatelet therapy 
HR (95% CI) 
     
 PAD vs. no vascular disease 1.48 (1.36 – 1.60) 1.65 (1.51 – 1.79) 
     Prior MI vs. no vascular disease 1.14 (1.07 – 1.22) 0.95 (0.90 – 1.00) 
      PAD vs. prior MI 1.27 (1.15 – 1.41) 1.72 (1.57 – 1.88) 
      
 
 
(Abbreviations: HF: heart failure; MI: myocardial infarction; PAD: peripheral artery disease;  HR: hazard 
ratio; 95% CI: 95% confidence interval) 
 
*Adjusted for sex (binary), hypertension (binary), diabetes (binary), prior stroke/transient ischemic attack 
(binary), COPD (binary), renal disease (binary), and age (continuous) 
 
e-Table 5. Sensitivity analysis censoring patients diagnosed with AF during follow-up: 
Hazard rate ratios of ischemic stroke and all-cause death after 1-year follow-up, according to 
vascular disease. 
 
  
ENDPOINT PRIMARY EFFECT ESTIMATES 
Ischemic stroke  
Crude HR 
(95% CI) 
Adjusted HR* 
(95% CI) 
     
 PAD vs. no vascular disease 1.78 (1.44 – 2.21) 1.29 (1.04 – 1.61) 
 Prior MI vs. no vascular disease 1.12 (0.96 – 1.29) 1.02 (0.88 – 1.18) 
 PAD vs. prior MI 1.60 (1.26 – 2.03) 1.30 (1.02 – 1.66) 
      
All-cause death  
Crude HR 
(95% CI) 
Adjusted HR* 
(95% CI) 
     
 PAD vs. no vascular disease 1.51 (1.39 – 1.64) 1.46 (1.34 – 1.59) 
 Prior MI vs. no vascular disease 0.85 (0.80 – 0.90) 0.94 (0.86 – 1.00) 
 PAD vs. prior MI 1.77 (1.61 – 1.95) 1.53 (1.39 – 1.68) 
      
 
(Abbreviations: HF: heart failure; HR: hazard rate ratio; MI: myocardial infarction; PAD: peripheral artery disease; 
95% CI: 95% confidence interval) 
 
*Adjusted for sex (binary), hypertension (binary), diabetes (binary), prior stroke/transient ischemic attack (binary), 
COPD (binary), renal disease (binary), and age (continuous) 
e-Table 6. Sensitivity analysis excluding patients with a history of stroke: Hazard rate ratios 
of incident stroke after 1-year follow-up, according to vascular disease. 
 
  
ENDPOINT PRIMARY EFFECT ESTIMATES 
Ischemic stroke 
 
Crude HR 
(95% CI) 
Adjusted HR* 
(95% CI) 
     
 PAD vs. no vascular disease 1.68 (1.42 – 2.00) 1.52 (1.28 – 1.81) 
 Prior MI vs. no vascular disease 1.09 (0.99 – 1.21) 1.09 (0.98 – 1.21) 
 PAD vs. prior MI 1.54 (1.28 – 1.86) 1.38 (1.14 – 1.67) 
      
 
(Abbreviations: HF: heart failure; HR: hazard rate ratio; MI: myocardial infarction; PAD: peripheral artery 
disease; 95% CI: 95% confidence interval) 
 
*Adjusted for sex (binary), hypertension (binary), diabetes (binary), prior stroke/transient ischemic attack 
(binary), COPD (binary), renal disease (binary), and age (continuous) 
Methodological details. Analysis on a risk-scale. 
 
In order to have the complete risk assessment of vascular disease in HF patients, both rates 
and relative risks are needed. Thus, regression analysis was used to compare the 1- and 5-
years relative risks of the endpoints according to the presence of PAD or prior MI. To this 
end, we used generalized linear regression alongside the pseudovalue method in order to take 
into account the competing risks of death (Klein J, Andersen P. Regression modeling of 
competing risks data based on pseudovalues of the cumulative incidence function. Biometrics. 
2005;61:223–229; Klein J, Logan B, Harhoff M, Andersen P. Analyzing survival curves at a 
fixed point in time. Stat Med. 2007;26:4505–4519). The pseudo-value regression technique 
reduces to simple regression (with a log-link function) on the event status indicator at 1 year 
in the absence of censoring, whereas censored observations (for which the event status is not 
observed) are replaced with pseudo-observations based upon Aalen-Johansen cumulative 
incidence estimates using the jackknife method. 
 
  
e-Table 7. Relative risks of ischemic stroke and all-cause death after 1-year follow-up, 
according to vascular disease. 
 
  
ENDPOINT PRIMARY EFFECT ESTIMATES 
Ischemic stroke  
Crude RR 
(95% CI) 
Adjusted RR* 
(95% CI) 
     
 PAD vs. no vascular disease 1.69 (1.38 – 2.08) 1.10 (0.84 – 1.45) 
 Prior MI vs. no vascular disease 1.11 (0.96 – 1.28) 0.95 (0.78 – 1.15) 
 PAD vs. prior MI 1.53 (1.22 – 1.93) 1.18 (0.82 – 1.69) 
      
All-cause death  
Crude RR 
(95% CI) 
Adjusted RR* 
(95% CI) 
     
 PAD vs. no vascular disease 1.43
 
(1.34 – 1.54) 1.32 (1.23 – 1.41) 
 Prior MI vs. no vascular disease 0.86 (0.82 – 0.91) 0.99 (0.94 – 1.04) 
 PAD vs. prior MI 1.67 (1.54 – 1.80) 1.20 (1.10 – 1.30) 
      
 
(Abbreviations: HF: heart failure; MI: myocardial infarction; PAD: peripheral artery disease; RR: relative risk; 
95% CI: 95% confidence interval) 
 
*Adjusted for sex (binary), hypertension (binary), diabetes (binary), prior stroke/transient ischemic attack 
(binary), COPD (binary), renal disease (binary), and age (continuous) 
e-Table 8. Relative risks of ischemic stroke and all-cause death after 5-years follow-up, 
according to vascular disease. 
 
 
 
ENDPOINT PRIMARY EFFECT ESTIMATES 
Ischemic stroke  
Crude RR 
(95% CI) 
Adjusted RR* 
(95% CI) 
     
 PAD vs. no vascular disease 1.35 (1.16 – 1.56) 0.98 (0.82 – 1.17) 
 Prior MI vs. no vascular disease 1.16 (1.06 – 1.27) 1.09 (0.98 – 1.21) 
 PAD vs. prior MI 1.16 (0.99 – 1.36) 0.85 (0.70 – 1.05) 
      
All-cause death  
Crude RR 
(95% CI) 
Adjusted RR* 
(95% CI) 
     
 PAD vs. no vascular disease 1.36 (1.31 – 1.42) 1.24 (1.20 – 1.29) 
 Prior MI vs. no vascular disease 0.88 (0.86 – 0.91) 0.95 (0.93 – 0.98) 
 PAD vs. prior MI 1.54 (1.47 – 1.61) 1.27 (1.22 – 1.32) 
      
 
(Abbreviations: HF: heart failure; MI: myocardial infarction; PAD: peripheral artery disease; RR: relative 
risk; 95% CI: 95% confidence interval) 
 
*Adjusted for sex (binary), hypertension (binary), diabetes (binary), prior stroke/transient ischemic attack 
(binary), COPD (binary), renal disease (binary), and age (continuous) 
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Abstract 
Objective: The risk of ischemic stroke, systemic thromboembolism, and all-cause death among heart failure patients 
previously diagnosed with diabetes mellitus is poorly described. We evaluated the risk of these endpoints among heart 
failure patients without diagnosed atrial fibrillation according to the presence of diabetes mellitus. 
Methods: Population-based nationwide cohort study of non-anticoagulated patients diagnosed with incident heart 
failure during 2000-2012, identified by record linkage between nationwide registries in Denmark. We calculated 
relative risks after 1 year to evaluate the association between diabetes and risk of events in 39,357 heart failure patients, 
among whom 18.1% had diabetes. Analysis took into account competing risks of death. 
Results: Absolute risks of all endpoints were higher in patients with diabetes compared to patients without diabetes 
after 1-year follow-up (ischemic stroke: 4.1% vs. 2.8%; thromboembolism: 11.9% vs. 8.6%; all-cause death: 22.1% vs. 
21.4%). Diabetes was significantly associated with an increased risk of ischemic stroke (adjusted relative risk [RR]: 
1.27, 95% confidence interval [CI]: 1.07-1.51); thromboembolism (RR: 1.20, 95% CI: 1.11-1.30); and all-cause death 
(RR: 1.17, 95% CI: 1.11-1.23). Additionally, time since diabetes diagnosis was associated with higher adjusted 
cumulative incidences of ischemic stroke, thromboembolism, and all-cause death (p for trend, p<0.001). 
Conclusions: Among heart failure patients without atrial fibrillation, diabetes was associated with a significantly 
increased risk of ischemic stroke, thromboembolism, and all-cause death compared to those without diabetes, even after 
adjustment for concomitant cardiovascular risk factors. Increased focus on secondary prevention in heart failure patients 
with diabetes may be warranted. 
 
Introduction  
Heart failure (HF) is associated with an increased risk 
of ischemic stroke and systemic thromboembolic 
events (TE), even without atrial fibrillation (AF)[1,2]. 
Comorbidities such as diabetes mellitus are common in 
patients with HF[3], and in previous studies of HF 
patients, diabetes has been associated with a higher risk 
of stroke and systemic TE[4–6]. In addition, previous 
non-HF studies have demonstrated that a longer 
duration of diabetes influence the risk of ischemic 
stroke[7,8]. A recent study identified insulin-treated 
diabetes as a predictor of stroke in HF patients without 
AF[9]. However, for the evaluation of possible risk 
factors for stroke risk stratification in patients with HF 
and without AF, quantifying the association between 
both presence and duration of diabetes and the risk of 
ischemic stroke, systemic TE, and all-cause death 
among HF patients is an important step. Additionally, 
this investigation will provide a basis for suggesting 
subgroups of HF patients who might benefit from 
thromboprophylaxis, as recommended in a recent  
 
 
 
study[10]. This is particularly relevant for HF patients 
without prior AF who are not traditionally considered  
candidates for thromboprophylaxis. However, 
assessing predictors of ischemic stroke and systemic 
TE risk in a high-mortality population such as HF 
patients (5-year mortality of 45-60%)[11,12] is not 
trivial because a competing risks setting in which 
careful consideration of the interplay between mortality 
and ischemic stroke/systemic TE risk is needed to 
provide meaningful risk assessment[13,14]. Thus, any 
analysis of ischemic stroke and systemic TE in such a 
high-risk population would need to take into account 
the competing risk of death, although this has not been 
considered in many previous studies of HF 
populations. 
 
The aim of this study was to prospectively and 
thoroughly investigate the association between diabetes 
and the risk of ischemic stroke, systemic TE, and all-
cause death in patients with incident HF without 
diagnosed AF (and not taking a vitamin K antagonist to 
  
avoid issues with effect modification by 
anticoagulation therapy) to possibly identify a high-risk 
subgroup which could be used in stroke risk 
stratification in the HF population. We investigated the 
hypothesis that the presence of diabetes in non-
anticoagulated incident HF patients without diagnosed 
AF would be associated with a higher risk of adverse 
events, and second, that this risk would increase with 
longer duration of diagnosed diabetes. 
 
Methods 
Registry Data Sources 
We used three different nationwide registries in this 
study:  i) Danish National Patient Registry[15] which 
has registered all hospital admissions along with 
diagnoses since 1977 and codes all diagnoses 
according to the 10
th
 revision of the International 
Classification of Diseases (ICD-10) since 1994; ii) The 
National Prescription Registry[16] which contains data 
on all prescriptions dispensed from Danish pharmacies 
since 1994, coded according to the Anatomical 
Therapeutic Chemical (ATC) Classification System; 
iii) The Danish Civil Registration System which holds 
information on date of birth, migration, vital status, 
date of death, and sex of all persons living in 
Denmark[17]. Data were linked via a unique personal 
identification number used in all Danish national 
registries. All three registries were up to December 31
st
 
2013. These registries have previously been well-
validated[15,16,18], and the diagnoses of HF, diabetes, 
AF, and ischemic stroke have been found to be 
valid[18–22]. 
 
Study Population 
The study population was identified as in- or 
outpatients aged>50 years, discharged with a primary 
diagnosis of incident HF (first-time diagnosis of HF) in 
the period January 1
st
 2000 - December 31
st
 2012 
(ICD-10: I50, I42.0, I11.0, I13.0, I13.2). Diabetes 
mellitus was identified using ICD codes or a claimed 
prescription of a glucose-lowering drug (ICD-8: 24900, 
24909, 25008, 25009; ICD-10: E10, E11.0; ATC: 
A10). Duration of diabetes was calculated from date of 
first diagnosis (ICD-8 or ICD-10 code), or from the 
date of first claimed prescription of a glucose-lowering 
drug, whichever came first, until the time of discharge 
with a diagnosis of HF. To restrict our analysis to 
patients without AF, we excluded those who had a 
prior diagnosis of AF or atrial flutter (ICD-10: I48) 
between 1994 and date of HF diagnosis. We also 
excluded patients treated with a vitamin K antagonist 
(ATC: B01AA03, B01AA04) within six months prior 
to the HF diagnosis (to avoid issues with effect 
modification by anticoagulation therapy). During our 
inclusion period, the use of non-vitamin K antagonist 
oral anticoagulants was almost non-existent in the HF 
population, and therefore, not relevant in this study. 
Patients with a diagnosis of cancer (ICD-10: C00-C97) 
within 5 years before HF diagnosis were also excluded, 
since cancer patients represents a subgroup with high 
stroke risk[23] and specialized thromboprophylactic 
treatment regimens.  
 
Additional comorbidities at baseline were identified 
using the Danish National Patient Registry and the 
Danish National Prescription Registry which have 
registered diagnoses (using ICD-10 codes) and 
prescriptions (using ATC codes) since 1994. 
Ascertainment of baseline medication status was based 
on medication purchase in a 45-day window before or 
after the date of HF diagnosis. ICD-codes and ATC-
codes used to define comorbidities and medical 
therapies are provided in the online-only Supplement 
[see eTable 1 in the Supplementary material]. 
 
Outcomes 
The primary endpoints were defined as an ischemic 
stroke diagnosis (ICD-10: I63, I64) or a diagnosis of a 
systemic TE (ischemic stroke (ICD-10: I63, I64), 
transient ischemic attack (ICD-10: G45), systemic 
arterial embolism (ICD-10: I74), or acute myocardial 
infarction (ICD-10: I21, I23)). Because of the high 
mortality in the HF population, all-cause death 
(according to The Danish Civil Registration System) 
was also included as a primary endpoint.  
Statistical Methods  
Baseline characteristics (at time of HF diagnosis) were 
described separately for patients with and without 
diabetes, using means and standard deviation for 
continuous measures and proportions for categorical 
measures.  
 
Time-to-event analysis was used to describe the 
association between diabetes and the risk of ischemic 
stroke, systemic TE, and all-cause death. Time at risk 
was measured from baseline date (date of HF 
diagnosis) and until an event of ischemic stroke or 
systemic TE, date of death, emigration, or end of study 
(December 31
st
 2013), whichever came first. 
Additionally, patients were censored if they initiated 
anticoagulant therapy during the follow-up period.  
 
Absolute risks of all endpoints were estimated based on 
Aalen-Johansen[24] estimator for competing risks data 
according to presence of diabetes. Regression analysis 
was used to compare the 1-year relative risk of the 
three endpoints according to presence of diabetes. To 
this end, we used generalized linear regression 
alongside the pseudo-value method in order to take into 
account the competing risk of death[25,26]. The 
pseudo-value regression technique reduces to simple 
regression (with a log-link function) on the event status 
indicator at 1 year in the absence of censoring. The 
associations between diabetes and risk of the three 
  
endpoints were presented using both crude relative 
risks and relative risks adjusted for age, sex, and 
cardiovascular risk factors, such as hypertension, 
vascular disease, renal disease, chronic obstructive 
pulmonary disease, and prior stroke/transient ischemic 
attack. We repeated these analyses after 5 years of 
follow-up in the Supplementary material. Additionally, 
we provided the results of each component of the 
systemic thromboembolic end point in the 
Supplementary material. 
 
In a secondary analysis with a more explorative focus, 
duration of diagnosed diabetes was analyzed as a 
categorical variable (duration of <5 years, 5-10 years, 
and >10 years). We used an inverse-probability-
weighting approach[27] to calculate adjusted 
cumulative incidence curves for all endpoints (taking 
into account competing risks)[24] for each duration 
category. P-values for trend were obtained by entering 
the categorical duration of the diagnosed diabetes 
variable as a continuous ordinal covariate in a linear 
regression model for the pseudo-values at 1 year, 
adjusting for concomitant risk factors as before. 
 
As a sensitivity analysis, since some patients might be 
taken glucose-lowering drug due to a pre-diabetic state, 
we repeated the main analysis when using only 
diagnosis codes (ICD-8/ICD-10 codes) to define 
patients with diabetes. Furthermore, we performed a 
similar sensitivity analysis, where we defined patients 
with diabetes only if they had a diagnosis code of 
diabetes and concomitantly had claimed a prescription 
for a glucose-lowering drug. We also performed a 
sensitivity analysis in which patients with a history of 
ischemic stroke were excluded (since a prior ischemic 
stroke diagnosis is a strong risk factor for a subsequent 
stroke)[28]. Additionally, as some patients might get a 
diagnosis of AF shortly after the HF diagnosis, a 
sensitivity analysis was performed by repeating the 
absolute and relative risk calculations when extending 
the definition of concomitant AF at baseline; presence 
of a prior diagnosis of AF at baseline or within 30 days 
after HF diagnosis. Furthermore, some patients are 
diagnosis with AF during follow-up; thus, we 
performed another sensitivity analysis by repeating the 
absolute and relative risk calculations after censoring 
patients who are diagnosed with AF during follow-up.  
 
Analyses were performed using Stata version 13 (Stata 
Corporation, College Station, TX, USA) and R version 
3.0.2 (The R Foundation for Statistical Computing). A 
two-sided p-value of <0.05 was considered statistically 
significant.  
 
Ethical Considerations 
No ethical approval is required for anonymous register 
studies in Denmark. The study was approved by the 
Danish Data Protection Agency (J. No. File No. 2012-
41-0633). 
 
Results 
The study population comprised 39,357 HF patients 
aged >50 years, among which 18.1% had diabetes 
[Figure 1]. The median follow-up period with respect 
to ischemic stroke was 2.5 years (interquartile range: 
0.6-5.3 years). The baseline characteristics of the study 
population are summarized in Table 1. A history of 
stroke/transient ischemic attack, systemic TE, 
myocardial infarction, vascular disease, hypertension, 
and renal disease was more frequent among patients 
with diabetes than in patients without diabetes. 
Additionally, patients with diabetes were more often on 
statins and antiplatelet therapy. 
 
The absolute risks of all endpoints were higher in 
patients with diabetes compared to patients without 
diabetes after 1-year follow-up (ischemic stroke: 4.1% 
vs. 2.8%; systemic TE: 11.9% vs. 8.6%; all-cause 
death: 22.1% vs. 21.4%) [Table 2]. After 1-year 
follow-up, diabetes was independently associated with 
an increased risk of ischemic stroke (adjusted relative 
risk [RR]: 1.27, 95% confidence interval [CI]: 1.07-
1.51); systemic TE (adjusted RR: 1.20, 95% CI: 1.11-
1.30); and all-cause death (adjusted RR: 1.17, 95% CI: 
1.11-1.23) [Table 2]. Similar conclusions were 
obtained after 5-years follow-up [see eTable 8 in the 
Supplementary material]. When examining the 
individual components of the systemic thromboembolic 
end point, diabetes was associated with an increased 
risk of myocardial infarction, and for the end point of 
transient ischemic attack and systemic embolism 
separately, the event numbers were too low to make 
any conclusions [see eTable 9 in the Supplementary 
material]. 
 
For the secondary exploratory investigation of the 
association between time since diabetes diagnosis and 
outcomes, Figure 2B and Figure 2C suggest a dose-
response relationship between diabetes diagnosis and 
the cumulative incidences of systemic TE and all-cause 
death (p for trend; systemic TE: p<0.001; all-cause 
death: p<0.001). For the endpoint of ischemic stroke, a 
dose-response relationship between time since diabetes 
diagnosis and outcome risk was less clear [Figure 2A] 
(p for trend; ischemic stroke: p<0.001). Raw numerical 
values for the absolute risks of ischemic stroke, 
systemic TE, and all-cause death after 1-year follow-
up, stratified according to duration of diabetes, are 
shown in eTable 7 in the Supplementary material. 
 
In the sensitivity analysis using only ICD-codes to 
define patients with diabetes, we found similar results 
as in the main analysis [see eTable 2 in the 
Supplementary material]. Likewise, in the sensitivity 
  
analysis using ICD-codes in combination with ATC-
codes to define patients with diabetes, the results were 
similar to the main analysis [see eTable 6 in the 
Supplementary material]. When excluding patients 
with prior ischemic stroke, the risk of ischemic stroke 
and systemic TE was lower in the whole study 
population. Diabetes was still associated with an 
increased risk of ischemic stroke, although borderline 
non-significant. However, for the endpoint of systemic 
TE and death the conclusions remained the same as in 
the main analysis [see eTable 3 in the Supplementary 
material]. In the sensitivity analysis, repeating the 
absolute and relative risk calculations after extending 
the definition of concomitant AF, we found very 
similar results as in the main analyses [see eTable 4 in 
the Supplement]. When censoring patients with HF 
who are diagnosed with AF during follow-up, similar 
results were found and the conclusions remained the 
same as in the main analysis [see eTable 5 in the 
Supplement]. 
 
 
Discussion 
In this large prospective study, we found a higher risk 
of ischemic stroke, systemic TE, and all-cause death 
among HF patients with diabetes compared to HF 
patients without diabetes after 1-year follow-up, and 
even after extensive adjustment for concomitant 
cardiovascular risk factors. Second, there was a dose-
response relationship between time since diabetes 
diagnosis and the cumulative incidences of systemic 
TE and all-cause death. To our knowledge, this is the 
first study to thoroughly examine diabetes as a risk 
factor of ischemic stroke/systemic TE and the 
association between duration of diabetes and the end 
points in a HF population without AF. 
 
Patients with diabetes have altered hemostasis, platelet 
activity, and vascular endothelial function contributing 
to a prothrombotic state[29]. In our study, patients with 
diabetes had more comorbidities, such as hypertension, 
vascular disease, prior stroke/systemic TE, and 
ischemic heart disease compared to HF patients 
without diabetes. All these comorbidities are well-
known risk factors of ischemic stroke and recurrent 
stroke. The presence of comorbidities and the 
prothrombotic state might partly explain the link 
between diabetes and the higher risk of systemic TE. 
However, we emphasize that our study focused on 
exploring the prognostic value of diabetes in relation to 
systemic thromboembolic risks; we cannot draw 
conclusions on causality. Furthermore, as mentioned, 
diabetes was associated with an increased risk of 
ischemic stroke and systemic TE even after adjustment 
for other cardiovascular risk factors which highlight the 
significance of this risk factor in the HF population 
without AF. 
 
A longer duration of diabetes has previously been 
demonstrated to be associated with the risk of ischemic 
stroke in the form of a dose-response relationship[7]. 
Additionally, duration of diabetes is associated with an 
increased risk of other cardiovascular diseases and 
cardiovascular mortality[30,31]. In our study, we found 
a dose-response relationship between the time since 
diabetes diagnosis and cumulative incidences of 
systemic TE and all-cause death. The relationship 
between time since diabetes diagnosis and risk of 
ischemic stroke, on the other hand, was more 
equivocal, which may be attributed to limitations of the 
register-based definition of diabetes duration (see 
limitations below).  
 
Clinical Perspectives 
The increasing prevalence of both HF and diabetes 
highlights the clinical relevance of our findings.  
In this study, diabetes was associated with an increased 
risk of ischemic stroke and most likely this 
comorbidity will be useful for stroke risk stratification 
in HF patients without AF. However, patients with 
diabetes are a very heterogeneous group with varying 
degrees of diabetes duration, glycemic control, and 
diabetic complications; thus, it may be necessary to 
subdivide these patients according to severity of 
diabetes for optimal risk stratification. Whether 
duration of diabetes will enhance the identification of 
high-risk HF patients need to be further examined in 
future studies. 
Currently, patients with HF and without AF are not 
routinely recommended antiplatelet or anticoagulant 
therapy[32]. HF patients with diabetes have an 
increased risk of various thromboembolic diseases and 
may represent a high-risk subgroup of HF patients 
without AF that could potentially benefit from 
intensive thromboprophylaxis. However, this 
speculation would need further examination in future 
studies.  
 
Strengths and Limitations   
The major strengths of this study are the validated 
outcomes and large sample size uniquely possible with 
this type of cohort study. Selection into the study was 
not an issue, since we investigated a nationwide 
population cohort of incident HF patients without AF, 
with limited loss to follow-up. We also accounted for 
the competing risk of death, an important issue when 
investigating risk predictors in populations with high 
mortality[14,33]. 
The study also has some important limitations. We 
were unable to distinguish between HF with preserved 
and reduced ejection fraction or estimate the functional 
classification, since we did not have access to 
echocardiograms. Whether the prevalence of stroke 
differs in patients with preserved and reduced ejection 
fraction is currently unknown due to inconsistent 
  
results[5,34–36]. However, no difference in embolic 
risk (risk of stroke, transient ischemic stroke, or 
systemic embolism) was found in a recent study of 
non-anticoagulated HF patients with reduced and 
preserved ejection fraction[34]. Similarly, in a post-hoc 
analysis of a study of AF patients with HF with 
reduced or preserved ejection fraction, no difference in 
ischemic stroke risk was found between the 
groups[35]. On the other hand, the functional 
classification among patients with HF would also vary 
over time and with treatments.  
The diagnosis of HF has previously been validated 
with a sensitivity of 29%, a specificity of 99%, and a 
positive predictive value of 81-100%[20,21]; thus, we 
did not capture all patients with HF and also cannot be 
certain that all patients identified as having HF had 
definite HF, which could lead to imprecision in the risk 
estimates. In addition, we cannot rule out that some 
patients without AF might have had undiagnosed AF, 
since heart disease is associated with an increased risk 
of developing AF and AF is ‘silent’ in up to a quarter 
of patients; however, in the sensitivity analysis, where 
patients were censored if they developed AF during 
follow-up, the conclusions remained the same as in the 
main analysis.  
We only included patients aged >50 years, as HF in 
persons aged <50 years might represent a different 
group of patients, for example patients with congenital 
heart disease. Accordingly, our findings may not apply 
to younger HF patients. Additionally, our study 
population was ethnically non-diverse, since we 
investigated a Danish HF population. Thus, our study 
results might not be generalizable to more diverse HF 
populations. 
Patients with diabetes but without a hospital-based 
diagnosis of diabetes and treated only non-
pharmacologically were not included in this study, 
thus, our population is unlikely to include patient 
groups with a reversible state of diabetes. This may 
explain the lower prevalence of diabetes (18%) in our 
cohort compared to other HF cohorts (approximately 
30%)[9,37]. Moreover, we were not able to distinguish 
between type 1 and type 2 diabetes which would be a 
very relevant separation.  
We did not have access to information regarding 
smoking habits, body mass index, and lipid profile 
which we recognized as important factors when 
investigating diabetes and ischemic stroke risk. 
However, since the focus was on the prognostic value 
of a diabetes diagnosis, not its causal role, confounding 
by possible stroke risk factors is not an issue of 
concern in this study. We investigated whether the 
presence of diabetes was associated with ischemic 
stroke, systemic TE, and death in patients with HF, and 
therefore, we adjusted for well-known cardiovascular 
risk factors for stroke. This was not an attempt to adjust 
for confounding and hereby explore the potential 
causal relationship between the exposure and 
outcomes, but to elucidate the potential predictive 
ability of the exposure to risk stratification in patients 
with HF, after adjustment for other possible risk 
factors. 
In the secondary, exploratory analysis we calculated 
the duration of diabetes as the time from first diagnosis 
with an ICD-8/ICD-10 code or from the first claimed 
prescription of a glucose-lowering drug, whichever 
came first, until the time of discharge with a diagnosis 
of HF. This register-based proxy for the duration of 
diabetes has important limitations; it can be affected by 
delayed diagnosis, changes over time in diagnostic 
criteria, and changes over time in medical treatment. 
Due to these limitations, we examined the association 
between duration of diabetes and risk of events as a 
secondary, explorative analysis. The above-mentioned 
limitations could explain the less clear dose-response 
relationship between time since diabetes diagnosis and 
the cumulative incidence of ischemic stroke.  
Finally, the diagnosis of ischemic stroke was defined 
by the Danish Hospital Discharge Register, and not all 
stroke endpoints have been defined by cerebral 
imaging, and thus, the data did not allow classification 
of various ischemic stroke types. We included 
unspecified stroke (ICD-10: I64) in the definition of 
ischemic stroke, as most strokes are of ischemic origin. 
However, we cannot rule out that some of these strokes 
might have been hemorrhagic strokes and thus, 
misclassified as ischemic strokes. Nonetheless, the 
ischemic stroke diagnosis has previously been 
validated[18]. 
In conclusion, diabetes was associated with a 
significantly higher risk of ischemic stroke, systemic 
TE, and all-cause death in HF patients without AF, 
which persisted after adjustment for concomitant 
cardiovascular risk factors, and longer time since 
diabetes diagnosis was associated with higher risks.  
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Table 1. Baseline characteristics of study population, stratified according to presence of diabetes. 
  
  
 
 
Clinical characteristics No diabetes Diabetes 
 
N, % (n) 81.9 (32,249) 18.1 (7,108) 
 
 
Sex (females), % (n) 45.7 (14,722) 38.3 (2,723) 
 
Mean age at baseline, years (SD) 74.5  (11.5)  72.1 (10.5) 
 
 
Baseline comorbidity, % (n)  
 
 
Previous stroke/TIA 12.0 (3,884)  17.1 (1,215) 
Previous myocardial infarction 24.0 (7,723) 29.8 (2,118) 
 Previous thromboembolism* 32.3 (10,415) 41.2 (2,929) 
 Vascular disease 29.8 (9,608) 39.8 (2,828) 
 Hypertension 27.4 (8,827)  49.8 (3,541) 
 
Renal Disease 4.6 (1,492)  8.5 (605) 
 
Liver Disease 0.4 (127) 0.7 (49) 
 
Hyperthyroidism 2.6 (830) 2.7 (191) 
 
COPD 13.2 (4,254) 13.9 (989) 
 
  
Baseline medication, % (n)  
 
 
ACE-inhibitors 50.4 (16,245) 55.4 (3,941) 
 
Angiotensin receptor blocker 9.0 (2,915) 16.9 (1,200) 
Beta-blockers 42.8 (13,808) 48.2 (3,424) 
 
Aldosterone antagonists 22.1 (7,119) 27.1 (1,923) 
 
Non-loop diuretics 37.8 (12,194) 43.8 (3,113) 
 
Loop diuretics 63.7 (20,548) 73.0 (5,185) 
 
Statins 27.6 (8,912) 44.9 (3,189) 
 
NSAIDs 13.9 (4,473) 14.8 (1,053) 
 
Aspirin 46.4 (14,973) 54.3 (3,859) 
 
Thienopyridines 10.3 (3,332) 13.2 (941) 
 
Insulins and analogues - 28.2 (2,003) 
 
Blood glucose lowering drugs - 54.7 (3,890) 
 
 
Abbreviations: COPD= Chronic obstructive pulmonary disease; NSAIDs= Non-
steroidal anti-inflammatory drugs; SD=Standard deviation; TIA=Transient 
ischemic attack. 
 
* Composite endpoint of ischemic stroke, transient ischemic attack, systemic 
embolism, acute myocardial infarction. 
 
 
  
Table 2. Absolute and relative risks of ischemic stroke, thromboembolism, and all-cause death after 1-year 
follow-up, stratified according to presence of diabetes. 
Endpoint  Overall No diabetes Diabetes 
No. of patients 39,357 32,249 7,108 
ISCHEMIC STROKE 
   
 Event number 1,116 839 277 
 Absolute risk, % 3.0 2.8 4.1 
 Crude relative risk - 1.00 (ref.) 1.49 (1.30-1.70) 
 Adjusted relative risk* - 1.00 (ref.) 1.27 (1.07-1.51) 
THROMBOEMBOLISM† 
   
 Event number 3,473 2,659 814 
 Absolute risk, % 9.9 8.6 11.9 
 Crude relative risk - 1.00 (ref.) 1.38 (1.28-1.49) 
 Adjusted relative risk* - 1.00 (ref.) 1.20 (1.11-1.30) 
ALL-CAUSE DEATH 
   
 Event number 7,980 6,499 1,481 
 Absolute risk, % 21.5 21.4 22.1 
 Crude relative risk - 1.00 (ref.) 1.03 (0.98-1.08) 
 Adjusted relative risk* - 1.00 (ref.) 1.17 (1.11-1.23) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), 
previous stroke/transient ischemic attack (binary), chronic obstructive pulmonary disease 
(binary), and renal disease (binary)  
 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, acute 
myocardial infarction 
 
 
 
 
Figure 1: Flowchart of patients included in the final study population. 
 
Figure 2: Adjusted cumulative incidence curve of the three endpoints according to duration of diagnosed diabetes. A) 
Adjusted cumulative incidence curve of ischemic stroke; B) Adjusted cumulative incidence curve of any 
thromboembolic event; C) Adjusted cumulative incidence curve of all-cause death. 
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eTable 1. ICD10-codes and ATC-codes used in the study.  
ICD 10-Codes and ATC-Codes used in the Study 
 Main diagnosis ICD 10-Codes 
Congestive heart failure I50.0-I50.9, I11.0, I13.0, I13.2 
Diabetes mellitus E10.0-E10.9, E11.0-E11.9 + (24900, 24909, 25008, 25009 (ICD-8)) + (ATC: A10) 
Endpoints ICD 10-Codes 
Stroke (ischemic) I63.0-I63.9, I64 
Ischemic stroke (Thromboembolic 
event) 
I63.0-I63.9, I64 
Transient ischemic attack 
(Thromboembolic event) 
G45.0-G45.9 (Not inclusive G45.3 (Amaurosis fugax)) 
Systemic embolism (Thromboembolic 
event) 
I74.0-I74.9 
Acute myocardial infarction 
(Thromboembolic event) 
I21.0-I21.9, I23.0-I23.9 
Comorbidities ICD 10-Codes 
Prior stroke (ischemic or hemorrhagic) I60.0-I60.9, I61.0-I61.9, I62.0-I62.9, I63.0-I63.9, I64.9 
Acute myocardial infarction I21.0-I21.9, I23.0-I23.9 
Vascular disease I21.0-I21.9, I23.0-I23.9, I70.0, I70.2-I70.9, I71.0-I71.9, I73.9 
Hypertension I10.0-I10.9, I11.0-I11.9, I12.0-I12.9, I13.0-I13.9, I15.0–I15.9 
Renal disease 
I12.0-I12.9, I13.0-I13.9, N00-N07, N11.0-N11.9, N14.0-N14.4, N17.0-N17.9, N18.0-
N18.9, N19, Q61.0-Q61.9 
Liver disease 
B15.0-B15.9, B16.0-B16.9, B17.0-B17.9, B18.0-B18.9, B19.0-B19.9, K70.4, K72.0-
K72.9, K76.6 
Hyperthyroidisme E05.0-E05.9, E06.0-E06.9 
Chronic obstructive pulmonary disease 
(COPD) 
J44.0-J44.9 
Atrial fibrillation and flutter (exclusion 
criteria) 
I48 
Cancer any type (exclusion criteria) C00-C97 
Concomitant medication ATC-Codes 
Warfarin (exclusion criteria) B01AA03 
Phenprocoumon (exclusion criteria) B01AA04 
Glucose-lowering medication A10 
ACE-inhibitors C09AA 
Angiotensin receptor blockers C09CA 
Beta-blockers C07 
Non-loop diuretics 
C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G,C09BA, 
C09DA, C09XA52  
Aldosterone antagonists C03DA 
Loop diuretics C03C 
Statins C10 
Non steroidal anti-inflammatory drugs 
(NSAIDs) 
M01A 
Aspirin B01AC06 
Thienopyridines B01AC04, B01AC22, B01AC24 
Insulins and analogous A10A 
Blood glucose lowering drugs A10B 
 
eTable 2. Sensitivity analysis (using only diagnosis codes in diabetes definition): Absolute and relative risks 
of ischemic stroke, systemic thromboembolic event, and all-cause death after 1-year follow-up, according to 
presence of diabetes. 
Endpoint  Overall No diabetes Diabetes 
ISCHEMIC STROKE 
   
 Event number 1,116 891 225 
 Absolute risk, % 3.0 2.8 4.3 
 Crude relative risk - 1.00 (ref.) 1.53 (1.32-1.77) 
 Adjusted relative risk* - 1.00 (ref.) 1.29 (1.08-1.54) 
SYSTEMIC THROMBOEMBOLISM† 
   
 Event number 3,757 3,065 692 
 Absolute risk, % 9.9 9.5 13.0 
 Crude relative risk - 1.00 (ref.) 1.37 (1.27-1.48) 
 Adjusted relative risk* - 1.00 (ref.) 1.18 (1.09-1.28) 
ALL-CAUSE DEATH 
   
 Event number 7,980 6,830 1,150 
 Absolute risk, % 21.5 21.4 22.0 
 Crude relative risk - 1.00 (ref.) 1.03 (0.97-1.09) 
 Adjusted relative risk* - 1.00 (ref.) 1.17 (1.10-1.23) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), previous stroke/transient 
ischemic attack (binary), chronic obstructive pulmonary disease (binary), and renal disease (binary)  
 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, acute myocardial infarction. 
 
  
eTable 3. Sensitivity analysis (excluding patients with prior ischemic stroke): Absolute and relative risks of 
ischemic stroke, systemic thromboembolic event, and all-cause death after 1-year follow-up, according to 
presence of diabetes. 
Endpoint  Overall No diabetes Diabetes 
ISCHEMIC STROKE 
   
 Event number 722 569 153 
 Absolute risk, % 2.1 2.0 2.6 
 Crude relative risk - 1.00 (ref.) 1.28 (1.07-1.53) 
 Adjusted relative risk* - 1.00 (ref.) 1.19 (0.98-1.45) 
SYSTEMIC THROMBOEMBOLISM† 
   
 Event number 2,835 2,235 600 
 Absolute risk, % 8.3 7.9 10.1 
 Crude relative risk - 1.00 (ref.) 1.28 (1.17-1.39) 
 Adjusted relative risk* - 1.00 (ref.) 1.12 (1.02-1.23) 
ALL-CAUSE DEATH 
   
 Event number 6,929 5,715 1,214 
 Absolute risk, % 20.5 20.5 20.7 
 Crude relative risk - 1.00 (ref.) 1.01 (0.96-1.07) 
 Adjusted relative risk* - 1.00 (ref.) 1.16 (1.10-1.23) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), chronic obstructive 
pulmonary disease (binary), and renal disease (binary)  
 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, acute myocardial infarction. 
 
  
eTable 4. Sensitivity analysis (excluding patients with an AF diagnosis within 30 days after the HF 
diagnosis): Absolute and relative risks of ischemic stroke, systemic thromboembolic event, and all-cause 
death after 1-year follow-up, according to presence of diabetes. 
Endpoint  Overall No diabetes Diabetes 
ISCHEMIC STROKE 
   
 Event number 1,063 794 269 
 Absolute risk, % 2.9 2.6 4.0 
 Crude relative risk - 1.00 (ref.) 1.52 (1.32-1.74) 
 Adjusted relative risk* - 1.00 (ref.) 1.30 (1.09-1.54) 
SYSTEMIC THROMBOEMBOLISM† 
   
 Event number 3,327 2,540 787 
 Absolute risk, % 9.0 8.4 11.7 
 Crude relative risk - 1.00 (ref.) 1.39 (1.29-1.50) 
 Adjusted relative risk* - 1.00 (ref.) 1.21 (1.11-1.31) 
ALL-CAUSE DEATH 
   
 Event number 7,817 6,359 1,458 
 Absolute risk, % 21.4 21.3 22.0 
 Crude relative risk - 1.00 (ref.) 1.03 (0.98-1.09) 
 Adjusted relative risk* - 1.00 (ref.) 1.17 (1.11-1.23) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), previous stroke/transient 
ischemic attack (binary), chronic obstructive pulmonary disease (binary), and renal disease (binary)  
 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, acute myocardial infarction. 
 
  
eTable 5. Sensitivity analysis (censoring patients developing AF during follow-up): Absolute and relative 
risks of ischemic stroke, systemic thromboembolic event, and all-cause death after 1-year follow-up, 
according to presence of diabetes. 
Endpoint  Overall No diabetes Diabetes 
ISCHEMIC STROKE 
   
 Event number 1,061 788 273 
 Absolute risk, % 2.9 2.6 4.1 
 Crude relative risk - 1.00 (ref.) 1.55 (1.36-1.78) 
 Adjusted relative risk* - 1.00 (ref.) 1.33 (1.11-1.58) 
SYSTEMIC THROMBOEMBOLISM† 
   
 Event number 3,377 2,579 798 
 Absolute risk, % 9.1 8.5 11.9 
 Crude relative risk - 1.00 (ref.) 1.39 (1.29-1.50) 
 Adjusted relative risk* - 1.00 (ref.) 1.21 (1.12-1.32) 
ALL-CAUSE DEATH 
   
 Event number 7,566 6,147 1,419 
 Absolute risk, % 20.8 20.7 21.5 
 Crude relative risk - 1.00 (ref.) 1.04 (0.99-1.10) 
 Adjusted relative risk* - 1.00 (ref.) 1.18 (1.12-1.24) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), previous stroke/transient 
ischemic attack (binary), chronic obstructive pulmonary disease (binary), and renal disease (binary)  
 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, acute myocardial infarction. 
 
  
eTable 6. Sensitivity analysis (using the combination of diagnosis codes and ATC-codes in diabetes 
definition): Absolute and relative risks of ischemic stroke, systemic thromboembolic event, and all-cause 
death after 1-year follow-up, according to presence of diabetes. 
Endpoint  Overall No diabetes Diabetes 
ISCHEMIC STROKE 
   
 Event number 1,116 934 182 
 Absolute risk, % 3.0 2.8 4.3 
 Crude relative risk - 1.00 (ref.) 1.51 (1.29-1.76) 
 Adjusted relative risk* - 1.00 (ref.) 1.28 (1.06-1.54) 
SYSTEMIC THROMBOEMBOLISM† 
   
 Event number 3,473 2,937 536 
 Absolute risk, % 9.2 8.8 12.5 
 Crude relative risk - 1.00 (ref.) 1.42 (1.30-1.54) 
 Adjusted relative risk* - 1.00 (ref.) 1.18 (1.08-1.30) 
ALL-CAUSE DEATH 
   
 Event number 7,980 7,051 929 
 Absolute risk, % 21.5 21.5 22.1 
 Crude relative risk - 1.00 (ref.) 1.03 (0.97-1.09) 
 Adjusted relative risk* - 1.00 (ref.) 1.21 (1.14-1.28) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), previous stroke/transient 
ischemic attack (binary), chronic obstructive pulmonary disease (binary), and renal disease (binary)  
 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, acute myocardial infarction. 
  
eTable 7. Figure 2 – raw numerical values: Absolute risks of ischemic stroke, systemic thromboembolism, 
and all-cause death after 1-year follow-up, stratified according to duration of diabetes. 
 
Duration of diabetes <5 years 5-10 years >10 years 
 
Absolute risk, % (95% CI) 
    
Ischemic stroke 3.6 (2.8-4.3) 4.3 (3.5-5.2) 4.5 (3.6-5.4) 
Systemic thromboembolism 11.0 (9.8-12.2) 11.3 (9.9-12.6) 13.7 (12.2-15.2) 
All-cause death 19.6 (18.1-21.2) 22.9 (21.0-24.7) 24.3 (22.4-26.2) 
 
  
eTable 8. Absolute and relative risks of ischemic stroke, systemic thromboembolic event, and all-cause 
death after 5-years follow-up, according to presence of diabetes. 
Endpoint  Overall No diabetes Diabetes 
ISCHEMIC STROKE 
   
 Event number 2,421 1,845 576 
 Absolute risk, % 7.3 6.8 9.6 
 Crude relative risk - 1.00 (ref.) 1.42 (1.30-1.55) 
 Adjusted relative risk* - 1.00 (ref.) 1.23 (1.10-1.36) 
SYSTEMIC THROMBOEMBOLISM† 
   
 Event number 6,193 4,751 1,442 
 Absolute risk, % 18.1 16.9 23.3 
 Crude relative risk - 1.00 (ref.) 1.38 (1.31-1.46) 
 Adjusted relative risk* - 1.00 (ref.) 1.20 (1.14-1.27) 
ALL-CAUSE DEATH 
   
 Event number 15,638 12,665 2,973 
 Absolute risk, % 48.7 47.8 52.4 
 Crude relative risk - 1.00 (ref.) 1.10 (1.06-1.13) 
 Adjusted relative risk* - 1.00 (ref.) 1.16 (1.14-1.19) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), previous stroke/transient 
ischemic attack (binary), chronic obstructive pulmonary disease (binary), and renal disease (binary)  
 
†Composite endpoint of ischemic stroke, transient ischemic attack, systemic embolism, acute myocardial infarction. 
 
  
eTable 9. Absolute risks of each component of the systemic thromboembolic end point (besides ischemic 
stroke) after 1-year follow-up, stratified according to duration of diabetes. 
Endpoint  Overall No diabetes Diabetes 
TRANSIENT ISCHEMIC ATTACK 
   
 Event number 226 184 42 
 Absolute risk, % 0.6 0.6 0.6 
 Crude relative risk - 1.00 (ref.) 1.02 (0.73-1.43) 
 Adjusted relative risk* - 1.00 (ref.) 0.83 (0.52-1.33) 
SYSTEMIC EMBOLISM 
   
 Event number 67 49 18 
 Absolute risk, % 0.2 0.2 0.3 
 Crude relative risk - 1.00 (ref.) 1.65 (0.96-2.84) 
 Adjusted relative risk* - 1.00 (ref.) 1.42 (0.65-3.13) 
ACUTE MYOCARDIAL INFARCTION 
   
 Event number 2,268 1,739 529 
 Absolute risk, % 6.0 5.6 7.7 
 Crude relative risk - 1.00 (ref.) 1.37 (1.25-1.51) 
 Adjusted relative risk* - 1.00 (ref.) 1.15 (1.03-1.27) 
 
*Adjusted for: sex (binary), age (continuous), hypertension (binary), vascular disease (binary), previous stroke/transient 
ischemic attack (binary), chronic obstructive pulmonary disease (binary), and renal disease (binary).  
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